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Abstract
Mutations in the visual pigment protein rod opsin are the most common cause of 
autosomal dominant retinitis pigmentosa (ADRP) and the majority of these 
mutations lead to the misfolding of the protein. Patients with ADRP experience 
progressive loss of vision leading to blindness and at the moment no effective 
therapy is available. In this study I have developed a cellular model that can mimic 
the gain-of function and dominant-negative disease mechanisms in rhodopsin 
ADRP patients. Whereas wild-type rod opsin translocated to the plasma membrane 
of the cells, P23H mutant rod opsin misfolded was retained in the ER and 
accumulated in intracellular inclusions. Several pharmacological compounds were 
tested in this model. The retinoids 9-c/s-retinal and 11-c/s-retinal reduced inclusion 
incidence, alleviated cell death and promoted the translocation of the mutant 
protein to the plasma membrane in cells expressing P23H rod opsin. In cells co­
expressing wild-type and P23H rod opsin these compounds restored the normal 
processing of the wild-type protein, indicating an alleviation of the dominant- 
negative mechanism of cell death. Chemical chaperones reduced inclusion 
incidence and cell death but, unlike retinoids, did not to promote the translocation 
of the mutant protein and did not alleviate the dominant-negative interaction 
between wild-type and P23H rod opsin. Heat shock protein inducers were also 
used. Some of these drugs reduced inclusion incidence and cell death in P23H 
cells. In addition, one partially promoted the translocation of the mutant protein and 
partially suppressed the dominant-negative mechanism of cell death induced by 
the mutant protein. Treatment with other compounds such as autophagy inducers 
also reduced inclusion incidence and cell death in cells expressing P23H rod opsin. 
These data have identified a range of compounds that demonstrate the ‘proof of 
principle’ that some of the gain of function and dominant-negative properties of 
mutant misfolded rod opsin can be manipulated. The efficacy of these compounds 
must be established in animal models prior to translation into the clinic.
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Chapter 1: Introduction
1.1 Structure of the vertebrate retina
The wall of the eye in higher vertebrates is coated by three different layers (Figure 
1.1). The external layer is robust and confers protection to the inner structures. It is 
opaque in the larger, posterior portion (sclera) and transparent in the smaller, 
anterior section (cornea), which provides the eye with most of its optical power. 
Together with the lens, the cornea refracts light, and as a result helps the eye to 
focus. The intermediate layer, also named choroid, is a vascular layer responsible 
for providing nutrients to the ocular tissues. Its anterior segment, the ciliary body, is 
responsible for the process of accommodation carried out by the lens. The retina is 
localised in the innermost layer and is responsible for converting light to visual 
signals and conveying them to the brain.
The adult retina consists of alternate layers of cell bodies and synaptic processes 
which are formed by six major neuronal cell types (Figure 1.2) (reviewed in detail 
by Bloomfield and Dacheux, 2001). The three layers of neurons present are the 
outer nuclear layer (ONL), inner nuclear layer (INL) and the ganglion cell layer 
(GCL). The ONL contains the cell bodies of photoreceptors. Vertebrate retinal 
photoreceptors are divided into two basic categories: rods and cones. Rods are 
more light-sensitive and used for vision at low light levels (scotopic vision, night 
vision). Cones need higher light levels and are used for daylight (photopic) vision. 
Furthermore, cones also provide colour vision. At intermediate (mesopic) light 
levels both rods and cones contribute to vision. The different sensitivity of rods and 
cones originates in their different morphological and biochemical properties such 
as different amounts of visual pigment and different amplification factors of the 
phototransduction cascade (see Figure 1.3). The sensitivity of rod vision is further 
increased by a high convergence of the rods onto their postsynaptic neurons, the 
rod bipolar cells, which improves the signal-to-noise ratio. As a consequence of 
these distinct functional properties rod/cone ratios vary considerably across
20
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Figure 1.1 Cross section of the human eye.
The retina is the innermost layer of the eye and is responsible for conveying 
visual signals to the brain. Adapted from Webvision 
(http://webvision.med.utah.edu/).
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mammals roughly correlating with the daily activity pattern (Ahnelt and Kolb, 2000). 
The INL contains the cell bodies of horizontal cells, bipolar cells and amacrine 
cells. The GCL contains displaced amacrine cells and ganglion cells which form 
the output from the retina to the brain via the optic nerve. These layers of cell 
bodies are separated by synaptic layers which contain most of the fine dendrites 
and synapses of the retina. These layers are the outer plexiform layer (OPL) which 
connects the ONL and the INL and the inner plexiform layer (IPL) which lies 
between the INL and the GCL (Figure 1.2).
1.2 Structure and function of rod photoreceptors
Vertebrate rod photoreceptors consist of a cell body, a light-sensitive outer 
segment and a synaptic terminal (reviewed by Bloomfield and Dacheux, 2001).
The cell body or rod inner segment (RIS) is divided into three regions namely 
nuclear, myoid and ellipsoid which contain most of the cell metabolic machinery. At 
either end of the cell body there are two fundamental functional domains, the 
synaptic terminal and the outer segment. The rod outer segment (ROS) is a 
membranous organelle derived from a modified primary cilium which is designed 
for light absorption and phototransduction. It consists of a stack of approximately 
1000 flattened disk membranes which are separated from and surrounded by 
plasma membrane and contain 104-106 molecules of rod opsin per disk which 
account for over 80% of the intrinsic membrane protein (Nir and Papermaster,
1983; Hicks and Molday, 1986). The plasma membrane of the outer segment is 
connected to the cell body via connecting cilium. Distally, the outer segments of 
rod photoreceptors are associated with apical processes of the retinal pigment 
epithelium (RPE). The RPE connects photoreceptors and the choriocapillaris, 
constitutes one aspect of the blood-retinal barrier and is necessary for 
photoreceptor development and function. In addition the RPE is responsible for the 
homeostasis of the photoreceptor environment, recycling and metabolism of 
vitamin A as part of the visual phototransduction cascade and shedding of 
photoreceptor disks as part of outer segment turnover (Thompson and Gal, 2003).
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Figure 1.2 Structural organisation of the retina in higher vertebrates.
a) Cross section of the human retina. The structure of the retina is based upon 
alternate layers of cell bodies and synaptic processes which are formed by six 
major neuronal cell types. RPE: Retinal pigment epithelium; OLM: Outer limiting 
membrane; ONL: Outer nuclear layer; OPL: Outer plexiform layer; INL: Inner 
nuclear layer; IPL: Inner plexiform layer; GCL: Ganglion cell layer; ILM: Inner 
limiting membrane b) Schematic diagram illustrating the cell types and organisa­
tional layers present in the retina of higher vertebrates. Adapted from Webvision 
(http://webvision.med.utah.edu/).
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1.3 Phototransduction and the visual cycle
The rod photoreceptor cell light sensor, rhodopsin, is composed of the rod opsin 
protein covalently linked to the chromophore, 11-c/s-retinal. Phototransduction 
begins when 11-c/s-retinal is isomerised by a captured photon (Figure 1.3) 
(reviewed in Park et a/., 2006). Upon photoisomerisation from 11-c/s-retinal to all- 
trans-retinal, rhodopsin undergoes a series of conformational changes resulting in 
the conversion of rhodopsin to metarhodopsin II (R*). R*, the active form of 
rhodopsin, interacts with and binds to the photoreceptor-specific heterotrimeric G 
protein transducin. Transducin activation involves the interaction between R* with 
the guanosine diphosphate (GDP)-bound form of the transducin apy trimer which 
results in the rapid exchange of bound GDP for guanosine triphosphate (GTP) on 
the a-subunit of transducin. This is followed by the dissociation of transducin from 
R* as well as the dissociation of the active a-subunit of transducin from its p and y 
subunits. The activated a-subunit of transducin disinhibits cyclic guanosine 
monophosphate (cGMP) phosphodiesterase (PDE), resulting in the hydrolysis of 
cGMP to 5'-GMP. The resulting decrease in cytoplasmic concentration of cGMP 
triggers the closure of cGMP-gated Ca2+ channels. The consequent reduction in 
cytosolic Ca2+ levels results in hyperpolarisation of the cell and the modified 
membrane potential becomes transmitted as a neural signal.
As in all G protein-coupled receptor (GPCR) signalling pathways it is necessary to 
inactivate all the activated intermediaries of phototransduction, so the pathway can 
be ready for signalling again (reviewed in Bunemann and Hosey, 1999). A rapid 
deactivation occurs through the phosphorylation of rhodopsin on multiple serine 
and threonine residues at the C-terminus region by rhodopsin kinase (Shichi and 
Somers, 1978). The phosphorylated rhodopsin is then bound by another protein, 
arrestin, inhibiting the interaction between rhodopsin and transducin and therefore 
preventing continuous signal transmission (Zuckerman and Cheasty, 1986). 
Following the binding of arrestin, all-frans-retinal is hydrolysed and released 
allowing a new molecule of the chromophore, 11-c/s-retinal, to bind.
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Figure 1.3 Vertebrate phototransduction.
Schematic diagram representing vertebrate phototransduction in the rod opsin 
segments (ROS) of rod photoreceptors including the mechanisms of activation 
and inactivation of rhodopsin. When light strikes the retina it activates rhodopsin 
(R) by causing the isomerization of covalently attached 11-c/s-retinal at Lys296 to 
all-trans-retinal (1). Activated rhodopsin (R*) interacts with and activates transdu- 
cin (2). The activation of transducin involves the exchange of guanosine diphos­
phate (GDP) for guanosine triphosphate (GTP),which results in the dissociation 
of the transducin a-subunit GTP from the transducin (py-subunit) complex and 
rhodopsin. The activated transducin (a)-GTP in turn activates cyclic guanosine 
monophosphate (cGMP) phosphodiesterase (PDE) (3), resulting in the hydrolysis 
of cGMP to 5’-GMP (4). The decrease in cGMP levels closes the cGMP-gated 
calcium channels (5) in the plasma membrane of photoreceptors leading to a 
decrease in calcium influx and the consequent hyperpolarization of the cell. The 
decrease in intracellular calcium concentration also disinhibits guanylate- 
cyclase-activating protein (GCAP) which leads to the activation of guanylate 
cyclase and consequent resynthesis of cGMP, ensuing the continuity of the cycle. 
The desensitisation of rhodopsin (R*/Rn*) is mediated by the phosphorylation of 
rhodopsin kinase (RK) (6), which induces the uncoupling of G-protein trimeric 
complexes and the consequent binding of arrestin (Arr) (7). Adapted from 
Mendes et al (2005).
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This results in the completion of the cycle by the release of arrestin and the 
dephosphorylation of rhodopsin by protein phosphatase A (PPA) (Palczewski et ai, 
1989). The recycling of the chromophore also occurs at this stage as all-trans- 
retinal reductase reduces all-frans-retinal to all-frans-retinol (vitamin A) which is 
consequently reconverted to 11-c/s-retinal in the RPE.
The absorption of a photon by rod opsin causes R* to stimulate the visual 
phototransduction cascade. This is quickly followed by R* decay to yield free all- 
frans-retinaldehyde (atRAL) and apo-opsin. Before light sensitivity can be restored 
to apo-opsin, the atRAL must be chemically re-isomerised to 11-c/s-retinaldehyde 
(11cRAL) by an enzymatic pathway called the visual cycle (Figure 1.4). Most steps 
in this pathway take place within the RPE and a key step in this pathway involves 
the all-trans to 11-c/s re-isomerisation of the retinoid. The isomerase has recently 
been identified as the Rpe65 (Jin et a/., 2005).
1.4 Rod opsin: the prototypical G-protein coupled receptor
1.4.1 Structure of rod opsin
The gene encoding human rod opsin was identified by Nathans and Hogness 
(1984) and had a length of approximately 7000 base pairs. The coding region of 
the human rhodopsin gene consisted of five exons which were interrupted by four 
introns located at positions analogous to those found in the previously 
characterised bovine rhodopsin gene (Nathans and Hogness, 1983). The amino 
acid sequence of human rhodopsin deduced from the nucleotide sequence of its 
gene was 348 residues long which had a molecular mass of -4 0  kDa and was 
93.4% homologous to that of bovine rod opsin (Nathans and Hogness, 1984). The 
rod opsin protein, as other GPCR's, is an integral membrane protein which 
comprises a cytoplasmic (intracellular) domain, an intradiscal (extracellular) 
domain and seven transmembrane helices whose crystal structure has recently 
been determined at a resolution of 2.8 A (Palczewski et a/., 2000) (Figure 1.5). This 
crystal structure suggested that rod opsin had a compact intradiscal area, parts of
26
HO
11cR E s ^ h ^>c - r
LRATl I llcREH .
»? /bounoiuy* 11cRAL £
W I V^CRALBP/
O C ^ O ,  J
11cR 0L c h .o h
f
Rpebb | isomerase
a/RE's LRAT a/ROL
RPE cell
HcRDH's
rhodopsin m c - n h  
(11CRAL) ^
apo-opsn metarhodopsm
afRAl 
|  a/l
a/ROl
CHO
o r ,o h
rod outer segment
Figure 1.4 Visual cycle for regeneration of rhodopsin.
The light-sensitive protein in rods is rhodopsin, in the membranes of the outer 
segment. The 11-c/s-retinaldehyde (11cRAL) chromophore is coupled to rhodop­
sin through a protonated Schiff-base linkage. Absorption of a photon (hv) induces 
11 -cis to all-trans isomerization of retinaldehyde to yield metarhodopsin, which 
activates the visual transduction cascade. The all-trans-retinaldehyde (atRAL) 
subsequently dissociates from apo-opsin and is reduced to all-trans-retinol 
(atROL) by all-frans-retinol dehydrogenase (atRDH). The atROL diffuses from 
the outer segment and is taken up by an RPE cell, where it is transferred to a 
fatty acid from phosphatidylcholine by lecithin-retinol acyl transferase (LRAT) to 
yield an all-frans-retinyl ester (atRE). The atRE is converted to 11-c/s-retinol 
(11cROL) by the Rpe65. The 11cROL is oxidized by one of several 11cROL 
dehydrogenases (11cRDHs) to yield 11cRAL. 11cROL and 11cRAL are bound to 
CRALBP. The 11cRAL diffuses back to the outer segment where it combines with 
apo-opsin to form a new rhodopsin pigment molecule. Modified from Jin et al 
(2005).
Figure 1.5 Ribbon drawings of the structure of rhodopsin obtained by 
diffraction data extending to 2.8 angstroms resolution.
A) Parallel to the plane of the membrane (stereoview). A view into the membrane 
plane is seen from the cytoplasmic (B) and intradiscal side (C) of the 
membrane. From Palczewski et al., 2000.
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which fold inwards to enclose the chromophore. This compact structure involves 
the second extracellular loop and Cys-187 which forms a disulfide bond with Cys- 
110 near the extracellular surface of transmembrane helix III. Furthermore, the 
intradiscal domain contains two asparagine-linked (N-linked) oligosaccharides 
attached to Asn-2 and Asn-15 although neither of these oligosaccharide chains 
appeared to make structural contacts with the protein. In contrast with the 
extracellular domain, the cytoplasmic domain was not as compact or highly 
organised (Palczewski et a/., 2000). These structural studies indicated higher 
plasticity in the C-terminus of rod opsin and this might be required for function.
1.4.2 Role of N-linked glycosylation in rod opsin folding and function
The role of N-linked glycosylation in the maturation of Drosophila rhodopsin was 
investigated by using in vitro mutagenesis and germline transformation to create a 
Drosophila mutant, delta Asn20, lacking the N-linked glycosylation site near the 
amino terminus of the major rhodopsin (O’Tousa, 1992). This mutation resulted in 
low rod opsin protein levels and age-dependent deterioration of rhabdomere 
organisation. This suggested that an N-linked glycosylation site, and likely 
glycosylation itself, might play a critical role in the maturation of Drosophila 
rhodopsin.
Work carried out in Khorana's lab has examined the role of N-linked glycosylation 
in vertebrate rod opsin folding and function (Kaushal et a/., 1994). Bovine wild-type 
rod opsin was expressed in transiently transfected COS-1 cells in the presence of 
the glycosylation inhibitor tunicamycin and the resulting non-glycosylated rod opsin 
was transported to the plasma membrane of the cell. However, non-glycosylated 
rhodopsin showed severe reduction of light-dependent activation of transducin 
when compared to the glycosylated rhodopsin (Kaushal et al., 1994). Furthermore, 
these authors investigated the role of N-linked glycosylation on rod opsin folding 
further by introducing amino acid replacements in the region of the two 
glycosylated sites. Mutations at or near Asn-2 had little effect on cell surface 
expression, binding to the chromophore or transducin activation (Kaushal et al.,
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1994). In contrast, mutations at Asn-15 or Lys 16 resulted in rod opsin which was 
defective in cellular transport and formed little or no chromophore with 11-c/s- 
retinal (Kaushal et al., 1994). These data combined suggested that glycosylation of 
rod opsin was not required for its folding to an apparently correct ground-state 
structure, but it appeared necessary for full activity in signal transduction.
1.4.3 Role of the intradiscal and cytoplasmic domains on rhodopsin 
structure and function
The role of the intradiscal domain in rod opsin structure and function was 
investigated by carrying out deletions in all the intradiscal loops and in the N- 
terminal tail of rod opsin (Doi et al., 1990). Most of the deletions in the intradiscal 
loops and the N-terminus were defective proteins which failed to bind the 
chromophore and showed mannose-rich oligosaccharides characteristic of 
glycosylation in the ER (Doi et al., 1990). These defective rod opsin structures 
resulted from relatively short deletions in the intradiscal loops B-C, D-E, F-G (see 
Figure 1.7 for the secondary structure of rod opsin) or the N-terminal tail and 
suggested that these segments were all cooperatively involved in forming a 
specific folding structure in the intradiscal face. In contrast, mutations in the loops 
C-D and E-F in the cytoplasmic domain did not affect regeneration of the rhodopsin 
chromophore but resulted in reduced or ablated ability to activate transducin 
(Franke et al., 1992). These data suggested that the intradiscal domain of rod 
opsin might have a structural function whereas the cytoplasmic domain might carry 
out biochemical and regulatory functions.
1.4.4 Synthesis of rod opsin in photoreceptors
Synthesis of rod opsin is initiated in the endoplasmic reticulum (ER) and further 
modifications occur in the Golgi of the RIS. In order to accomplish the long 
distance transport of newly synthesised rod opsin on post-Golgi carriers towards 
the ROS these vesicles fuse with the plasma membrane surrounding the 
connecting cilium through which rod opsin is delivered to the ROS. The importance 
of the C-terminus of rod opsin for its transport to the ROS was demonstrated by Tai
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and colleagues (1999) which suggested that dynein was responsible for the 
translocation of rhodopsin-bearing vesicles along microtubules and that this 
interaction occurred directly between the C-terminal cytoplasmic tail of rhodopsin 
and Tctex-1, a dynein light chain. Furthermore, transgenic mice showed abnormal 
accumulation of the Q344ter mutant rod opsin in the plasma membrane of the 
photoreceptor cell body, indicating that the rod opsin C-terminus is required for 
efficient transportation to or retention in the outer segment (Sung et al., 1994).
More specifically, the C-terminus sorting motif of rod opsin appeared to bind 
specifically to the small GTPase ARF4, a member of the ARF family of membrane 
budding and protein sorting regulators (Deretic et al., 2005) which was essential for 
the generation of post-Golgi carriers targeted to the ROS of retinal photoreceptors.
1.5 Mutations in rod opsin cause autosomal dominant retinitis
pigmentosa (ADRP)
Retinitis pigmentosa (RP) is the name given to a heterogeneous group of inherited 
disorders with an incidence of 1 in 3500 and for which there is currently no cure.
RP is a highly variable disorder with some patients developing symptomatic visual 
loss in childhood whereas others remain asymptomatic until mid-adulthood. The 
first symptoms in many patients are difficulties with dark adaptation and night 
blindness in adolescence followed by loss of mid-peripheral visual field in 
adulthood. As the disease progresses peripheral vision is lost, resulting in tunnel 
vision, prior to central vision being lost. These visual symptoms are a result of the 
gradual degeneration of the two photoreceptor types: rods, which mediate 
achromatic vision in dim conditions; and cones, which are necessary for colour 
vision and fine acuity in daylight. Ultrastructural studies in the retinas of RP 
patients obtained at autopsy indicate a reduced density of rods and cones in the 
affected regions (Flannery etal., 1989; Chappie eta!., 2001). Furthermore, the 
photoreceptors were characterised by shortened and severely distorted outer 
segments. In addition to photoreceptors, other areas of the retina are also affected 
by RP, although it is widely accepted that these secondary effects are a result of 
photoreceptor degeneration and not necessarily a direct consequence of RP. The
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rate of retinal degeneration can be measured by the rod electroretinogram (ERG) 
amplitudes, a measure of retina function. Patients with RP have ERG's which are 
reduced in amplitude, becoming progressively smaller as the disease evolves. At 
advanced stages of RP pigmentary deposits can be observed on the surface of the 
retina (Figure 1.6) hence the name retinitis pigmentosa. Mutations linked non- 
syndromic to RP have been identified in over 35 genes. The underlying genes for 
26 of these loci have been reported (http://www.sph.uth.tmc.edu/RetNet/ provided 
in the public domain by the University of Texas Houston Health Science Center, 
Houston, TX). For autosomal dominant RP (ADRP), which accounts for 20% to 
40% of all cases, 14 genes have been identified and population surveys of subsets 
of these genes suggest that the known ADRP genes may account for between one 
fourth to one half of cases or families screened at the Laboratory for Molecular 
Diagnosis of Inherited Eye Diseases, Houston (Sullivan et al., 2006).
Mutations in the rhodopsin gene represent the most common single cause of RP. 
Dryja and colleagues (1990) were the first to associate a mutation in the rhodopsin 
gene to RP by identifying a point mutation which replaced proline for histidine at 
position 23 (P23H) in the intradiscal domain of rod opsin. Since then over 120 point 
mutations (Figure 1.7) and at least 10 small deletions in the rhodopsin gene have 
been identified in patients with RP (Appendix A). Although some of the mutations in 
the rhodopsin gene cause recessive RP (E150K, G174S, E249ter and G284S) and 
congenital stationary night blindness (CSNB) the vast majority is associated with 
ADRP.
Seminal work by Nathans and Khorana groups showed that several pathological 
mutations in the rhodopsin gene failed to fold correctly (Sung et al., 1991; Kaushal 
and Khorana, 1994; Sung etal., 1994). Following the analysis of several mutations 
in structure-function studies two different classes of ADRP-linked rod opsin 
mutations were proposed. Class I mutations occurred in the C-terminus of the 
protein, resembled wild-type protein in their translocation to the plasma membrane 
and formed a functional chromophore with 11-c/s-retinal. The vast majority of the
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Figure 1.6 A comparison of normal and retinitis pigmentosa (RP) fundus.
Retinal dystrophies are classified by ophthalmoscopic findings (fundus exami­
nation), psychophysics and electrophysiology, age of onset, and genetics or 
family history. Fundus examination in RP patients typically shows pigmentation 
in a bone-spicule’ pattern in the retina, pallor of the optic nerve and narrowing 
of retinal blood vessels.
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ADRP mutations however were named Class II which resulted in misfolding of the 
mutant protein defined by the inability to form a functional chromophore with 11- 
c/'s-retinal and retention in the ER. Recent detailed studies of other rod-opsin 
mutations have suggested that different biochemical and cellular defects might also 
arise and this resulted on the proposal of a new expanded classification for rod 
opsin mutations to encompass these new data (Figure 1.7) (Mendes et al., 2005).
The requirement of a tertiary structure in the intradiscal region with a disulfide bond 
between Cys-110 and Cys-187 for the correct assembly and/or function of 
rhodopsin have been elucidated by Davidson and colleagues (1994). Furthermore, 
it was suggested that the formation of a disulfide bond in the intradiscal domain 
other than the Cys-110 and Cys-187 resulted in the misfolding of the protein and 
the inability to bind the chromophore. More recently, other studies suggested that 
the replacement of cysteine at position 110 by alanine (C110A), phenylalanine 
(C110F) and tyrosine (C110Y) led to the formation of an abnormal Cys-185 - Cys- 
187 disulfide bond which resulted in the absence of 11-c/s-retinal binding (Hwa et 
al., 1999). These observations have since been confirmed by mass spectrometric 
analysis and extended to several other misfolded rod opsin mutants which 
contained the abnormal disulfide bond Cys-185 - Cys-187 in the intradiscal domain 
(Hwa eta!., 2001).
1.6 Potential mechanisms of cell death in rhodopsin RP
An understanding of the mechanisms of cell death initiated by these rod opsin 
mutations is fundamental in order to delineate future therapeutic strategies. The 
pharmacological approaches reported in this Thesis represent therapeutic 
strategies aimed at Class II mutants only. Dominance in ADRP patients could be 
due to loss-of-function, gain-of function, dominant-negative mutations, or any of the 
above in combination (Wilson and Wensel, 2003). There are two lines of evidence 
suggesting that loss-of-function mutations alone are not likely to cause ADRP. 
Firstly, none of the dominant rod opsin alleles that have been investigated appear 
to be null mutations. Secondly, heterozygous rhodopsin knockout mice showed
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Figure 1.7 Secondary structure of rod opsin.
Secondary structure of rod opsin showing the location of point mutations listed in 
Appendix A where the transmembrane helices are labelled A-G. Mutated residues 
are highlighted in colours corresponding to different classifications. Class I 
mutants (light blue) refer exclusively to rod opsin mutations that fold normally but 
are not correctly transported to the ROS. Class II (green) refers to mutations that 
misfold, are retained within the ER and cannot easily reconstitute with 11-c/s- 
retinal. Class III mutations correspond to mutations that affect endocytosis 
(purple). Class IV mutations do not affect folding per se but might affect rod-opsin 
stability and post-translational modification (orange). Class V (dark blue) mutants 
have no obvious initial folding defect but show an increased activation rate for 
transducin. Mutants that appear to fold correctly but lead to the constitutive 
activation of rod opsin in the absence of chromophore and in the dark constitute 
Class VI (red). Mutations that have no observed biochemical or cellular defect, or 
have not been studied in detail, should remain unclassified (grey). The secondary 
structure of rod opsin is based on the crystal structure by Palczewski et al (2000) 
(Figure 1.4). Modified from Mendes et al (2005).
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little photoreceptor degeneration (Lem etal., 1999). These observations suggest 
that haploinsufficiency, or the inadequate expression of rod opsin, in itself is not the 
cause of ADRP. This leaves the possibility that the dominant alleles might be due 
to gain-of-function or dominant-negative mutations.
1.6.1 Gain of function mechanisms
1.6.1.1 The unfolded protein response
In transfected cells heterologously expressed wild-type rod opsin translocates to 
the plasma membrane, whereas class II mutant rod opsins, such as P23H (the 
most common cause of ADRP in North America) are retained within the ER (Sung 
etal., 1991; Kaushal and Khorana, 1994; Frederick et al., 2001; Saliba etal., 2002; 
Chappie and Cheetham, 2003). Furthermore, some mutant rod opsins are bound 
by the ER-resident chaperones BiP and Grp94 (Anukanth and Khorana, 1994). In 
addition to the folding and maturation of proteins, the ER performs other essential 
functions such as lipid synthesis and Ca2+ storage. The tight regulation and 
maintenance of ER homeostasis is vital. Disturbance of Ca2+ homeostasis during 
hypoxia, or imbalance between the demand and capacity of the protein-folding 
apparatus, initiates an adaptive response of the cell, termed the unfolded protein 
response (UPR, or ER stress response) (Rutkowski and Kaufman, 2004). The 
accumulation of misfolded rod opsin within the ER is likely to cause ER stress and 
could induce the UPR. The UPR is known to alleviate ER stress by reducing the 
accumulation of misfolded proteins. ER-localized chaperones are induced, protein 
synthesis is slowed, and protein degradation enhanced. However, if ER stress 
cannot be alleviated, the UPR can culminate in cell death by apoptosis (Pathway 1, 
Figure 1.8). Some of the molecules and mechanisms implicated in the transition 
from adaptive response to pro-apoptotic cascade have been identified; including 
CHOP, caspase activation, Ca2+ release and mitochondrial signalling.
Unfortunately, little is understood about how these mechanisms are integrated and 
able to commit a cell to apoptosis. Nevertheless, the possible overloading of the 
UPR by Class II mutant rod opsins represents an attractive potential mechanism 
for the induction of cell death in RP (Frederick et al., 2001).
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1.6.1.2 Aggregation and inclusion formation
The retention of Class II mutant rod opsins in the ER by the cellular quality control 
machinery is followed by their retro-translocation from the ER and degradation by 
the ubiquitin proteasome system (UPS) (Saliba etal., 2002; llling etal., 2002). Like 
other aggregation prone proteins, if the mutant rod opsin is not degraded by the 
UPS it aggregates in the cytosol. These protein aggregates then coalesce into 
ubiquitinated proteinaceous inclusions (Saliba et al., 2002; llling etal., 2002;
Kopito, 2000). Protein aggregation can directly impair the function of the UPS 
(Bence, 2001) and P23H rod opsin expression inhibited UPS activity in HEK-293 
cells (llling et al., 2002). Ubiquitin-dependent proteolysis has a central role in 
regulating many fundamental cellular events, and such an inhibition by mutant rod 
opsins could stimulate further aggregation and initiate a cascade that would lead to 
apoptosis (Pathway 2, Figure 1.8; Figure 1.9).
Rod opsin aggregates may possess other gain of function properties that could 
affect photoreceptor viability. For example, prefibrillar protein aggregates may have 
inherent and common pathways for cytotoxicity involving Ca2+ and reactive oxygen 
species (Bucciantini etal., 2004) (Pathway 3, Figure 1.8). Furthermore, rod opsin 
aggregates and inclusions can recruit other cellular proteins, such as chaperones 
(Saliba et al., 2002; Chappie and Cheetham, 2003) or wild-type rod opsin. 
Chaperones may not be ‘trapped’ within such structures, but could be actively 
attempting to rescue other proteins from these aggregates and inclusions (Kim et 
al., 2002). The sequestration of photoreceptor proteins could have deleterious 
effects on photoreceptor viability (Pathway 4, Figure 1.8). The depletion of 
essential cellular components by sequestration in protein aggregates has been 
proposed as a potential disease mechanism for several neurodegenerative 
diseases and may also be relevant to retinal degeneration, as has been 
demonstrated for spinocerebellar ataxia type 7 (SCA7) polyglutamine aggregates 
and CRX, a homeodomain transcription factor which contains a glutamine rich 
region (Chen et al., 2004).
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Figure 1.9 Schematic diagram illustrating the process of inclusion forma­
tion in the cell.
Misfolded rod opsin (1) can be retrotranslocated from the ER and be ubiqui- 
tinated and rapidly degraded by proteasome (2) or aggregate and inhibit the 
proteasome (3). Small aggregates (4 and 5) can transported to the microtubule 
organising center (MTOC) and coalesce into large intracellular inclusions where 
they co-localise with molecular chaperones (6).
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Electron dense inclusions of rhodopsin have been observed in both human ADRP 
and animal models of rhodopsin ADRP (Bunt-Milam et al., 1983; Li et al., 1998), 
but the presence of inclusions tends to be a feature of the later stages of disease. 
Therefore, their significance to the disease process is unclear. In cultured cells the 
formation of these inclusions requires an intact microtubule network (Saliba et al., 
2002; llling et al., 2002) and is it likely that their presence would interfere with the 
normal function of the cytoskeleton within photoreceptors (Pathway 5, Figure 1.8). 
Alternatively, intracellular inclusions have been suggested to be a protective 
mechanism against more toxic smaller aggregates (Arrasate etal., 2004), or 
another attempt by the cell to degrade the aggregated protein by autophagy 
(Ravikumar et al., 2004). Microtubules in photoreceptors are organized around the 
basal bodies within the specialized non-motile connecting cilium at the junction 
between the outer and inner segment. This highly specialized microtubule 
organization could limit the capacity of photoreceptors to clear protein aggregates 
by the type of dynein-mediated processes that concentrate aggregated proteins in 
pericentriolar inclusion bodies (Kopito, 2000). Without such a mechanism to 
sequester toxic rod opsin aggregates into inclusion bodies the photoreceptor could 
be more exposed to aggregate related toxicity and this could lead to 
photoreceptors dying without the formation of visible inclusions.
Although the role of large inclusions in disease is unclear their formation is a 
surrogate marker of misfolding (Kopito, 2000) (Figure 1.9). This marker was 
exploited in a cellular model (Chapter 3) in order to monitor P23H rod opsin 
misfolding.
1.6.2 Dominant-negative mechanisms
Although the mechanisms discussed so far point towards ADRP being caused by 
gain-of-function mutations in the rod opsin gene, other studies suggest that a 
dominant-negative pathogenesis could be equally plausible. Studies of some Class 
II mutants of Drosophila rhodopsin, NinaE (e.g. ninaE0*; S137F), showed that the 
misfolded mutant rod opsin had a dominant effect on the post-translational
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maturation of the normal rod opsin protein (Kurada et al., 1998). Such a potential 
dominant-negative effect has been confirmed by recent studies in mammalian cells 
(Saliba et al., 2002). Co-expression of a Class II mutant rod opsin with wild-type 
rod opsin in COS-7 cells led to the formation of intracellular proteinaceous 
inclusions that contained the wild-type protein (Saliba et al., 2002). This suggested 
that when both wild-type and mutant rod opsin were co-expressed, as in 
heterozygous ADRP patients, the mutant rod opsin could affect the processing of 
the wild-type protein. More recently, these observations have been extended to 
show that Class II mutants can impair the delivery of the wild-type protein to the 
plasma membrane in HEK-293 cells (Rajan and Kopito, 2005). Furthermore, the 
mutant and wild-type rod opsin appeared to form high molecular weight, detergent- 
insoluble complexes, in which the two proteins were in close (<70 A) proximity. Co­
expression of Class II mutants also resulted in the enhanced proteasome-mediated 
degradation and steady-state ubiquitination of the wild-type protein (Rajan and 
Kopito, 2005).
Mice lacking rod opsin fail to form rod outer segments and develop progressive 
retinal degeneration, indicating that rhodopsin plays an important role in 
assembling or stabilizing outer segments (Humphries et al., 1997; Lem et al.,
1999). As heterozygous rhodopsin knock-out mice show very mild retinal 
degeneration (Lem et al., 1999), there must be a rhodopsin ‘threshold’ between 
zero and one copy for photoreceptor integrity. In the absence of wild-type rod opsin 
a Class II mutant rod opsin also will not elaborate outer segments (Frederick et al.,
2001), suggesting that these mutants cannot contribute to the stabilization of the 
outer segment. Curiously, when wild-type protein is present, the bulk of the mutant 
protein is in the outer segment, hinting that the interplay between the mutant and 
wild-type protein may work both ways (Li et al., 1996; Frederick et al., 2001). A 
dominant effect of misfolding mutant rod opsins on the biosynthesis and/or 
maturation of the wild-type protein could reduce the amount of newly synthesized 
wild-type rod opsin that matures beyond the ER in photoreceptors. This would 
reduce the amount of rod opsin that gets to the outer segment possibly leading to
41
outer segment shortening and ultimately photoreceptor instability (Pathway 12, 
Figure 1.8).
1.7 Protein misfolding and aggregation underlie the pathogenesis 
of a variety of neurodegenerative diseases
In order to become functionally active, a newly synthesised polypeptide chain must 
fold into a unique three-dimensional structure. In the cell protein folding may fail as 
a result of mutations, posttranslational modifications, or environmental stresses 
such as changes in pH or temperature. Many misfolded proteins inappropriately 
expose hydrophobic domains which are normally buried in the protein or at the 
interface with other subunits. Furthermore, integral membrane proteins such as rod 
opsin have extensive hydrophobic stretches which are normally embedded in the 
lipid bilayer (Palczewski et al., 2000). In either case failure to translocate or 
integrate such proteins renders these hydrophobic domains exposed to the 
aqueous environment of the cytosol which can lead to protein aggregation.
Protein folding is facilitated by molecular chaperones that are recruited to assist in 
the folding of newly synthesised nascent chains, but are also involved in the 
assembly and disassembly of supramolecular protein structures. Many molecular 
chaperones also named heat shock proteins (Hsp's) are synthesised in response 
to environmental stresses and comprise several classes of proteins (e.g Hsp90, 
Hsp70, Hsp60, and small Hsp's). Molecular chaperones such as Hsp70 transiently 
interact with unfolded or partially folded intermediates and prevent their 
hydrophobic surfaces from forming incorrect intermolecular and intramolecular 
interactions, therefore promoting the folding of polypeptide chains (reviewed in 
Barral et al., 2004).
Aggregation of mutant proteins in the brain is a widely characterised and well 
accepted phenomenon in a variety of neurodegenerative diseases: such as tau 
and p-amyloid in Alzheimer's disease (reviewed by Selkoe, 2001); a-synuclein in 
Parkinson’s disease (reviewed by Paleologou et al., 2005); polyglutamine
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expansions in Huntington’s disease (Trottier et al., 1995); and accumulation of 
prion protein in prion protein diseases (Grenier etal., 2006). Far less established is 
whether the formation of these inclusions is related to toxicity or cytoprotection. 
Some studies suggested a link between inclusion formation and toxicity. For 
example, expression of pathological polyglutamine repeats in 293 Tet-Off cell lines 
resulted in the formation of toxic intracellular inclusions determined by nuclear 
observations (Waelter et al., 2001). In addition, there was a redistribution of the 
ER-resident chaperone BiP and the heat-shock proteins Hsp40 and Hsp70 
suggesting a cellular response to stress. Furthermore, inclusions appeared to be 
encircled by the intermediate filament vimentin and contain several proteasomal 
subcomplexes which might inhibit proteasomal activity and disrupt the UPR 
pathway of the cell leading to further aggregation (Waelter et al., 2001). Different 
studies, however, indicated that inclusion formation can be dissociated from toxicity 
and might represent a cellular protective response to aggregation. In order to 
investigate the relationship between inclusions and toxicity in a cell model of 
Parkinson's disease, Tanaka and colleagues (2004) over-expressed a-synuclein 
and its interacting partner synphilin-1 using engineered 293T cells, followed by the 
manipulation of inclusion incidence using proteasome inhibitors and microtubule 
disrupting agents. These authors suggested that a-synuclein-induced apoptosis 
was not coupled with increased prevalence of inclusion-bearing cells and that the 
caspase inhibitor z-VAD-fmk while significantly reducing the number of apoptotic 
cells had no impact on the percentage of aggresome-positive cells. Consequently, 
this data indicated a disconnection between inclusion formation and apoptosis, and 
supported a protective role for these inclusions from the toxicity associated with the 
combined over-expression of alpha-synuclein and synphilin-1 (Tanaka etal.,
2004).
Although it is unclear whether large intracellular inclusions are toxic perse or 
represent a cytoprotective response to aggregation, the accumulation of misfolded 
proteins is increasingly recognized as a key pathogenic feature of degenerative 
diseases. Furthermore the inhibition of early misfolding steps and consequent
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aggregation of mutant huntingtin exon 1 protein prevented photoreceptor 
degeneration and improved motor function in a fly model of Huntington’s disease 
(Ehrnhoefer et al., 2006). In terms of delineating therapeutic strategies for 
rhodopsin RP it would be important to assess if the pharmacological manipulation 
of misfolded rod opsin can be achieved and whether it has beneficial effects.
1.8 Aims of this thesis
Previous studies investigating the Class II misfolding rod opsin mutants suggested 
that the mutant protein misfolded, was retained in the ER and coalesced in 
intracellular inclusions. The main aim of this thesis was to develop a cellular model 
using wild-type and P23H rod opsin which mimics the disease process in ADRP 
patients and allows the analysis of both the gain of function and the dominant- 
negative mechanisms of cell death induced by these mutations. Futhermore, the 
model could be used to test and characterise novel rod opsin mutations identified 
in patients.
This model was used to determine if pharmacological compounds can alleviate the 
gain of function mechanism of cell death in cells expressing P23H rod opsin either 
by reducing inclusion incidence, promoting the folding of mutant protein, or 
reducing cell death.
The model was also used to assess if the interaction between wild-type and P23H 
rod opsin in a cell model of rhodopsin RP could be suppressed by pharmacological 
agents and consequently be beneficial in a potential dominant-negative 
mechanism of cell death occurring in ADRP patients.
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Chapter 2: Materials and methods
2.1 Reagents
1-deoxynojirimycin (1-DNJ), 17-Allylamino-17-demethoxygeldanamycin (17-AAG), 
4',6-Diamidino-2-phenylindole dihydrochloride (DAPI), 9-c/s-retinal, dimethyl 
sulphoxide (DMSO), geldanamycin, N-butyldeoxynojirimycin (NB-DNJ), radicicol, 
rapamycin, resveratrol, trehalose, trimethylamine N-oxide (TMAO) were purchased 
from Sigma (Poole, UK). 11-c/s-retinal was a kind gift from Prof Paula Booth 
(University of Bristol). Arimoclomol was a kind gift from Dr Linda Greensmith (UCL, 
Institute of Neurology) Celastrol was from Cayman Chemical Company (Tallinn, 
Estonia). Salubrinal was purchased from Calbiochem (Darmstadt, Germany). 
Lipofectamine and plus reagent were from Invitrogen (Paisley, UK). EndoH and 
PNGaseF were from New England Biolabs (Hitchin, UK). The primary antibody 
1D4 to rhodopsin was obtained from Professor Robert Molday (UBC) via the 
National Cell Culture Centre, (Minneapolis, MN). Cy3 goat anti-mouse Cy3 
conjugated secondary antibody was from Jackson Immuno Research Laboratories 
(West Grove, PA) and the goat anti-mouse antibody conjugated to horseradish 
peroxidase was from Pierce (Rockford, IL). Bovine WT opsin in pMT3 was a gift 
from Prof Daniel Oprian (Brandeis). Wild-type and mutant untagged and GFP- 
tagged rod opsins were obtained from Richard Saliba (Saliba et al., 2002).
2.2 Site-directed mutagenesis (SDM) of rod opsin constructs
G90V-GFP was constructed by using the QuikChange II site-directed mutagenesis 
(SDM) kit purchased from Stratagene (La Jolla, CA) using WT-GFP as a template. 
The conditions for PCR are listed below:
5 pi of 10* reaction buffer (Stratagene)
5 ng of WT-GFP
125 ng of forward primer: 5' CATGGTCTTCGGTGTCTTCACCACCACCC 3'
125 ng of reverse primer: 5' GGGT GGT GGT GAAGACACCGAAGACCAT G 3'
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0.2 mM of dNTPs (Stratagene)
1 pi 50x polymerase mix (Stratagene) 
ddhhO to a final volume of 50 pi
Cycling parameters:
1) 95°C
2) 95°C 
55°C 
68°C 5 minutes and 45 seconds
30 seconds
30 seconds
1 minute
2.2.1 Transformation and purification of SDM products
Following the thermal cycling the digestion of the amplification products was 
carried out by adding 1 pi of the Dpn I restriction enzyme (10 U/pl). Each reaction 
mixture was mixed by pipetting the solution up and down several times prior to 
centrifugation for 1 minute and incubation at 37°C for 1 hour in order to digest the 
parental, non-mutated, supercoiled dsDNA. The transformation of XL1-Blue 
supercompetent cells was carried out on ice. 50 pi of the supercompetent cells 
were added to a 14 ml Falcon tube prior to the transfer of 1 pi of the Dpn l-treated 
DNA. This mixture was heat-shocked at 42°C for 45 seconds and placed on ice for 
2 minutes. 0.5 ml of Luria-Bertani (LB) broth pre-heated to 42°C was added and 
the transformation reactions were incubated at 37°C for 1 hour shaking at 225 rpm. 
100 pi of transformation reactions were then plated on agar plates containing 30 
pg/ml kanamycin and incubated at 37°C for 16 hours.
5 ml of LB broth containing 30 pg/ml kanamycin were inoculated with a single 
colony and incubated for 16 hours at 37°C. Plasmid DNA was purified from the 
overnight culture using a GFX Micro Plasmid Prep Kit purchased from Amersham 
Pharmacia Biotech (Little Chalfont, UK) according to the manufacturers 
instructions. 1.5 ml of inoculated LB broth were placed into 1.5 ml microcentrifuge 
tubes and centrifuged for 30 seconds to pellet the cells. The supernatant was
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removed and the pellets wee resuspended in 150 pi of solution I (100 mM Tris- 
HCL, 10 mM EDTA, 400 pg/ml Rnase I), followed by the addition of 150 pi solution 
II (1 M NaOH, 5.3% SDS) and incubated at 22°C for 2 minutes. Then 300 pi of 
solution III were added to the cell lysates and mixed by inverting the 1.5 ml tubes 
10 times. The lysates were centrifuged at 17500g for 5 minutes at 22°C. The 
supernatant was transferred to a GFX column (containing a glass fibre matrix) and 
incubated for 1 minute at 22°C. The GFX columns were centrifuged for 30 seconds 
at 17500g and then washed by adding 400 pi of wash buffer (10 mM Tris-HCL pH
8.0, 1 mM EDTA, 80% ethanol). The GFX columns were then centrifuged for 60 
seconds at 17500g to remove the wash buffer. The DNA was eluted from the 
columns by the addition of 50 pi of sterile ddH20 and then the columns were 
centrifuged for 1 minute to collect the DNA solution in sterile 1.5 ml microcentrifuge 
tubes. The resulting purified DNA was then analysed for the presence of the 
correct insert by restriction enzyme digests. The DNA was then sequenced to 
ensure that the plasmid contained the correct mutation.
2.3 Cell culture
2.3.1 Transfection of SK-N-SH cells
SK-N-SH human Caucasian neuroblastoma cells were obtained from the European 
Collection of Cell Cultures (ECACC) (Salisbury, UK), and grown in 
DMEM/NUT.MIX.F12 with Glutamax-I, 10% v/v heat inactivated foetal bovine 
serum (FBS), 50 U/ml penicillin and 50 pg/ml streptomycin in an humidified 
atmosphere of 6% CO2 at 37°C. For fluorescence, permanox 8-well chamber slides 
were seeded at a concentration of 2.5x104 cells per chamber. 24 hours after 
seeding cells were transfected using 0.5 pi of lipofectamine enhanced with 1 pi of 
plus reagent per chamber in 100 pi of serum-free media for 3 hours according to 
the manufacturer instructions. The total amount of plasmid DNA used was 200 
ng/chamber. For single plasmid studies 100 ng of the plasmid were added together 
with 100 ng of pcmvTag3a. For co-transfection studies 100 ng of each plasmid
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were added. Following this period, 20% v/v FBS media was added in equal 
volume in order to restore a 10% v/v FBS solution.
For biochemical assays, 6-well plates or 96-well plates were used and both the cell 
density and the transfection conditions were adjusted to the size of the surface 
area. 6-well plates were seeded with 5x105 cells per well with each well being 
transfected 24 hours later using 4 pi of lipofectamine, 8 pi of plus reagent and a 
total amount of plasmid DNA of 1.6 pg per well in 800 pi of serum-free media for 3 
hours. 96-well plates were seeded at 5x103 per well and each well was transfected 
using 0.1 pi of lipofectamine, 0.2 pi of plus reagent and a total of 40 ng of plasmid 
DNA in 50 pi of serum-free media for 3 hours. In both cases, following the 3 hour 
period, 20% v/v FBS media was added in equal volume in order to restore a 10% 
v/v FBS solution.
2.3.2 Drug treatments
All drug treatments were carried out upon the re-establishment of the 10% v/v FBS 
concentration following the 3 hours serum-free period unless otherwise stated. The 
list of compounds used in this study is shown in Table 2.1.
2.4 Fluorescence and immunofluorescence microscopy
2.4.1 Fluorescence
SK-N-SH cells transfected with GFP-tagged opsin were washed three times with 
4°C phosphate buffer saline (PBS: 137 mM NaCI, 2.7 mM KCI, 8.1 mM Na2HP04,
1.5 mM KH2P 04i pH 7.3 at 25 °C) 24 hours after transfection, followed by fixation 
with 3.7% v/v paraformaldehyde for 15 minutes at 22°C. Cells were then washed 
four times in PBS and incubated with 2 pg/ml DAPI (stock 10 mg/ml of 4',6- 
Diamidino-2-phenylindole dihydrochloride in DMSO) in PBS for 5 minutes in the 
third wash.
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Compound Stock Supplier
9-c/s-retinal 50 mM in ethanol Sigma
11-c/s-retinal 1.8 mg in ethanol Prof Paula Booth
DMSO >99% Sigma
TMAO 1 M in dH20 Sigma
4-PBA Powder Fluka
Trehalose Powder Fluka
Arimoclomol 100 mM in dH20 Prof Linda Greensmith
Celastrol 100 mM in DMSO Cayman
Geldanamycin 10 mM in DMSO Sigma
Radicicol 5 mM in ethanol Sigma
17-AAG 10 mM in methanol Sigma
Rapamycin 5 mM in chloroform Sigma
Salubrinal 100 mM in DMSO Calbiochem
Resveratrol 10 mM in ethanol Sigma
1-DNJ 5 mM in dH20 Sigma
NB-DNJ 5 mM in dH20 Sigma
Table 2.1 List of pharmacological agents used in this study.
All compounds were added immediately after the serum-free transfection period 
and were diluted in a 20% FBS media unless otherwise stated.
49
2.4.2 Immunofluorescence
24 hours after transfection cells were washed three times with 4°C PBS and fixed 
using 3.7% v/v paraformaldehyde for 15 minutes followed by two washes with 
PBS. Permeabilisation was carried out using 0.1% v/v Triton X-100 for 5 minutes, 
followed by two washes in PBS. Prior to the incubation with antibodies cells were 
blocked for 30 minutes at 22°C with a blocking solution consisting of 3% w/v 
albumin and 10% v/v normal donkey serum in PBS. Cells were incubated with 1D4 
rhodopsin antibody (0.5 pg/ml) in blocking solution for 1 hour at 22°C followed by 
three washes in PBS and incubation for 1 hour at 22°C with donkey anti-mouse 
Cy3 conjugated secondary antibody (1:100) in blocking solution. Cells were 
consequently washed four times in PBS and DAPI was used at a concentration of 
2 pg/ml in PBS for 5 minutes in the third wash. Inclusion incidence and cellular 
morphology counts were carried out using a 40x objective in a Leica DMRBE 
epifluorescence microscope. Fluorescence and immunofluorescence were 
visualised using a Zeiss LSM 520 laser scanning confocal microscope. The 
following excitation/emission conditions were used in separate channels with the 
63x oil immersion objective: DAPI 364/475-525 nm, GFP 488/505-530 nm, Cy3 
543/560 nm.
2.5 Assessment of the cellular localisation of rod opsin
Inclusion incidence was carried out by scoring the percentage of transfected cells 
which contained inclusions. Cellular morphology studies were carried out by 
scoring the predominant localisation of rod opsin in transfected cells: plasma 
membrane (PM), ER, and inclusions as a percentage of transfected cells. The data 
presented in the dominant-negative studies represents the predominant cellular 
localisation of untagged wild-type rod opsin in co-transfected cells. Before initiating 
these experiments I have carried out extensive training which comprised counting, 
analysing and discussing cellular morphology in parallel with Professor Michael 
Cheetham in order to gain proficiency and standardise results. The data presented 
in this Thesis represent experiments which were carried out double blind with
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Professor Michael Cheetham loading unknown samples randomly in 8-chamber 
slides and Hugo Mendes analysing cellular morphology and counting inclusions 
unaware of the respective treatments. For each condition 400 cells were counted 
and each experiment was repeated at least four times.
2.6 Preparation of cell extracts for Western blotting
24 hours after transfection cells were washed twice with 4°C PBS and lysed using 
190 pi 1% v/v Triton X-100 in PBS + 10 pi protease inhibitor cocktail for use with 
mammalian cell and tissue extracts (Sigma). Cells lysates were scraped from wells 
and collected in 1.5 ml microcentrifuge tubes on ice prior to centrifugation at 
17500g for 30 minutes at 4°C. The amount of protein in the soluble cell lysates was 
calculated by a protein assay based on the method of Bradford and 10 pg of cell 
lysate protein were mixed with an equal volume of 2x modified Laemmli sample 
buffer (1x sample buffer: 50 mM Tris-HCL pH 6.8, 2% w/v SDS, 10% v/v Glycerol, 
2.5% v/v 2-mercaptoethanol, 0.1% w/v bromophenol blue) and run on a 10% v/v 
polyacrylamide gel. The stacking gel was made up of 4% v/v polyacrylamide in 
0.375 M Tris-HCL (pH 6.8) with 0.1% w/v SDS. The resolving gel was made up of 
10% v/v polyacrylamide in 0.125 M Tris-HCL (pH 8.8) containing 
acrylamide:bisacrylamide in a ratio of 30:1. The Tris-glycine running buffer 
contained 25 mM Tris-HCL, 250 mM Glycine and 0.1% SDS. Bio-Rad (Hercules, 
CA) low range molecular weight markers were used as molecular weight 
standards.
Proteins were transferred from 10% v/v polyacrylamide gels to nitrocellulose using 
a semi dry electrophoretic transfer cell (Bio-Rad). The electrotransfer buffer was 
made up of 25 mM Tris, 192 mM glycine and 20% v/v methanol. Electrotransfer of 
proteins was carried out for 15 minutes at 15 V. For immunodetection of rod opsin 
on the mitrocellulose blots, 1D4 was used at a concentration of 1.33 pg/ml in PBS 
plus 5% w/v Marvel™ plus 0.1% v/v Tween-20 for 1 hour followed by three 5 
minute washes in PBS + 0.1% v/v Tween 20. The blot was then incubated with
51
goat anti-mouse HRP 1:30000 in PBS plus 1% w/v Marvel™ plus 0.1% v/v Tween- 
20 followed by three 5 minute washes in PBS + 0.1% v/v Tween 20.
The ECL plus chemiluminescent detection reagent was purchased from GE 
Healthcare (Amersham, UK) and used according to the manufacturer’s 
instructions. The mobility of different opsin glycoforms were determined by 
digesting 10 pg of soluble cell lysates using Endoglycosidase H (EndoH) and 
Peptide N-glycosidase F (PNGaseF) for 2 hours at 37°C. The deglycosylation 
reactions were as follows:
EndoH reaction:
EndoH cloned from Streptomyces plicatus and over expressed in E.coli was 
supplied in 20 mM Tris-HCL (pH 7.5), 50 mM NaCI, 5 mM Na2 EDTA. 10x G5 
buffer: 0.5 M sodium citrate (pH 5.5).
Triton-X soluble lysate 10 pg
10xG5 buffer 2 pi
EndoH (500 U/pl) 1 pi (500 U)
ddH20  to 20 pi
Total reaction volume 20 pi
Reaction was incubated for 2 hours at 37 °C
PNGaseF reaction:
PNGaseF purified from Flavobacterium meningosepticum was supplied in 20 mM 
Tris-HCL (pH 7.5 at 25°C), 50 mM NaCI, 5 mM Na2EDTA and 50% glycerol. 10x 
G7 buffer: 0.5 M sodium phosphate (pH 7.5 at 25 °C).
Triton-X soluble lysate 10 pg
10xG7 buffer 2 pi
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PNGaseF (500 U/|jl) 1 M> (500 U) 
ddH20  to 20 Ml
Total reaction volume 20 pi
Reaction was incubated for 2 hours at 37 °C
2.7 Rod opsin fractionation assay
SK-N-SH cells were seeded on 6-well dishes and transfected with GFP-tagged rod 
opsin as described above. Total, soluble and insoluble fractions were obtained 24 
hours after transfection. Total fractions were obtained by lysing cells with 190 pi of 
RIPA buffer + 10 pi of protease inhibitor cocktail (RIPA buffer: 50 mM Tris-HCL pH
8.0, 150 mM w/v NaCI, 1 mM EDTA, 1% v/v NP-40, 0.1% w/v SDS, 0.05% w/v 
sodium deoxycholate). Soluble fractions were obtained by lysing cells with 190 pi 
of RIPA buffer + 10 pi of protease inhibitor cocktail followed by centrifugation at 
17500g for 30 minutes at 4°C and removal of the supernatant. Insoluble fractions 
were obtained by re-suspension of the pellet in 190 pi of RIPA buffer + 10 pi 
protease inhibitor cocktail. Protein concentration was measured by a protein assay 
based on the Bradford method. 50 pg of the total and soluble fractions were loaded 
onto a 96-well dish. The amount of insoluble fraction loaded was based on the 
volume corresponding to 50 pg of soluble fraction. Each condition was then 
normalised to 200 pi with RIPA buffer. Fluorescence was measured by using a 
Tecan Safire microplate reader with 488/509 nm emission/excitation wavelengths 
with a bandwidth of ± 2.5 nm and optimal gain. Experiments were carried out at 
least three times in triplicates (n=3) and the data shown is representative of one 
experiment.
2.8 Lactate dehydrogenase (LDH) cell death assay
SK-N-SH cells were seeded on a 96-well dish at a concentration of 5x103 
cells/well. 24 hours later cells were transfected with GFP-tagged opsin and the 
LDH assay obtained from Roche (Basel, Switzerland) was carried out 24 hours and 
48 hours after transfection. 96-well dishes were centrifuged at 250g for 15 minutes 
at 22°C. 100 pi of supernatant was removed and placed in another 96-well dish.
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100 |jl of reaction mixture (250 |jl of diaphorase/NAD+ mixture plus 11.25 ml of dye 
solution containing iodotetrazolium chloride and sodium lactate) per well, prepared 
according to the manufacturers instructions, were added to the supernatants and 
incubated at 22°C for 30 minutes protected from light. Absorbance was then 
measured at 492 nm using a Tecan Safire microplate reader. Experiments were 
carried out at least three times in triplicates (n=3) and the data shown is 
representative of one experiment.
The LDH activity was determined in an enzymatic test: In the first step NAD+ was 
reduced to NADH/H+ by the LDH-catalyzed conversion of lactate to pyruvate. In the 
second step the catalyst (diaphorase) transferred H/H+ from NADH/H+ to the 
tetrazolium salt I NT (2-[4-iodophenyl]-3-[4-nitrophenyl]-5-phenyltetrazolium 
chloride) which was reduced to formazan.
An increase in the amount of dead or plasma membrane-damaged cells resulted in 
an increase of the LDH enzyme activity in the culture supernatant. This increase in 
the amount of enzyme activity in the supernatant directly correlated to the amount 
of formazan formed during a limited time period. Therefore, the amount of color 
formed in the assay was proportional to the number of lysed cells. The formazan 
dye formed is water-soluble and showed a broad absorption maximum at about 
500 nm, whereas the tetra-zolium salt INT showed no significant absorption at 
these wavelengths.
2.9 Caspase-3 activity assay
A colorimetric caspase-3 activity assay was used based on the protocol of 
Novoselova TV et al (2005). SK-N-SH cells were seeded in a 6-well dish at a 
concentration of 5x105 cells/well followed by transfection with GFP-tagged opsin 24 
hours later. 24 hours or 48 hours after transfection cells were washed twice with 
4°C PBS followed by lysis with 190 pi buffer A (25 mM HEPES pH 7.5, 1 mM 
EDTA, 5 mM EGTA, 50 mM NaCI) + 10 pi protease inhibitor cocktail. 100 pi of 
buffer B (50 mM HEPES pH 7.5, 20% v/v glycerol, 1 mM EDTA, 5 mM DTT
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containing 200 |jM DEVD-pNA caspase-3 substrate (Calbiochem) was added to 50 
pg of total protein followed by incubation for 4 hours at 37°C. Absorbance was 
measured at 405 nm using a Tecan Safire microplate reader. Experiments were 
carried out at least three times in triplicates (n=3) and the data shown is 
representative of one experiment.
2.10 Fluorescence resonance energy transfer (FRET)
2.10.1 Cloning of WT and P23H rod opsin into CFP and YFP vectors
WT-GFP rod opsin was digested with Agel and Bam HI using the multicore 
restriction enzyme buffer (Promega): 1x buffer is 25 mM Tris-Acetate (pH 7.5 at 
37°C), 100 mM potassium acetate, 10 mM magnesium acetate, 1 mM DTT. DNA 
samples were mixed with 6x blue orange loading dye (orange G, bromophenol blue 
and xylene cyanol) and were loaded onto a 1% w/v agarose gel made up in 1x 
Tris-acetate (TAE) buffer: 40 mM TAE and 1 mM EDTA. DNA was visualised on a 
UV transilluminator and the band corresponding to rod opsin was excised using a 
scalpel. DNA was recovered using a gel purification kit purchased from Qiagen 
(Crawley, UK).
Ligation reactions of rod opsin to pECFP-N1 and pEYFP-N1 were carried out by 
using a ratio of vector DNA to insert DNA of 1:4 in the presence of 1x T4 DNA 
ligase and 1x T4 DNA ligase buffer (10x T4 ligase buffer: 300 mM Tris-HCL (pH 
7.8), 100 mM MgCb, 100 mM DTT and 10 mM ATP) in a total volume of 10 pi. The 
reaction mixtures were incubated at 4 °C for 16 hours. 5 pi of the ligation reaction 
was added to 50 pi of competent JM109 E.coli cells and incubated for on ice for 20 
minutes prior to heat shock at 42 °C for 120 seconds. Cells were then added to 
pre-warmed (42°C) LB broth and incubated at 37 °C for 60 minutes. 50 pi and 200 
pi of cell suspension were plated onto agar plates containing 30 pg/ml of 
kanamycin which were then incubated for 16 hours at 37 °C. CFP and YFP 
plasmid purification was carried out as described in Chapter 2.2.1.
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2.10.2 Cell culture and FRET measurements
24 hours before transfection SK-N-SH cells were seeded on Matek dishes at a 
concentration of 5x104 cells/dish. Cells were transfected using lipofectamine and 
plus reagent as described above. The total amount of plasmid DNA used was 400 
ng/dish and cells were transfected as follows: 200 ng WT-CFP + 200 ng WT-YFP; 
200 ng WT-CFP + 200 ng P23-YFP and 200 ng P23H-CFP + 200 ng P23H-YFP in 
a serum-free media for 3 hours prior to reconstitution to a 10% FBS media. After 
24 hours FRET acceptor bleaching was carried out on live cells maintained in a 
humidified atmosphere of 6% CO2 at 37°C using a Leica TCS SP2 AOBS.
2.11 Statistical analysis
Paired and unpaired Student’s t-tests were carried out where appropriate. The sets 
of values were considered statistically significant the p £ 0.05.
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Chapter 3: Development and characterisation of a
cellular model for rhodopsin RP
3.1 Introduction
Despite the wealth of genetic data originating from several research groups the 
precise mechanisms by which mutations in rod opsin induce rod cell death remain 
largely unknown. Dominance and consequent rod photoreceptor cell death in 
ADRP patients can either be attributed to loss-of-function mutations, gain-of- 
function mutations, or dominant-negative mutations (Wilson and Wensel, 2003). 
However, the interpretation of several studies suggested that loss-of-function 
mutations were unlikely to be the causative factor of ADRP in humans. Firstly, 
none of the dominant rod opsin alleles that have been investigated appears to be a 
null mutation. Secondly, hemizygous mice with a single copy of rod opsin (+/-) 
showed mild photoreceptor degeneration when compared to the homozygous (-/-) 
counterparts (Frederick et al., 2001). Consequently these observations suggest 
that dominant alleles in ADRP are either due to gain-of-function or dominant- 
negative mutations.
The development of therapeutic strategies for late onset neurodegenerative 
diseases is a major challenge and this is only partially associated with the poor 
understanding of the mechanisms of cell death. The late onset of these diseases 
makes the creation of relevant in vivo models costly and time consuming with each 
experimental cycle taking several weeks, months or years. In order to test a variety 
of pharmacological compounds with the potential to be of use for patients with 
these conditions it is paramount to develop rapid and less expensive in vitro 
assays which mimic the disease process in a shorter period of time.
Soon after the identification of rod opsin mutations in early nineties several 
research groups heterologously expressed rod opsin molecules in mammalian cell
57
culture in order to investigate the relationship between those mutations and the 
potential mechanisms of rod cell death (Sung et al., 1991; Sung et al 1993;
Kaushal and Khorana 1994). The expression of wild-type rod opsin in cell culture 
revealed properties which related to its in vivo function in photoreceptors such as 
correct folding, translocation from the ER to the plasma membrane and 
reconstitution with the chromophore, 11-c/s-retinal. On the other hand the majority 
of mutants characterised (Class II) misfolded, were retained in the ER, 
accumulated in large intracellular inclusions and failed to reconstitute with the 
chromophore.
Mammalian cell culture has been used to investigate the mechanisms associated 
with a variety of other neurodegenerative diseases. For example, in vitro model 
systems were used to demonstrate that the formation of huntingtin protein 
inclusions was dependent on the polyglutamine repeat length (Scherzinger et al., 
1997), although it remained unclear if inclusion formation was the cause of 
Huntington's disease or merely a consequence of disease progression. Other 
laboratories used truncated fragments of the huntingtin protein in NG108-15 
mouse-rat neuroblastoma-glioma hybrid cells and associated inclusion formation to 
cell death (Lunkes and Mandel, 1998) although these data were contradicted by 
Saudou et al (1998) who indicated that aggregation of a mutant huntingtin fragment 
in striatal neurons in culture perse was not required to induce cell death.
Cell models were also used to investigate cell death mechanisms in Parkinson's 
disease. Following the identification of mutations in a-synuclein as the cause of 
some rare forms of familial Parkinson’s disease, cell culture models using human 
neuroblastoma SH-SY5Y demonstrated that human wild-type and mutant a- 
synuclein self-aggregated and induced apoptotic cell death suggesting that the 
accumulation of a-synuclein and its degradation products may play a role in the 
development of the pathogenesis of this disease (El-Agnaf et al., 1998).
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Other studies have investigated the mechanisms associated with Alzheimer's 
disease where its neuropathology involved the accumulation of (3-amyloid peptide 
(AP) in senile plaques. For example, experiments in primary neuronal cultures have 
indicated that Alzheimer's disease-linked mutated forms of A3 precursor protein 
caused aggregation of Ap and consequent neuronal loss (Loo etal., 1993). 
Importantly, cell culture models have been widely used to study not only the 
mechanisms of disease but also potential therapeutic interventions in 
neurodegenerative diseases as it will be discussed in later Chapters.
The characterisation of a cell model for rhodopsin RP is described in this chapter 
using SK-N-SH human neuroblastoma cells. This model has several benefits 
compared to other previously published rhodopsin RP cell culture models. Firstly, 
both the gain-of-function and the dominant-negative mechanisms of cell death for 
any potential rod opsin mutation can be investigated. Secondly, due to its high 
transfection efficiency the efficacy of drugs which might be of benefit for rhodopsin 
RP patients can not only be qualitatively but also quantitatively assessed against 
possible mechanisms of photoreceptor cell death
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3.2 Results
3.2.1 Localisation of WT and P23H rod opsin in SK-N-SH cells
The green fluorescent protein (GFP) from the jelly fish Aequorea victoria has 
become a widely used molecular reporter which facilitates the investigation of a 
variety of processes from gene reporting to intercellular trafficking both in vivo and 
in vitro. A variety of proteins fused with GFP including rod opsin (Saliba etal.,
2 0 0 2 ) mostly maintain similar biological properties and intracellular trafficking 
patterns of their untagged counterparts. GFP-tagged rod opsin constructs 
described in Saliba et al (2002) were expressed in SK-N-SH cells in order to 
determine the localisation of wild-type and P23H rod opsin, a prototypical Class II 
rod opsin mutant. 24 hours after transfection the SK-N-SH cells were fixed and 
visualised using fluorescence microscopy.
When GFP was transfected into SK-N-SH cells it showed a cytoplasmic staining 
pattern. In contrast, wild-type rod opsin (Figure 3.1b) was predominantly present 
on the plasma membrane of SK-N-SH cells. This was in agreement with previously 
reported cell based models (Sung et al., 1991; Kaushal and Khorana, 1994; Saliba 
et al., 2 0 0 2 ) which investigated rod opsin and was the result of correct folding and 
consequent translocation through the secretory pathway from the ER to the plasma 
membrane of the cells.
P23H rod opsin (Figure 3.1c), on the other hand, was retained in the ER and no 
predominant plasma membrane staining was observed. Furthermore, in a 
proportion of the cells mutant rod opsin accumulated in large intracellular 
inclusions. Intracellular inclusions are a common feature of a variety of 
neurodegenerative diseases where the mutant protein misfolds and aggregates 
(Chapter 1). In addition to a different cellular localisation pattern, the levels of P23H 
rod opsin fluorescence were reduced when compared to the wild-type rod opsin.
60
Inclusions
£ 40
WT P23H
O  WT
□  P23H
e
50-
45 -</>
I  4 0 - 
f i  35 - 
-  30- 
25 -
8 15-
10 -
5 -
6 9 18 24 36 48
Hours after transfection (h)
Figure 3.1 Characterisation of cellular morphology and inclusion incidence 
in cells transfected with WT and P23H rod opsin.
SK-N-SH cells were transfected with pEGFP-N1 (a), WT-GFP (b) and P23H-GFP 
(c) and fixed after 24 hours. GFP fluorescence was represented in green and 
DAPI-stained nuclei represented in blue, a) Cells expressing the empty GFP 
vector showed a general cytoplasmic staining, b) Expression of WT rod opsin 
resulted in a predominantly plasma membrane (PM) staining pattern (arrow),
c) P23H rod opsin expression led to retention of the mutant protein in the ER 
(arrowhead) or accumulation in large intracellular inclusions (*). Scale bar =
10 pm. d) Quantification of cellular morphology in cells expressing WT and P23H 
rod opsin after 24 hours, e) Time course of inclusion incidence in WT and P23H 
cells. Error bars represent ± 2x standard error (2SE).
61
The incidence of inclusions observed in the controls was relatively consistent 
throughout the range of experiments performed. Inclusions were in present in -2 -  
3% of cells expressing wild-type rod opsin after 24 hours (Figure 3.1d) possibly 
due to the property that when transiently transfecting cells it is impossible to control 
the amount of rod opsin expressed in each cell and high amounts of any protein 
might lead to the saturation of the cellular machinery and consequent misfolding. In 
cells expressing P23H rod opsin, however, the inclusion incidence varied between 
20% and 30% although in the vast majority of studies -25%  of the cells in the 
transfected population had inclusions after 24 hours (Figure 3.1d) whereas the 
remaining cells had mutant rod opsin retained in the ER suggesting widespread 
misfolding and inability to progress through the secretory pathway.
A time-course of inclusion incidence in wild-type and P23H cells was carried out by 
fixing the cells at various time points after transfection (Figure 3.1e). P23H cells 
were first observed to form inclusions 6  hours after transfection and inclusion 
incidence rose steadily after. Inclusions were present in -25%  of cells after 24 
hours and -40%  of transfected cells after 48 hours. Despite having higher inclusion 
incidence in P23H cells after 48 hours, 24 hours was chosen as the most 
appropriate time point for morphological analysis as deleterious effects on cellular 
morphology started appearing in P23H-transfected cells subjected to longer 
incubation periods probably due to cell death (Figure 3.5). On the other hand, low 
levels of inclusions appeared after 18 hours in WT cells and the inclusion incidence 
remained at the 2-3% basal levels independent of the incubation period (Figure 
3.1e).
By using the human neuroblastoma cell line SK-N-SH it was possible to 
differentiate wild-type and P23H rod opsin on the basis of morphology and 
inclusion incidence. The quantitative analysis of inclusion incidence could therefore 
serve as a surrogate marker of protein misfolding and allow the investigation of the 
extent to which a mutation causes rod opsin misfolding. Moreover, this quantitative
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approach could be used to test the effect of drugs on the rod opsin misfolding itself 
or on the consequences of misfolding (see later Chapters).
3.2.2 Morphological assessment of the rod opsin mutants K296E, G90D, 
G90V and F276V
3.2.2.1 K296E
Keen and colleagues (1991) identified a severe form of RP associated with a 
mutation in rhodopsin which involved a base substitution at codon 296. This altered 
the lysine residue which functions as the attachment site for the chromophore, 1 1 - 
c/'s-retinal, mutating it to glutamic acid (K296E). This mutation rendered K296E rod 
opsin unable to bind 1 1 -c/s-retinal and resulted in the mutant protein being 
constitutively active (Zhukovsky et al., 1991). K296E-GFP plasmid DNA produced 
by Saliba et al (2002) was expressed in SK-N-SH cells and showed morphological 
properties associated with Class II mutants such as inability to translocate to the 
plasma membrane, retention in the ER, and accumulation in large intracellular 
inclusions (Figure 3.2a-b) which was in agreement with previous studies (Saliba et 
al., 2 0 0 2 ).
3.2.2.2 G90D
The mutation glycine to aspartic acid at position 90 (G90D) of rod opsin is a Class 
VI mutation which causes congenital night blindness and constitutively activates 
rod opsin (Rao et al., 1994). When expressed in SK-N-SH cells G90D rod opsin 
translocated to the plasma membrane (Figure 3.2c-d) and exhibited a phenotype 
similar to that of wild-type rod opsin. This was in contrast with the K296E mutation 
which, while also constitutively activating rod opsin, showed morphological 
properties of a Class II mutant.
3.2.2.3 G90V
We were approached by Dr Andrew Webster (Institute of Ophthalmology, 
Moorfields Eye Hospital) and asked to characterise a novel mutation which 
involved the substitution of glycine for valine at codon 90 of rod opsin (G90V). This
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Figure 3.2 Characterisation of cellular morphology in cells expressing 
K296E, G90D, G90V and F276V rod opsin.
SK-N-SH cells were transfected with K296E-GFP (a-b), G90D-GFP (c-d), G90V- 
GFP (e-f) and F276V-GFP (g-h) and fixed after 24 hours, a) Expression of K296E 
rod opsin resulted in retention of the protein in the ER (arrowhead) and accumu­
lation in intracellular inclusions (*). Expression of both G90D (c) and G90V (e) rod 
opsin led to a phenotype similar to WT with the majority of cells showing a 
predominant PM staining (arrows), g) Cells expressing F276V rod opsin showed 
retention in the ER (arrowhead) and accumulation in intracellular inclusions (*) 
albeit to a lesser extent than K296E cells. Scale bar = 10 jim . Error bars repre­
sent ± 2SE.
amino acid change was identified in a family with CSNB (Kabaranou et al., 2004).
A G90V-GFP rod opsin plasmid was created by site directed mutagenesis (see 
Chapter 2 for details). G90V rod opsin translocated to the plasma membrane and 
exhibited a phenotype similar to G90D and the wild-type protein (Figure 3.2e-f). 
Despite the similar phenotypes of G90D and G90V observed in this cell model for 
rhodopsin RP, Neidhardt and colleagues (2006) have recently suggested by 
homology modelling that the G90V mutation could lead to misfolding. They 
identified this change in a Swiss family where it caused a phenotype compatible 
with ADRP unlike the G90D mutation which caused CSNB (Rao et al., 1994).
3.2.2.4 F276V
Dr Smaragda Kamakari (University of Crete) and colleagues identified a mutation 
in a family of Greek RP patients which involved the substitution of phenylalanine 
for valine at codon 276 of rod opsin. When F276V rod opsin was expressed in SK- 
N-SH cells it misfolded, was retained in the ER and accumulated in large 
intracellular inclusions (Figure 3.2g-h) indicating that this mutation could be 
classified as a Class II. However, the phenotype was less severe than other 
misfolding mutations (e.g P23H and K296E) as ~60% of F276V cells showed 
plasma membrane staining (Figure 3.2h).
3.2.3 Characterisation of soluble WT and P23H rod opsin species
The biosynthesis of glycoproteins involves both the ER and the Golgi of the cell. 
Cotranslational insertion in the ER is responsible for the synthesis of the 
polypeptide and addition of the core oligosaccharide, the covalent coupling of 
glycan and polypeptide, and for the initial modification of the glycans. Once the 
glycoproteins have folded and oligomerised properly they are trafficked to the Golgi 
where this process is continued by further trimming and modification of N-linked 
glycans. Bovine rod opsin is N-linked glycosylated at asparagine residues 2 and 15 
(Hargrave et al., 1977) and the oligosaccharides are modified as the protein 
translocates through the secretory pathway prior to reaching the plasma 
membrane in cell culture.
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In order to investigate the degree of N-linked glycosylation and consequent 
maturity of wild-type and P23H rod opsin species, SK-N-SH cells were seeded on
6 -well dishes as described in Chapter 2 and transfected with untagged wild-type or 
P23H rod-opsin prior to lysis after 24 hours with 190 pi of 1% Triton-X + 10 pi of 
protease inhibitor cocktail. Untagged rod opsin species were used as GFP-tagged 
opsins were retained in the stacking gel and failed to enter a 10% SDS-PAGE gel. 
100 pi of total protein fraction was removed at this stage (T) and the remainder was 
separated into soluble (S) and insoluble (P) fractions by centrifugation at 17500g 
for 15 minutes at 4°C. Wild-type and P23H transfections had a similar transfection 
efficiency (-40% ) as observed by immunofluorescence microscopy and 10 pg of 
total protein was loaded and resolved in a 10% SDS-PAGE gel followed by 
immunoblotting with anti-rhodopsin antibody 1D4 which was targeted to the C- 
terminus of rod opsin.
Total and soluble fractions of wild-type rod opsin expressed in SK-N-SH cells 
displayed a similar band pattern with various opsin species migrating from -36  kDa 
to -6 0  kDa (Figure 3.3a). Rod opsin species residing in the ER can be 
distinguished from Golgi and post Golgi species by digestion with the enzyme 
endoglycosidaseH (EndoH). This enzyme exclusively cleaves high mannose 
oligosaccharides or hybrid structures from N-linked glycoproteins and, therefore, 
will only digest ER resident rod opsin species (which are high mannose 
glycoforms) to the core peptide. Most of the wild-type rod opsin species showed 
resistance to digestion with EndoH (Figure 3.3b) suggesting that they had already 
progressed in the secretory pathway from the ER to the Golgi and the plasma 
membrane. Peptide N-glycosidase F (PNGaseF) is an amidase which cleaves 
between the innermost N-acetyglucoseamine and asparagine residue of high 
mannose, hybrid and complex oligosaccharides from N-linked glycoprotein, 
essentially cleaving all N-linked oligosaccharides from glycoproteins. Digestion with 
PNGaseF caused a mobility shift of wild-type rod opsin species as a single -32  
kDa band (Figure 3.3b - arrowhead) suggesting that this corresponded to 
deglycosylated species. These data were in agreement with previously published
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Figure 3.3 Characterisation of soluble WT and P23H rod opsin species.
SK-N-SH cells were transfected with untagged WT or P23H rod opsin and lysed 
with 1% Triton-X 100 after 24 hours, a) 10 pg protein (T), 10 pg 1% Triton-X 
soluble protein (S) and an equal volume of insoluble (P) fraction were resolved on 
a 10% SDS-PAGE gel followed by immunoblotting with 1D4 anti-rhodopsin 
antibody. The 36 kDa band (arrow) is likely to represent glycosylated rod opsin. 
The 25 kDa band (*) and its dimer (**) might represent rod opsin species with a 
truncated N-terminus. b) Triton-X soluble WT species resisted digestion with 
EndoH whereas Triton-X soluble P23H rod opsin (arrow) was mostly cleaved by
EndoH. Digestion with PNGaseF resulted in one major band migrating to ~32
kDa in both WT and P23H-expressing cell lysates (arrowhead). The position of 
molecular weight markers in kDa is shown on the left.
P23H
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data by our lab (Saliba et al., 2002) and others (llling et al., 2002) which suggested 
that wild-type rod opsin migrated as a somewhat broad species bearing complex 
oligosaccharides. No detectable levels of insoluble rod opsin species in the pellet 
fraction were observed when using the anti-rhodopsin antibody 1D4.
The total and soluble fractions of P23H rod opsin expressing cell lysates showed 
three major resolved bands at approximately 25 kDa, 36 kDa and 50 kDa (Figure 
3.3a). The 36 kDa band was likely to represent monomers of glycosylated forms of 
P23H rod opsin. This species was cleaved by EndoH (Figure 3.3b) suggesting that 
they were likely to represent immature P23H rod opsin retained in the ER.
Following digestion with PNGaseF (Figure 3.3b) P23H rod opsin migrated as a 
major ~32 kDa band which was likely to correspond to deglycosylated rod opsin 
species. The immunoreactive species which migrated faster than the ~32 kDa 
band present in this study (~25 kDa) has also been observed in published blots of 
mutant rod opsin (Saliba etal., 2002; Kaushal and Khorana, 1994). This band and 
its dimer (~50 kDa) was not detected when using the N-terminal-specific 4D2 
rhodopsin antibody suggesting that this band might represent rod opsin species 
with a cleaved N-terminus (M. Kosmaoglou, personal communication).
Furthermore, there was considerably less soluble P23H rod opsin than wild-type 
rod opsin. As the transfection efficiencies were similar in both sets of cell lysates it 
is likely that a proportion of P23H rod opsin was either being degraded by the cell 
or aggregating into insoluble forms, as previously shown (Saliba et al., 2002; llling 
et al., 2 0 0 2 ).
Despite various optimisation attempts using different lysis buffers and SDS sample 
buffers the immunoblotting of detectable amounts of the insoluble fractions of wild- 
type and P23H rod opsin was not achieved with most, if not all, the rod opsin 
species not being able to enter the resolving gel. In order to investigate the 
insoluble rod opsin species, a rod opsin fractionation assay was developed which 
was based on the fluorimetric quantification of GFP-tagged rod opsin expressed in 
SK-N-SH cells. While not allowing a qualitative assessment of the insoluble rod
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opsin species this assay provided a quantitative measurement of the extent of 
insoluble rod opsin present in cells expressing the wild-type and P23H proteins.
3.2.4 Development of a rod opsin fractionation assay
The rod opsin fractionation assay was carried by expressing the control GFP- 
vector pEGFP-N1, WT-GFP and P23H-GFP in SK-N-SH cells followed by lysis 
after 24 hours. This assay was optimised by testing a variety of lysis buffers with 
different centrifugation g forces for varied amounts of time. The combination that 
resulted in the highest difference between insoluble amounts of wild-type and 
P23H rod opsin used RIPA as the lysis buffer and the insoluble fraction was 
obtained by centrifugation at 17500g for 30 minutes at 4°C.
The results of this assay are shown in Figure 3.4 and represent the fluorescence 
levels of 50 pg of total protein. The GFP control (Figure 3.4a) was present at a 
higher level in the soluble than in the insoluble fraction (~2 0 :1 ) which was expected 
as it has been widely documented as a soluble protein and fluorescence 
microscopy observations indicated a generalised cytoplasmic staining and absence 
of inclusions in SK-N-SH cells (Figure 3.1a). Similarly WT-GFP showed a higher 
ratio of soluble to insoluble fraction fluorescence (~8 :1 ) which was predicted based 
on the cellular localisation and morphology observed (Figure 3.4b). In complete 
contrast with wild-type rod opsin, the ratio of soluble and insoluble fluorescence in 
P23H rod opsin transfected cells was roughly 1:2 (Figure 3.4c). Furthermore, the 
soluble and the total levels of P23H rod opsin were considerably lower than those 
of wild-type rod opsin which confirmed the morphological observations and the 
soluble fraction steady state levels obtained by Western blots.
This assay enabled the quantification of the soluble and insoluble rod opsin 
species present in transfected SK-N-SH cell lysates. It could, therefore, be used to 
complement the morphological and biochemical data obtained with immunoblotting 
in identifying useful pharmacological therapies in the cell model of rhodopsin RP.
69
pEGFP-N1 WT-GFP P23H-GFP
n
□  Total
□  Soluble
□  Insoluble
m
□  PEGFP-N1
□  WT-GFP
□  P23H-GFP
Figure 3.4 Rod opsin fractionation assay.
SK-N-SH cells were transfected with pEGFP-N1, WT-GFP and P23H-GFP and 
lysed with 190 pi RIPA buffer and 10 pi of protease inhibitor cocktail after 24 
hours. 100 pi were removed and corresponded to the total fraction. The remain­
ing cell lysate was separated into soluble and insoluble fractions by centrifuga­
tion. a) Cells expressing GFP showed a ratio of soluble to insoluble protein of 
-20:1. b) WT cells showed a ratio of soluble to insoluble fraction of -8:1. c) P23H 
cells had ratio of soluble to insoluble protein of -1:2 and the total rod opsin levels 
were-40% of the WT levels, d) P23H-GFP had the highest levels of insoluble rod 
opsin shown as percentage of total protein when compared to the WT or GFP. 
Error bars represent ± 2SE.
70
3.2.5 Effect of WT and P23H rod opsin on cell death and apoptosis
Cell death is a common and necessary process during the nervous system 
development in general and the photoreceptors in particular (reviewed in detail by 
Stone et a/., 1999). The retina is highly stable and can maintain its structure and 
function for the full life of the individual, in humans for many decades. Despite this, 
in healthy adult eyes hundreds of thousands of photoreceptors die throughout life 
(Gao and Hollyfield, 1992) and these processes can be greatly accelerated by 
mutations in a variety of genes, including the rhodopsin gene (Pierce, 2001).
3.2.5.1 Lactate dehydrogenase (LDH) cell death assay
A commercially available lactate dehydrogenase (LDH) assay was used in order to 
assess the effect of the expression of wild-type and P23H rod opsin on cell death.
The optimisation of this assay was carried out by expressing wild-type and P23H 
rod opsin in SK-N-SH cells for 24 hours and 48 hours. P23H rod opsin cells 
showed higher levels of LDH release after 24 (p < 0.05) (Figure 3.5a) and 48 hours 
(p ^ 0.001) (Figure 3.5c) than their wild-type counterparts. Treatment of cells 
expressing P23H rod opsin with 1 pM staurosporine, a potent kinase inhibitor, 
resulted in maximal LDH release. The absorbance for the control GFP transfection 
was removed from the raw absorbance values and these data are shown in Figure 
3.5b and Figure 3.5d for 24 and 48 hours respectively in order to better show any 
rod opsin specific effects. The results of this assay were more robust after 48 hours 
than after 24 hours, therefore, 48 hours was used as the standard time point in 
subsequent experiments.
3.2.5.2 Caspase-3 apoptotic assay
Since the identification of mutations in rod opsin as the cause of ADRP there has 
been a widespread debate on the mechanisms leading to photoreceptor cell death
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Figure 3.5 Lactate dehydrogenase (LDH) cell death assay.
LDH levels were measured in SK-N-SH cells 24 (a-b) and 48 hours (c-d) after 
transfection, a) Cells expressing P23H rod opsin had higher levels of LDH 
release (p £ 0.05) than their WT counterparts, b) LDH release levels in WT and 
P23H cells after 24 hours following subtraction of the GFP background levels, c) 
LDH assay carried out in cells expressing pEGFP-N1, WT-GFP and P23H-GFP 
after 48 hours showed increased LDH release levels in cells expressing P23H 
(p £ 0.001) then compared to the WT cells. Treatment of P23H cells with 1 pM 
staurosporine led to maximal LDH release, d) LDH release in WT and P23H cells 
after 48 hours following subtraction of the baseline GFP background levels. Error 
bars represent ± 2SE.
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with some research groups suggesting that this is a consequence of caspase- 
dependent apoptotic pathways (Samardzija et al., 2006) while others suggested 
that photoreceptor degeneration occurred by a mechanism not involving of 
caspase activation (Zeiss et al., 2004). Several studies which characterised the 
mechanisms of cell death in a variety of animal models favoured the apoptotic- 
dependent photoreceptor degeneration and these include Royal College of 
Surgeons rats (RCS) (Tso etal., 1994) and light-induced photoreceptor 
degeneration in albino rats (Abler et al., 1996). On the other hand, other research 
groups have suggested that light-induced photoreceptor apoptosis in Balb/c mice 
was independent of the activation of several caspases, including caspase-3, which 
is a key regulator of apoptosis (Donovan and Cotter, 2002). Furthermore, 
photoreceptor degeneration could not be inhibited by using the broad range 
caspase inhibitor zVAD-fmk (Donovan and Cotter, 2002).
It was, therefore, important to establish if there were caspase-dependent apoptotic 
pathways induced by the wild-type or P23H rod opsin in a cell model of rhodopsin 
RP. For that purpose a colorimetric caspase activation assay was used based on 
Novoselova et al (2005). The assay was carried out using a commercially available 
caspase-3 substrate. This colorimetric substrate for caspase-3 and related 
caspases was designed so it would assess the amino acid sequence DEVD which 
was based on the caspase-3 cleavage site in poly (ADP-ribose) polymerase 
(PARP). Caspase-3 and related caspase activity can be quantified by 
spectrophotometric detection of free pNA (A = 400 nm) after cleavage from the 
peptide substrate Ac-DEVD-pNA, using a multi-well plate reader and absorbance.
Caspase-3 activity was measured after 24 hours (Figure 3.6a) and 48 hours 
(Figure 3.6c). P23H rod opsin showed higher levels of caspase-3 activity when 
compared to wild-type rod opsin both after 24 (p < 0.005) and 48 hours (p < 0.001). 
The absorbance levels of GFP alone were removed from the raw values and these 
data are shown in Figure 3.5b and Figure 3.5d for 24 and 48 hours respectively.
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Figure 3.6 Caspase-3 activity assay.
Caspase-3 activity levels were measured in SK-N-SH cells 24 (a-b) and 48 
hours (c-d) after transfection, a) Measurement of caspase-3 activity in cells 
expressing pEGFP-N1, WT-GFP and P23H-GFP after 24 hours. There were 
increased caspase-3 activity levels in P23H cells (p £ 0.005) when compared 
to their WT counterparts, b) Levels of caspase-3 activity in WT and P23H 
cells after 24 hours following subtraction of the GFP background levels, c) 
Caspase-3 activity assay carried out in cells expressing pEGFP-N1, WT-GFP 
and P23H-GFP after 48 hours. Increased caspase-3 activity levels were 
observed in P23H cells (p £ 0.001) when compared with WT cells and treat­
ment of P23H cell lysates with 1 pM z-VAD-fmk inhibited caspase-3 activity,
d) Caspase-3 activity in WT and P23H cells after 48 hours following subtrac­
tion of the GFP background levels. Error bars represent ± 2SE.
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The differences between rod opsin species were more robust after 48 hours so this 
was adopted as the standard time point for the caspase-3 activity assay in all 
subsequent experiments. When z-VAD-fmk was added to the assay after lysis, 
absorbance levels in P23H cells were reduced to levels lower than those of the 
wild-type protein showing that the absorbance signal corresponded to caspase-3 
activity.
The LDH and caspase-3 activity assays suggested that the expression of mutant 
rod opsin in cells resulted in higher levels of LDH release and caspase-3 activity 
when compared to the expression of their wild-type counterparts and gave this 
model the scope for analysing the effects of potential pharmacological treatments 
for rhodopsin RP on cell death and apoptosis.
3.2.6 WT and P23H rod opsin co-localise in SK-N-SH cells
A dominant-negative effect of a P23H mutant rod opsin on the wild-type rod opsin 
has been suggested in mammalian cells with the mutant rod opsin leading to the 
accumulation of wild-type protein in intracellular inclusions (Saliba et a/., 2002). 
Furthermore, P23H appeared to interfere with the normal processing of wild-type 
rod opsin to the plasma membrane as both species were present at a close 
proximity (<70 A) suggesting an interaction between the two rod opsin species 
(Rajan and Kopito, 2005).
In order to test the potential dominant-negative effects of the mutant rod opsin on 
the wild-type protein, equal amounts of WT-pMT3 and WT-GFP or WT-pMT3 and 
P23H-GFP were expressed in SK-N-SH cells. Cells were fixed 24 hours later and 
immunostained with the anti-rhodopsin antibody 1D4. This antibody only detected 
the untagged rod opsin species as the GFP-tagged rod opsins had GFP fused to 
the antibody recognition sequence in the C-terminus of rod opsin.
When cells expressed untagged and GFP-tagged wild-type rod opsin the vast 
majority of the cells showed predominantly plasma membrane staining (Figure
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Figure 3.7 Co-expression of WT and P23H rod opsin results in the co­
localisation of both opsin species in intracellular inclusions.
Confocal microscopy of SK-N-SH cells, a-c) Co-expression of untagged WT and 
WT-GFP rod opsin resulted in the normal translocation of both opsin species to 
the plasma membrane of cells (arrows): a) 1D4 immunostaining (red); b) GFP 
fluorescence (green); c) merge with DAPI (blue), d-f) Co-expression of untagged 
WT and P23H-GFP resulted in the disruption of the normal translocation of the 
WT protein to the plasma membrane and led to its retention in the ER 
(arrowhead) and intracellular inclusions where it co-localised with the mutant 
protein (*): d) ID4 immunostaining (red); e) GFP fluorescence (green); f) merge 
with DAPI (blue). Scale bar = 10 pm.
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Figure 3.8 Morphological and biochemical assessment of the dominant- 
negative effect of P23H rod opsin on the WT protein.
a) Morphological characterisation of the effect of P23H rod opsin on the traffick­
ing of the WT protein. This assessment was carried out by scoring the cellular 
localisation of untagged WT rod opsin, immunodetected by the anti-rhodopsin 
antibody 1D4, in co-transfected cells. Co-expression of untagged WT and 
WT-GFP rod opsin resulted in the co-localisation of both rod opsin species in the 
plasma membrane (PM) of the cells. Co-transfection with untagged WT and 
P23H-GFP rod opsin led to retention of the WT protein in the ER and the accu­
mulation of WT protein in intracellular inclusions. Error bars represent ± 2SE b)
10 fig of soluble protein were loaded onto a 10% SDS-PAGE gel. Co-expression 
of untagged WT and P23H-GFP reduced the amount of soluble WT rod opsin 
detected by the anti-rhodopsin antibody 1D4. The position of molecular weight 
markers in kDa is shown on the left.
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3.7a-c, Figure 3.8a). In contrast, when wild-type was expressed with P23H rod 
opsin there was a change in the localisation of the wild-type protein. Co-transfected 
cells showed a co-localisation of the two rod opsin species in the ER (arrowhead) 
or in large intracellular inclusions (asterisk) (Figure 3.7d-f) suggesting that the 
mutant rod opsin was preventing the normal translocation of the wild-type protein 
to the plasma membrane of the cells. When the cellular morphology was quantified 
in co-transfected cells -65% showed ER staining and -15% had both opsin 
species accumulated in intracellular inclusions (Figure 3.8a). However, some co­
transfected cells (-15%) had a predominantly plasma membrane staining 
suggesting that the effect of P23H rod opsin on wild-type rod opsin, while 
significant was not absolute. This recruitment of the wild-type protein to the large 
intracellular inclusions might contribute to the reduction in the levels of soluble wild- 
type rod opsin that were observed in a Western blot using the rhodopsin antibody 
1D4 when the wild-type protein was expressed with P23H (Figure 3.8b). 
Furthermore, a close interaction between wild-type and P23H rod opsin or the 
formation of hybrid dimers might render the wild-type protein unstable and prompt 
its degradation by the proteasome.
3.2.7 The dom inant-negative effect of the P23H rod opsin on the w ild-type  
protein can occur at low relative am ounts of the mutant protein
The effect of different relative concentrations of P23H and wild-type rod opsin on 
the cellular localisation of the wild-type protein in co-transfected cells was analysed 
(Figure 3.9). When the relative amount of P23H-GFP and WT-GFP plasmid DNA 
was 1:10, there was a reduction in the percentage of co-transfected cells showing 
a normal translocation of the wild-type protein when compared to co-transfected 
cells expressing untagged and GFP-tagged wild-type rod opsin (Figure 3.8a). The 
interference of the mutant protein on the wild-type localisation increased at ratios of 
1:5 and 1:2 and was almost maximal at the ratio of 1:1 where the majority of co­
transfected cells had wild-type protein retained in the ER. These data indicate that 
the dominant-negative effect of the P23H rod opsin on the mutant protein can 
occur at low relative amounts of P23H rod opsin.
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Figure 3.9 The dominant-negative effect of the P23H rod opsin on the wild- 
type protein can be observed at low levels of P23H plasmid DNA relatively 
to WT rod opsin.
SK-N-SH cells were co-transfected with various relative ratios of untagged WT 
and P23H-GFP rod opsin. After 24 hours immunocytochemistry was carried out 
using the rhodopsin antibody 1D4. The cellular localisation of WT rod opsin in 
co-transfected cells was assessed and scored as plasma membrane (PM), ER. 
and inclusions.
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3.2.8 Measurement of the interaction between WT and P23H rod opsin by 
fluorescence resonance energy transfer (FRET)
An interesting application of fluorescent proteins is their use in fluorescence 
resonance energy transfer (FRET) which is a quantum physical process in which 
energy is transferred from one fluorophore (donor) to another (acceptor). The 
sensitivity to distance and orientation makes FRET an ideal method to identify 
protein-protein interactions, such as any potential interactions between wild-type 
and P23H rod opsin or the aggregation of mutant rod opsin. The energy transfer 
efficiency (FRETeff) is directly related to the distance r separating a given donor 
and acceptor pair by:
FRETeff=1/[1+(r/Ro)6]
The resolution of FRET is thus defined by R0 which is typically <10-70 A. R0 
depends on the extent of overlap between the donor emission and the acceptor 
spectra, the absorption coefficient for the acceptor, the quantum yield of the donor, 
and the relative orientation of the donor and acceptor. In any case, when distances 
separating donor and acceptor are superior to 2Ro, no FRET can occur. From this, 
it is possible to distinguish between two proteins being present in the same cellular 
compartment for instance, from those undergoing specific protein-protein 
interactions. FRET acceptor bleaching involves measuring the donor “de- 
quenching” in the presence of an acceptor. This can be done by comparing donor 
fluorescence intensity in the same sample before and after destroying the acceptor 
by photobleaching. If FRET was initially present, a resultant increase in donor 
fluorescence will occur on photo bleaching of the acceptor. The energy transferred 
efficiency can be quantified as:
FRETeff= (Dpost-Dpre)/Dpost
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where Dpost is the fluorescence intensity of the donor after acceptor 
photobleaching, and Dpre the fluorescence intensity of the donor before acceptor 
photobleaching. The FRETeff is considered positive when Dpost > Dpre.
Rajan and Kopito (2005) have reported that co-expression of wild-type (YFP) and 
P23H (CFP) rod opsin in HEK-293 cells resulted in FRET in solution indicating a 
close interaction between the rod opsin species. However, a major unresolved 
question of that study was where within the cell the interaction between the P23H 
and the wild-type protein was occurring. It could either happen in the ER leading to 
wild-type rod opsin misfolding and the arrest of processing or is the processing 
inhibited as a result of subsequent aggregation possibly leading to co-aggregation 
in the cytoplasm and in inclusions.
In order to address these questions and test if FRET could be used to monitor 
aggregation wild-type and P23H rod opsin were inserted into pECFP-N1 and 
pEYFP-N1 vectors as described in Chapter 2. In preparation for the FRET assay, 
cells were seeded on Matek dishes and transfected with WT-CFP + WT-YFP, WT- 
CFP + P23H-YFP and P23H-CFP + P23H-YFP for 24 hours prior to bleaching. 
FRET measurements were carried out by comparing donor fluorescence intensity 
(CFP) in the same sample before and after destroying the acceptor (YFP) by photo 
bleaching. Importantly, FRET was detected in inclusions of SK-H-SH cells 
expressing P23H-CFP and P23H-YFP (Figure 3.10e). However, the FRET signal 
was too weak to be detected outside the inclusions possibly due to low CFP 
expression/detection levels. Although is was not clear why this was the case, CFP 
expression levels were consistently lower than the YFP counterparts even when 
using the CFP vector alone suggesting that there might have been a malfunction or 
an incorrect alignment of the CFP laser in the confocal microscope set up. A 
solution-based FRET assay was also attempted but low signal to noise ratio 
resulted in poor reproducibility.
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Figure 3.10 Fluorescence resonance energy transfer (FRET) was detected 
in P23H rod opsin inclusions.
SK-N-SH cells co-expressing with P23H-CFP and P23H-YFP were bleached in 
highlighted region of interest (ROI) at a wavelength of 525 nm in live cells 24 
hours after transfection (c-d) and resulted in energy transfer detected at 425 nm 
(a-b). e) FRET was detected in intracellular inclusions suggesting that both P23H 
opsin species were in close proximity (<70 A). A thermal colour scale was used 
and ‘hot’ colours illustrate areas where FRET was measured. Scale bar =10 pm.
3.3 Discussion
The detailed characterisation of the intracellular distribution of rod opsin in both cell 
and animal models is important as it can be used to characterise potential 
pathological mechanisms. The data described in this chapter have continued these 
studies and demonstrated that when expressed into SK-N-SH cells, wild-type and 
P23H rod opsin had different phenotypes. In agreement with previously published 
cell culture models (Saliba etal., 2002; llling etal., 2002) wild-type rod opsin 
appeared to fold correctly and was translocated through the secretory pathway to 
the plasma membrane of the cell whereas P23H rod opsin most likely misfolded, 
was retained in the ER and coalesced into large intracellular inclusions.
Previous animal and cell culture models support the observations from the data 
presented here which suggested that misfolding and the possible cytotoxicity of the 
mutant protein could be major cause of cell death. Studies carried out in transgenic 
Xenopus Laevis expressing the P23H rod opsin have demonstrated that P23H rod 
opsin induced retinal degeneration whereas the expression of the wild-type rod 
opsin did not (Tam and Moritz, 2006). Moreover, P23H rod opsin was misfolded 
and predominantly present in the RIS, a pattern consistent with retention in the ER. 
The detrimental effect of mutant rod opsin on photoreceptor degeneration was also 
observed when transgenic mice expressed three N-terminus rod opsin mutations 
(V20G, P23H, P27L -  VPP) on a homozygous rod opsin (-/-) background 
(Frederick et a/., 2001). This resulted in mutant protein retention in the ER and 
consequent inability to transport and support outer segment formation, leading to 
rod cell death.
The data presented in this chapter suggest that P23H rod opsin expression in SK- 
N-SH cells resulted in increased LDH release and caspase-3 activity when 
compared to the wild-type protein. Following fluorescent microscopy observations 
P23H rod opsin transfected cells always appeared less healthy even though the 
cell density and transfection efficiency were similar to that of wild-type rod opsin.
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Furthermore, cells transfected with P23H rod opsin would start to die and 'float off 
after 48 hours whereas wild-type transfected cells remained attached to the cell 
culture plastic.
There are several lines of evidence suggesting that Class II rod opsin mutants 
such as P23H might exert a dominant-negative effect on the processing and 
transport of WT rod opsin. Work carried out on the Drosophila NinaE-encoded Rh1 
rhodopsin suggested that Class II mutants exerted a dominant-negative effect on 
wild-type rod opsin (Kurada et al., 1998). A dominant-negative effect has recently 
been demonstrated in mammalian cells (Saliba etal., 2002; Rajan and Kopito, 
2005) and was confirmed in our model with P23H rod opsin affecting the normal 
processing of wild-type rod opsin to the secretory pathway. The presence of this 
dominant-negative effect of the P23H rod opsin on the wild-type suggested that 
when attempting to manipulate mutant rod opsin using pharmacological agents it 
might be required to restrict this interaction between wild-type and Class II 
mutants, and as well as reversing misfolding of the mutant protein or the 
consequences of misfolding.
The fact that FRET could only be measured in inclusions prevented the 
investigation of protein-protein interactions outside the inclusions and consequently 
prevented the biophysical assessment of where within the cell was the interaction 
between the P23H and the wild-type protein occurring. Consequently FRET could 
not be used to test drugs for a potential suppression of the dominant-negative 
interaction between the P23H and the wild-type protein.
The following chapters describe the effects of different classes of pharmacological 
compounds on the morphology, biochemistry and cell death of wild-type and P23H, 
and K296E rod opsin. This was achieved exploring the two potential mechanisms 
of cell death in photoreceptor degeneration which result in misfolding, aggregation 
and toxicity associated to Class II mutations: gain-of-function and dominant- 
negative effects on wild-type protein. The next chapter describes the effects of
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retinoids, which are pharmacological chaperones for rod opsin, on the wild-type 
and P23H protein.
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Chapter 4: Pharmacological chaperones
4.1 Introduction
As many of the misfolding disease-causing proteins may not be inherently non­
functional, several therapeutic strategies have involved assisting their folding and 
consequent trafficking though the secretory pathway. One of these strategies uses 
a group of compounds named pharmacological chaperones and aims to overcome 
folding defects in processing mutants by binding to substrate molecules. Impaired 
trafficking of lysosomal hydrolases to late endosomes causes lysosomal storage 
diseases in humans. Fabry disease, for example, is caused by the lysosomal 
deficiency of a-galactosidase (a-Gal A) which results in lysosomal accumulation of 
glycosphingolipid globotriosylceramide Gb3 (Brady etal., 1967). Pharmacological 
chaperone treatment with 1-deoxygalactonorijimycin (1-DGJ), which acts as a 
competitive inhibitor of a-Gal A, stabilised and corrected the trafficking defect of 
misfolded a-Gal mutants (Yam etal., 2005).
It has been suggested that pharmacological selective compounds can rescue cell 
surface expression and function of GPCR misfolding mutants. Vitamin A 
supplementation reduced the course of photoreceptor degeneration in transgenic 
mice carrying the dominant rod opsin mutation T17M (Li etal., 1998). Other studies 
investigated V2 vasopressin receptor (V2 R) mutants which failed to fold properly 
and therefore were not routed to the cell surface (Morello et al., 2000). These 
mutants are responsible for nephrogenic diabetes insipidus (NDI), a rare X-linked 
disease characterised by a loss of anti-diuretic response to the hormone arginin- 
vasopressin resulting in the inability of affected patients to concentrate their urine, 
leading to large urinary output. Treatment of HEK-293 cells expressing V2R with 
the non-peptidic V2R antagonists SR121463A and VPA-985 increased cell-surface 
expression and rescued the function of V2R mutants by promoting their proper 
folding and consequent maturation (Morello etal., 2000). Pharmacological 
chaperones were also used to rescue ER-retained gonadotropin-releasing
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hormone receptor (GnRHR) mutants responsible for hypogonadotropic 
hypogonadism (Janovick et al., 2002). As with the V2R mutants, treatment with a 
receptor antagonist restored cell-surface expression and signalling activity in a 
variety of GnRHR mutants tested.
Vitamin A has long been known to be fundamental for several important functions 
such as vision, embryonic growth and development and immune competence 
(reviewed in Blomhoff and Blomhoff, 2006). 11-c/s-retinal, an aldehyde form of 
vitamin A, initiates phototransduction by a photochemical reaction where opsin- 
bound 11-c/s-retinal is isomerised to all-frans-retinal. Retinoids are a class of 
compounds which encompass retinoid analogs, with or without biological activity, 
and other compounds which are not closely related to retinol but elicit biological 
vitamin A or retinoid activity.
A potential therapeutic strategy for Class II ADRP patients is to use retinoids as 
pharmacological chaperones which would correct the misfolding of mutant rod 
opsin by binding specifically to its non-native and native forms. Previous studies 
suggested that a vitamin A supplemented diet reduced the rate of decline of both 
ERG's a-wave and b-wave in the Class II T17M transgenic mice but had no effect 
on the ERG amplitude in the Class I P347S mice (Li et al., 1998). Furthermore, 
treatment of COS-7 cells with 9-c/s-retinal increased the amount of P23H rod opsin 
reaching the plasma membrane of the cells (Saliba et al., 2002). Addition of 11-c/s-
7-ring retinal, a 7-membered ring analogue of 11-c/s-retinal, in stable cell lines 
expressing P23H rod opsin also resulted in the folding of mutant opsin and 
consequent translocation through the secretory pathway (Noorwez et al., 2003). 
These data suggested that the addition of some retinoids during the course of 
protein biosynthesis might induce a more native-like folding of the mutant protein.
A similar effect was observed when 9-c/'s-retinal and 11-c/s-retinal were added to 
stable cell lines during rod opsin synthesis which resulted in increased folding and 
consequent translocation to the plasma membrane (Noorwez etal., 2004). In this 
chapter the effects of retinoids on the cell model of rhodopsin RP are assessed.
87
The retinoids used were the chromophore, 11-c/s-retinal, and its functional 
geometric isomer, 9-c/s-retinal whose structures are shown in Figure 4.1.
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9-c/s-retinal 11 -c/s-retinal
Figure 4.1 Representation of the molecular structure of 9-c/s-retinal and 
11-c/s-retinal.
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4.2 Results
4.2.1 Retinoids reduce inclusion incidence and promote the trafficking of 
P23H rod opsin through the secretory pathway
The effect of 9-c/s-retinal and 11 -c/'s-retinal on P23H rod opsin folding was 
analysed in the cell model of rhodopsin RP. The addition of retinoids and 
consequent incubation period were carried out in the dark in order to prevent the 
isomerisation of the compounds. SK-N-SH cells expressing P23H rod opsin were 
treated with different concentrations of 9-c/s-retinal and 11-c/s-retinal ranging from 
2 |jM to 20 |jM which were determined based on previously published studies. The 
optimal concentration, determined in terms of reduction of inclusion incidence, was 
10 pM for both 9-c/s-retinal and 11 -c/s retinal. Treatment with both 9-c/s-retinal and 
1 1 -c/s-retinal had no effect in cells expressing wild-type rod opsin with the majority 
of cells showing plasma membrane staining (Figure 4.2a-c). In P23H cells, 
however, retinoids reduced inclusion incidence and promoted the trafficking of 
P23H rod opsin to the plasma membrane of the cells (Figure 4.2d-f). This effect 
was not seen in cells expressing K296E rod opsin where no morphological 
changes were observed as a result of treatment with retinoids (Figure 4.2g-i). This 
suggested that retinoids lost their efficacy when the site of retinal attachment was 
disrupted and their effect on inclusion incidence required binding to rod opsin.
In cells expressing P23H rod opsin treatment with 9-c/s-retinal reduced inclusion 
incidence from 26.92% ± 5.18 in the controls to 10.07% ± 7.48 (p £ 0.005) 
suggesting an alleviation of the gain-of-function mechanism in this Class II 
mutation (Figure 4.3a). Treatment with 11-c/s-retinal reduced the inclusion 
incidence to 9.63% ± 2.03 (p < 0.001) of transfected cells (Figure 4.3a). In addition 
to a reduction in inclusion incidence there was a significant change in cellular 
morphology as 58.29% ± 9.99 (p £ 0.001) of P23H cells treated with 9-c/s-retinal 
(Figure 4.3b) and 42.29% ± 10.50 (p ^ 0.001) of cells treated with 11-cis-retinal 
(Figure 4.3b) showed plasma membrane staining in contrast with the vehicle- 
treated controls where no cells showed predominant plasma membrane staining.
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Figure 4.2 Retinoids promote translocation of P23H rod opsin to the plasma 
membrane of the cell.
Morphological assessment of SK-N-SH cells expressing WT-GFP (a-c), P23H- 
GFP (d-f), and K296E-GFP (g-i) and treated with retinoids as indicated for 24 
hours post transfection and then fixed with 3.7% paraformaldehyde. All controls 
were vehicle-treated and this resulted in no observable phenotypical change. 
Treatment with either 10 pM 9-c/s-retinal or 10 pM 11-c/s-retinal resulted in no 
morphological change in cells expressing the WT protein with the majority show­
ing plasma membrane staining. In P23H cells 9-c/s-retinal and 11-c/s-retinal 
reduced inclusion incidence and facilitated the processing of the mutant opsin to 
the plasma membrane (arrows). Treatment with retinoids resulted in no morpho­
logical changes in cells expressing K296E rod opsin where the protein was either 
retained in the ER (arrowheads) or accumulated in large intracellular inclusions.
GFP fluorescence is represented in green and DAPI staining is represented in 
blue. Scale bar =10 pm.
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Figure 4.3 9-c/s-retinal and 11-c/s-retinal reduce inclusion incidence in 
P23H cells and promote the translocation of P23H rod opsin to the plasma 
membrane.
a) The inclusion incidence in SK-N-SH cells expressing WT-GFP, P23H-GFP and 
K296E-GFP rod opsin was assessed following treatment with retinoids as 
indicated for 24 hours. Retinoids had no effect in the incidence of inclusions in 
cells expressing WT or K296E. 10 pM 9-c/s-retinal (p £ 0.005) and 10 pM 11-c/s- 
retinal (p £ 0.001) reduced inclusion incidence in P23H cells, b) Morphological 
assessment of P23H cells following treatment with retinoids. 10 pM 9-c/s-retinal 
(p £ 0.001) and 10 pM 11-c/s-retinal (p £ 0.001) promoted the translocation of 
P23H rod opsin to the plasma membrane of the cells. Error bars represent ± 2SE.
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4.2.2 Treatment with 9-c/s-retinal and 11 -c/s-retinal increase the amount of 
soluble rod opsin in P23H cells
A biochemical characterisation of soluble rod opsin species present following the 
treatment with retinoids was carried out. SK-N-SH cells expressing untagged wild- 
type and P23H rod opsin were treated with 10 pM 9-c/s-retinal or 10 pM 11-c/s- 
retinal for 24 hours prior to lysis using 4°C 1% Triton X-100 in PBS plus protease 
inhibitor cocktail. Figure 4.4 shows a Western blot of soluble wild-type and P23H 
rod opsin species immunodetected by the anti-rhodopsin antibody 1D4. Treatment 
with retinoids failed to increase the amount of soluble wild-type rod opsin and the 
majority of these species were EndoH resistant (Figure 4.4a). In contrast, 
increased amounts of soluble P23H rod opsin were detected following treatment 
with 9-c/s-retinal and 11-c/s-retinal (Figure 4.4b). The P23H rod opsin species 
which migrated to ~36 kDa were rendered EndoH resistant (arrow) following 
treatment with 9-c/s-retinal and 11 -c/s-retinal suggesting that these species were 
sufficiently folded to exit the ER and continue their translocation through the 
secretory pathway.
4.2.3 Retinoids reduce the amount of insoluble P23H rod opsin present in 
cells expressing the mutant protein
The effect of retinoids on the amount of insoluble rod opsin species was analysed 
by carrying out a rod opsin fractionation assay as described in Chapter 3. The total 
rod opsin levels were ~50% lower in P23H cells than in wild-type cells and the 
treatment with 9-c/s-retinal and 11-c/s-retinal did not affect the overall levels of 
wild-type or mutant rod opsin (Figure 4.5a). However, when the insoluble rod opsin 
was assessed (Figure 4.5b), retinoids reduced the percentage of insoluble protein 
from 60.57% ± 3.92 in the vehicle-treated controls to 38.73% ± 2.41 (p < 0.005) 
following treatment with 9-c/s-retinal and 32.44% ± 1.91 (p < 0.005) following 
treatment with 11-c/s-retinal. These reduced levels of insoluble P23H rod opsin 
were in agreement with the reduction in inclusion incidence observed following 
retinoid treatment.
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Figure 4.4 Treatment with retinoids results in an increase of soluble P23H 
rod opsin species which are EndoH resistant.
SK-N-SH cells expressing WT-pMT3 (a) or P23H-pMT3 (b) were treated with 10 
pM 9-c/s-retinal or 10 pM 11-c/s-retinal as indicated for 24 hours prior to lysis with 
1% Triton-X 100. 10 pg of protein from Triton-X soluble fractions were resolved 
on a 10% SDS-PAGE gel followed by immunoblotting with 1D4 anti-rhodopsin 
antibody, a) Soluble WT rod opsin levels were unchanged following treatment 
with 9-c/s retinal or 11-c/s-retinal. b) Retinoids increased the levels of soluble 
P23H rod opsin and resulted in the detection of EndoH resistant species (arrow). 
The position of molecular markers in kDa is shown on the left.
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Figure 4.5 Treatment with retinoids decreases the amount of insoluble P23H 
rod opsin.
SK-N-SH cells expressing WT-GFP or P23H-GFP were treated with retinoids for
24 hours prior to lysis with 190 pi of RIPA buffer + 10 pi protease inhibitor cocktail
and spectro-fluorometric analysis, a) 10 pM 9-c/s-retinal and 10 pM 11-c/s-retinal 
did not significantly alter the total levels of either the WT or the P23H cells, b) 
9-c/s-retinal (p s 0.005) and 11-c/s-retinal (p £ 0.005) reduced the amount of 
insoluble P23H rod opsin. Retinoids had no effect in the insoluble levels of the 
WT protein. Error bars represent ± 2SE.
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4.2.4 9-c/s-retinal and 11-c/s-retinal reduce LDH release and caspase-3 
activity in cells expressing P23H rod opsin
In order to assess if retinoids had a positive effect on the gain-of-function 
mechanism induced by the P23H mutation, LDH release (Figure 4.6a) and 
caspase-3 activity (Figure 4.6b) were assessed in cells treated with these 
compounds. 9-c/s-retinal reduced LDH release from 0.515 ± 0.037 to 0.172 ± 0.014 
(p < 0.001) whereas 11-c/s-retinal was less efficient, reducing LDH release to 
0.322 ± 0.032 (p < 0.005). Treatment with either 9-c/s-retinal or 11-c/s-retinal 
reduced caspase-3 activity to levels similar to those of the wild-type protein. 
Caspase-3 activation levels were 0.967 ± 0.226 in the vehicle-treated controls and 
those were reduced to 0.370 ± 0.137 (p £ 0.01) by 9-cis-retinal and 0.265 ±0.102 
by 11-c/s-retinal (p < 0.005).
4.2.5 Retinoids alleviate the dominant-negative effect of P23H on the wild- 
type protein
Following the analysis of retinoid treatment on the gain-of-function mechanism 
induced by P23H rod opsin these compounds were tested on the dominant- 
negative effect of the P23H rod opsin on the wild-type protein. As shown in 
Chapter 3, P23H opsin had a dominant-negative effect on the wild-type protein as 
it prevented its normal translocation through the secretory pathway to the plasma 
membrane of the cells. Treatment with 10 pM 9-c/s-retinal (Figure 4.7d-f) or 10 pM 
11-c/s-retinal (Figure 4.7g-i) appeared to suppress this effect as an increased 
number of co-transfected cells had the wild-type protein present on the plasma 
membrane. The morphological assessment of the effect of retinoids on the cellular 
morphology of cells expressing wild-type and P23H rod opsin is shown in Figure 
4.8. Treatment with 9-c/s-retinal resulted in an increase in the percentage of co­
transfected cells showing the wild-type protein on the plasma membrane from 
15.28% ± 3.86 in the vehicle-treated controls to 57.44 ± 5.44 (p < 0.001). 11-c/s- 
retinal also alleviated the dominant-negative effect of the P23H rod opsin on the
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Figure 4.6 9-c/s-retinal and 11-c/s-retinal reduce LDH release and caspase-3 
activity in cells expressing P23H rod opsin.
a) SK-N-SH cells expressing P23H rod opsin had higher LDH release levels 
when compared to WT cells. Treatment with 10 pM 9-c/s-retinal (p £ 0.001) 
reduced LDH release in P23H cells to WT levels and 10 pM 11-c/s-retinal was 
less efficient, reducing LDH release by -35% (p 5 0.005). b) P23H cells had 
increased levels of caspase-3 activity when compared to WT. Treatment with 10 
pM 9-c/s-retinal (p s 0.01) and 10 pM 11-c/s-retinal (p s 0.005) reduced 
caspase-3 activity to levels similar to WT. Error bars represent ± 2SE.
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Figure 4.7 Retinoids suppress the dominant-negative effect of the P23H 
mutant on the WT protein and promote the translocation of the WT rod 
opsin to the plasma membrane.
Confocal imaging of SK-N-SH cells co-transfected with untagged WT rod opsin 
and GFP-tagged P23H opsin and treated with retinoids as indicated for 24 hours. 
The red channel represents 1D4 immunostaining and the green channel repre­
sents GFP staining. Co-transfection of WT and P23H opsin resulted in an impair­
ment of the normal trafficking of the WT opsin through the secretory pathway 
towards the plasma membrane of the cell (arrowhead) (a-c). Treatment with 10 
pM 9-c/s-retinal (d-f) and 10 pM 11-c/s-retinal (g-i) appeared to supress the 
dominant-negative effect of the mutant protein on the WT rod opsin resulting in 
WT plasma membrane staining (arrows). Scale bar = 10 pm.
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Figure 4.8 Morphological assessment of the effect of retinoids on the 
dominant-negative effect of P23H rod opsin on the WT protein.
SK-N-SH cells were transfected with equal amounts of WT-pMT3 and P23H- 
GFP plasmids followed by treatment with 10 pM 9-c/s-retinal or 10 pM 11-c/s- 
retinal as indicated for 24 hours prior to fixation and immunostaining with the 
anti-rhodopsin antibody 1D4. Co-transfected cells were scored for the predomi­
nant cellular localisation of the WT protein. 10 pM 9-c/s-retinal (p £ 0.001) and 
10 pM 11-c/s-retinal (p £ 0.005) promoted the translocation of the WT protein to 
the plasma membrane of the cells. Furthermore, 10 pM 9-c/s-retinal (p £ 0.01) 
and 10 pM 11-c/s-retinal reduced the incidence of inclusions containing the WT 
protein. Error bars represent ± 2SE.
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wild-type protein, albeit not to the extent of 9-c/s-retinal, as 41.59% ± 8.96 (p < 
0.005) of the co-transfected cells had wild-type rod opsin on the plasma 
membrane. These results correlate with the effect of retinoids on P23H rod opsin 
alone where 9-c/s-retinal and 11-c/s-retinal promoted the translocation of the P23H 
protein to the plasma membrane of 58.29% and 42.29% of the cells respectively.
In addition retinoids reduced the percentage of co-transfected cells with 
intracellular inclusions containing the wild-type protein from 14.63% ± 2.88 in the 
vehicle-treated controls to 8.40% ± 2.44 (p < 0.01) after treatment with 9-c/s-retinal 
and 10.30% ± 4.35 after treatment with 11-c/s-retinal (not significant).
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4.3 Discussion
The data presented here indicate that 9-c/s-retinal and 11-c/s-retinal can act as 
pharmacological chaperones by increasing the amount of correctly folded P23H 
rod opsin that can exit the ER. This had a positive effect in both the gain-of- 
function and dominant-negative mechanisms induced by the P23H rod opsin. For 
the gain-of function mechanism of P23H rod opsin this was demonstrated by the 
reduction in inclusion incidence, the presence of mature glycosylated rod opsin 
species in soluble cell lysates, and protective effects against LDH release and 
caspase-3 activity. In the dominant-negative mechanism the interaction between 
wild-type and P23H rod opsin was suppressed resulting in the increased presence 
of wild-type protein in the plasma membrane of co-transfected cells and reduction 
in inclusions which contained the wild-type protein. Saliba et al (2002) added 9-c/s- 
retinal to cells expressing P23H rod opsin 16 hours after transfection and observed 
increased levels mature rod opsin in the soluble fraction measured by Western 
blotting and increased P23H rod opsin present in the plasma membrane of COS-7 
cells. However, these authors did not observe a decrease of inclusion incidence 
following the incubation with 9-c/s-retinal. This suggested that although the ligand 
can be used to promote mutant rod opsin folding and prevent its degradation, once 
a rod opsin inclusion has formed treatment with ligand cannot disaggregate it.
9-c/s-retinal, an isomer of 11-c/s-retinal, has been widely used for vision 
experiments due to its ease of synthesis in vitro and consequent ready availability. 
The rod pigment formed with 9-c/s-retinal, isorhodopsin, is photosensitive and 
appears to be very similar to rhodopsin as determined by both in vitro studies and 
in vivo studies using isolated photoreceptors (Corson etal., 1990). One of the most 
abundant proteins in the RPE is RPE65 and when this protein is mutated or 
lacking, as in the RPE65 knockout (Rpe65'7~) mouse the synthesis of 11-c/s-retinal 
did not occur, however, a minimal photoreceptor response from rod photoreceptors 
was observed which appeared to be mediated by isorhodopsin (Fan et al., 2003). 
Furthermore, Rpe65-/'mice kept in prolonged darkness had increased isorhodopsin
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suggesting that there might be a pathway in the eye for the regeneration of this 
retinoid that is independent of the RPE and light (Fan et al., 2003). The data 
presented in this Chapter suggested that both 9-c/s-retinal and 11 -c/'s-retinal had 
equal positive effects on both the gain of function and dominant-negative 
mechanisms induced by the P23H rod opsin. Consequently these data did not 
provide conclusive evidence on which of these compounds might be more 
beneficial for cells expressing the mutant rod opsin.
The data presented here correlates with previously published studies which 
suggested that the biosynthesis of P23H rod opsin and its incorporation into the 
plasma membrane could be rescued through the addition of 1 1 -c/s-retinal, or its 
analogues, such as 9-c/s-retinal or 11-c/'s-7-ring retinal (Noorwez et al., 2003; 
Noorwez et al., 2004). These authors showed that all these three retinoids bind to 
P23H rod opsin via a Schiff base linkage to the chromophore binding site at 
Lys296 and allow for proper folding of the mutant protein. In addition, P23H rod 
opsin with 11-c/s-retinal or 9-c/s-retinal as chromophore responded to photon 
absorption albeit with a decrease in absorption at 500 nm and formation of 
intermediates absorbing at shorter wavelengths whereas 11-c/s-7-ring retinal 
formed locked, non-photoisomerisable and non-bleachable form of P23H 
rhodopsin in cell membranes (Noorwez et al., 2004). These in vitro studies also 
suggested that the binding of P23H rod opsin to all these ligands was very weak 
and resulted in poor thermal stability. In structural terms Pro23 is located in the 
intradiscal domain of rod opsin in close proximity to the retinal plug and it is likely 
that its replacement with a different amino acid might disrupt the retinal plug and 
alter its structure resulting in thermal instability. The data presented here suggests 
that retinoids might bind P23H rod opsin thereby stabilising it or they may bind non­
native folding intermediaries acting as a scaffold for subsequent folding. These 
actions combined result in a shift in the folding equilibrium of P23H species 
towards a folded state which appeared to be beneficial to the cells.
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Based on these in vitro data one can speculate that the susceptibility of P23H 
patients or VPP mice (Naash et al., 1996) to light-induced retinal degeneration 
might be related to poor thermal stability of the P23H rod opsin and the release of 
11-c/s-retinal which could potentially have phototoxic effects. The poor thermal 
stability of P23H rod opsin suggests that it might be necessary to develop novel 
1 1 -c/s-retinal analogues which allow the formation of a stable protein in the dark 
and functional phototransduction.
103
Chapter 5: Chemical Chaperones/Kosmotropes
5.1 Introduction
A variety of studies in the past 12 years have described the use of a group of low 
molecular weight compounds which reversed the mislocalisation or aggregation of 
proteins involved in a variety of human diseases associated with protein misfolding. 
These compounds have been named kosmotropes or chemical chaperones and 
include: polyols such as glycerol; solvents such as dimethyl sulfoxide (DMSO); 
methylamines such as trimethylamine-N-oxide (TMAO); fatty acids such as 4- 
phenylbutyric acid (4-PBA); and sugars such as trehalose among others. There are 
two mechanisms of action associated with these compounds. Firstly, these 
compounds might increase the hydration of proteins and consequently promote 
their stabilisation by enhancing the free-energy difference between a partially 
folded protein, which has a higher surface area, and a more compact native 
structure (Back et al., 1979). Secondly, chemical chaperones might reduce the free 
movement of proteins to prevent aggregation of partially folded molecules (Singer 
and Lindquist, 1998).
The potential use of kosmotropes as a therapy for protein misfolding disorders 
initially involved the most common mutation in the gene encoding the cystic fibrosis 
transmembrane conductance regulator (CFTR) protein (AF508 CFTR) of cystic 
fibrosis patients (White et al., 1990). Newly synthesised AF508 CFTR protein failed 
to fold correctly, was retained in the ER and did not translocate to the cell surface 
where it normally functioned as a cAMP-regulated chloride channel (Cheng et al., 
1990). Treatment of cells expressing the AF508 CFTR mutant with a number of 
chemical chaperones such as glycerol and TMAO resulted in the correct 
processing of the mutant CFTR protein and its appearance at the plasma 
membrane (Brown et al., 1996).
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This folding defect was temperature-dependent as the processing of AF508 CFTR 
reverted towards that of wild-type as the incubation temperature was reduced from 
37°C to 30°C (Denning etal., 1992). This led to appearance of cAMP-regulated 
chloride channels in the plasma membrane resulting in the cells acquiring 
competence for cAMP-stimulated chloride exchange, indicating a functional CFTR 
protein. This recovery was mimicked when cells were cultured in the presence of 
chemical chaperones such as glycerol, DMSO, and TMAO at 37°C (Powell and 
Zeitlin, 2002) suggesting the possibility of a therapeutic strategy based on these 
compounds.
Chemical chaperones have also been reported to reverse intracellular retention of 
several other misfolded proteins such as a-antitrypsin (Burrows et al., 2000), 
aquaporin-2 (Tamarappoo and Verkman, 1999), a-galactosidase A (Yam etal., 
2005), and P-glycoprotein (Loo and Clarke, 1997).
In addition, chemical chaperones have reduced aggregate formation in a model of 
Machado-Joseph disease/spinocerebellar ataxia-3 (MJD/SCA3) (Yoshida et al., 
2 0 0 2 ) and in a model of autosomal dominant oculopharyngeal muscular dystrophy 
(OPMD) (Bao etal., 2002). Furthermore, trehalose reduced polyglutamine 
aggregation in a mouse model of Huntington’s disease (Tanaka et al., 2004).
Kosmotropes were not effective in all experimental models, however, as a study by 
Yang and colleagues (1999) demonstrated that treatment with glycerol and TMAO 
resulted in a rapid acceleration of the A|3 peptide assembly into fibrillar structures, 
which are a central feature of Alzheimer's disease. An overall assessment of these 
data, however, suggested that chemical chaperones could potentially rescue a 
variety of nuclear, cytoplasmic, cell surface and secreted proteins from protein 
misfolding events. These compounds could therefore be useful in rescuing 
misfolded P23H rod opsin. This Chapter describes the effect of DMSO, TMAO, 4- 
PBA and trehalose in the cellular model for rhodopsin RP. The molecular 
structures of these chemical chaperones are shown in Figure 5.1.
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Figure 5.1 Representation of the molecular structures of the chemical 
chaperones dimethyl sulphoxide (DMSO), trimethylamine-N-oxide (TMAO), 
4-phenylbutyric acid (4-PBA) and trehalose.
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5.2 Results
5.2.1 Effect of chemical chaperones on inclusion incidence and cellular 
morphology in P23H-transfected cells
5.2.1.1 Dimethyl sulphoxide (DMSO)
Prior to treatment with chemical chaperones, SK-N-SH cells were transfected with 
WT-GFP or P23H-GFP rod opsin as described in Chapter 2. DMSO had a positive 
effect on P23H rod opsin inclusion incidence after 24 hours. Treatment with DMSO 
led to a dose-dependent decrease in inclusion incidence. The lowest concentration 
of DMSO to have an effect on inclusion incidence was 0.025%. The largest 
decrease in inclusion incidence was achieved using 0.25% DMSO which reduced 
inclusion incidence from 27.44% ± 5.58 in the untreated controls to 6.63% ± 1.05 
(p £ 0.001) (Figure 5.2). Using concentrations higher than 0.25% DMSO failed to 
reduce the incidence of inclusions further. The same DMSO dose-response curve 
was carried out in cells expressing wild-type rod opsin and no differences were 
observed in the cellular morphology at concentrations lower than 0.25% (Figure 
5.2c). When cells were treated with concentrations of DMSO higher than 0.25% 
and observed before fixation, increased levels of rounded cells detached from the 
culture surface which appeared to be in osmotic shock were seen. This effect 
appeared to be non-specific as it was observed in both the wild-type and P23H 
cells. Treatment with 0.25% DMSO, however, did not appear to promote the 
translocation of P23H rod opsin to the plasma membrane of the cells (Figure 5.2e).
5.2.1.2 Trimethylamine-N-oxide (TMAO)
Treatment with TMAO for 24 hours resulted in a dose-dependent decrease in 
inclusion incidence in cells expressing P23H rod opsin. The lowest concentration of 
TMAO to have a positive effect on inclusion incidence was 50 pM. The most 
effective concentration was 5 mM which resulted in the largest decrease in 
inclusion incidence from 27.35% ± 2.56 in the untreated controls to 6.52% ± 1.21
(p^ 0.001)
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Figure 5.2 Dimethyl sulphoxide (DMSO) reduces inclusion incidence in cells 
expressing P23H rod opsin.
a) SK-N-SH cells expressing P23H-GFP rod opsin were treated with different 
concentrations of DMSO (percentage of w/v) for 24 hours. The most effective 
concentration was 0.25% DMSO which reduced inclusion incidence from 27.44% 
± 5.58 in the untreated controls to 6.63% ± 1.05 (p £ 0.001). Error bars represent 
± 2SE. b-e) DMSO reduced inclusion incidence in P23H cells but did not 
promote the translocation of the mutant protein to the plasma membrane of the 
cells. Asterisks highlight inclusions. Scale bar = 10 pm
(Figure 5.3a). TMAO treatment had no effect on inclusion incidence in cells 
expressing wild-type rod opsin when used at a concentration lower than 5 mM 
(Figure 5.3c). Higher concentrations of TMAO did not appear to decrease the 
incidence of inclusions further. When cells treated with higher doses of TMAO were 
observed after 24 hours before fixation, increased levels of rounded cells detached 
from the culture surface which appeared to be in osmotic shock were seen 
although this effect was less severe than the one seen with DMSO. This 
detrimental effect appeared to be non-specific as it was observed in both wild-type 
and P23H cells. As with DMSO, treatment with TMAO did not appear to elicit the 
translocation of the mutant protein to the plasma membrane (Figure 5.3e).
5.2.1.3 4-Phenylbutyric acid (4-PBA)
4-PBA is a low molecular weight fatty acid which has been reported to act as a 
chemical chaperone that reduced the amount of mutant proteins retained in the ER 
in conditions associated with cystic fibrosis (Rubenstein and Zeitlin, 1998) and liver 
injury (Vilatoba et al., 2005). The effect of 4-PBA on inclusion incidence after 24 
hours in cells expressing P23H rod opsin was assessed (Figure 5.4a). The lowest 
concentration of 4-PBA to have an effect on inclusion incidence was 1 mM and the 
concentration which resulted in the largest decrease in inclusion incidence was 1 0  
mM. This led to a reduction in inclusion incidence from 24.52% ± 2.23 in the 
untreated controls to 5.95% ± 1.78 (p £ 0.001). Treatment with 4-PBA showed no 
effect on wild-type cells at doses lower than 10 mM (Figure 5.4c).Treatment with 
higher concentrations of 4-PBA resulted in the appearance of dysmorphic cells, but 
not rounded and in osmotic shock as seen with high doses of DMAO and TMAO. 
This effect appeared to be non-specific as it was observed in both wild-type and 
P23H cells Treatment with 10 mM 4-PBA did not appear to promote the 
translocation of mutant protein to the plasma membrane (Figure 5.4e).
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Figure 5.3 Treatment with trimethylamine-N-oxide (TMAO) reduces inclu­
sion incidence in cells expressing P23H rod opsin.
a) SK-N-SH cells were transfected with P23H-GFP rod opsin and treated with 
different concentrations of TMAO for 24 hours. The most effective concentration 
was 5 mM TMAO which reduced inclusion incidence from 27.32% ± 2.56 in the 
untreated controls to 6.52% ± 1.21 (p s 0.001). Error bars represent ± 2SE. b-e) 
Treatment with TMAO reduced inclusion incidence in P23H cells but did not 
promote the translocation of the mutant protein to the plasma membrane of the 
cells. Asterisks highlight inclusions. Scale bar = 10pm.
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Figure 5.4 Inclusion incidence is reduced in cells expressing P23H rod 
opsin following treatment with 4-phenylbutyric acid (4-PBA).
a) SK-N-SH cells were transfected with P23H-GFP rod opsin and treated with 
different concentrations of 4-PBA for 24 hours (a). The most effective concentra­
tion was 10 mM 4-PBA which reduced inclusion incidence from 24.52% ± 2.23 in 
the untreated controls to 5.95% ± 1.78 (p £ 0.001). Error bars represent ± 2SE. 
b-e) Treatment with 4-PBA reduced inclusion incidence but did not promote the 
translocation of mutant rod opsin to the plasma membrane of the cell. Asterisks 
highlight inclusions. Scale bar =10 pm.
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5.2.1.4 Trehalose
Treatment with trehalose resulted in a milder decrease in inclusion incidence in 
cells expressing P23H rod opsin (Figure 5.5a), when compared to the other 
chemical chaperones DMSO, TMAO and 4-PBA. The lowest concentration to have 
an effect on inclusion incidence was 1 mM and the most effective concentration 
was 50 mM which resulted in a decrease of inclusion incidence from 22.38% ±
3.36 in the untreated controls to 10.37 ± 2.51 (p < 0 .0 0 1 ). Treatment with trehalose 
at concentrations lower than 50 mM had no effect on the cellular morphology of 
wild-type cells (Figure 5.5c). Higher concentrations of trehalose resulted in 
deleterious effects on cellular morphology, including rounded cells detached from 
the culture surface. Although trehalose reduced inclusion incidence, it did not 
appear to promote the translocation of P23H rod opsin to the plasma membrane of 
the cells (Figure 5.5e).
5.2.2 Influence of chemical chaperones on P23H opsin species
The effect of chemical chaperones on the levels of soluble and EndoH resistant 
P23H opsin species was analysed by SDS-PAGE followed by immunoblotting with 
1D4 (Figure 5.6). Treatment with DMSO, TMAO, 4-PBA and trehalose failed to 
promote EndoH resistance of mature opsin species (arrow) indicating that these 
compounds were unable to assist the folding of the mutant protein so it would exit 
from ER to the Golgi.
5.2.3 Efficacy of chemical chaperones on inclusion incidence decreases 
once inclusion are formed
In order to assess if chemical chaperones were effective in reducing inclusion 
incidence once the inclusions had formed SK-N-SH cells expressing P23H-GFP 
rod opsin were treated with 0.25% DMSO or 5 mM TMAO immediately after 
transfection (Oh), 6  hours after transfection (6 h) and 12 hours after transfection 
(12h) then fixed 24 hours after transfection (Figure 5.7). 0.25% DMSO reduced 
inclusion incidence from 26.15% ± 4.18 in the untreated controls to 5.68% ± 1.74 
(p < 0 .0 0 1 ) at
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Figure 5.5 Trehalose reduces inclusion incidence in cells expressing P23H 
rod opsin.
a) SK-N-SH cells were transfected with P23H-GFP rod opsin and treated with 
different concentrations of trehalose for 24 hours. The most effective concentra­
tion was 50 mM trehalose which reduced inclusion incidence from 22.38% ± 3.36 
in the untreated controls to 10.37% ± 2.51 (p £ 0.001). Error bars represent 
± 2SE. b-e) Trehalose reduced inclusion incidence in P23H cells but no increase 
in plasma membrane staining was observed. Asterisks highlight inclusions. Scale 
bar = 10 pm.
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Figure 5.6 Chemical chaperones fail to elicit EndoH resistance in soluble 
P23H rod opsin.
SK-N-SH cells expressing untagged P23H rod opsin were treated with chemical 
chaperones, as indicated, for 24 hours. Cells were lysed and the soluble fraction 
was obtained as described in Chapter 3. 10pg of soluble cell lysate protein were 
resolved on a 10% SDS-PAGE gel followed by immunoblotting with 1D4. Chemi­
cal chaperones failed to promote mature P23H rod opsin species (arrow). The 
position of molecular weight markers in kDa are shown on the left.
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Figure 5.7 Chemical chaperones have lower efficacy at reducing inclusion 
incidence if added after inclusions are formed.
SK-N-SH cells were transfected with P23H-GFP rod opsin and treated with 
0.25% DMSO or 5 mM TMAO as indicated which were added immediately after 
transfection (Oh), 6 hours after transfection (6h) and 12 hours after transfection 
(12h). Serum media in the controls was added at Oh, 6h, and 12h to mimic the 
conditions of drug treatments at different time points. Both DMSO (p s 0.001) and 
TMAO (p £ 0.001) reduced inclusion incidence in P23H cells when added at Oh. 
DMSO (p £ 0.01) and TMAO (p £ 0.005) showed lower efficacy if added 6 hours 
after transfection. DMSO (not significant) and TMAO (not significant) failed to 
reduce inclusion incidence if added after 12 hours. Error bars represent ± 2SE.
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24 hours. DMSO was less efficient at reducing inclusion incidence when it was 
added after 6  hours which resulted in the presence of inclusions in 14.24% ± 6.58 
(p < 0.01) of the cells, and DMSO lost its efficacy at reducing inclusion incidence 
when it was added after 12 hours as inclusions were present in 22.63% ± 3.00 (not 
significant) of the cells. When cells were treated with 5 mM TMAO immediately 
after transfection it resulted in a decrease in inclusion incidence from 26.15% ± 
4.18 in the untreated controls to 6.01% ± 2.74 (p < 0.001). However, this effect was 
reduced when TMAO was added after 6  hours as 14.17% ± 2.86 (p < 0.005) of the 
cells had inclusions. When TMAO was added after 12 hours it lost its efficacy as 
22.94 ± 5.54 (not significant) of the cells had inclusions.
5.2.4 Chemical chaperones reduce inclusion incidence in cells expressing 
K296E rod opsin
A previously published study (Saliba et al., 2002) and data presented in this study 
(Figure 3.2a-b) suggested that K296E rod opsin was misfolded, retained in the ER 
and accumulated in intracellular inclusions. As described in Figure 4.3a the specific 
pharmacological chaperone action of retinoids did not reduce inclusion incidence in 
K296E cells due to the disruption of the chromophore binding site. It was, 
therefore, important to assess if the non-specific effects of chemical chaperones on 
protein stabilisation and prevention of aggregation could have a positive effect on 
cells expressing K296E mutant rod opsin. SK-N-SH cells expressing K296E-GFP 
rod opsin were treated with 0.25% DMSO or 5 mM TMAO for 24 hours prior to 
fixation. Treatment with DMSO resulted in a decrease in inclusion incidence in 
K296E cells from 15.64% ± 3.55 in the untreated controls to 6.25% ± 0.42 (p < 
0.001) (Figure 5.8). A similar reduction in inclusion incidence in K296E cells was 
observed with TMAO as it resulted in a decrease in inclusion incidence to 6.20% ± 
2.42 (p< 0.001) (Figure 5.8).
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Figure 5.8 Chemical chaperones reduce inclusion incidence in cells 
expressing K296E rod opsin.
SK-N-SH cells expressing K296E-GFP rod opsin were treated with 0.25% (w/v) 
DMSO and 5 mM TMAO as indicated for 24 hours. DMSO reduced inclusion 
incidence from 15.64 ± 3.55 in the untreated controls to 6.25 ± 0.42 (p £ 0.001) 
whereas TMAO reduced inclusion incidence to 6.20 ± 2.42 (p  ^0.001). Error bars 
represent ± 2SE.
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5.2.5 Treatment with chemical chaperone reduces the amount of insoluble 
rod opsin in cell lysates of P23H cells
In order to assess the effect of chemical chaperones on the levels of total and 
insoluble rod opsin a rod opsin fractionation assay was carried out as described in 
Chapter 2. Treatment with DMSO, TMAO, 4-PBA and trehalose did not affect the 
total levels of either wild-type or P23H rod opsin expressed in SK-N-SH cells 
(Figure 5.9a). Treatment with 0.25% DMSO and 5 mM TMAO reduced the 
percentage of insoluble P23H opsin from 59.57% ± 5.04 in the untreated controls 
to 40.60% ± 2.89 (p < 0.01) and 37.96% ± 4.14 (p < 0.01) respectively (Figure 
5.9b). 10 mM 4-PBA and 50 mM trehalose appeared slightly more effective 
reducing the percentage of insoluble mutant opsin to 26.32% ± 1.36 (p < 0.005) 
and 26.32% ±1.52 respectively (p < 0.005) (Figure 5.9b).
5.2.6 Chemical chaperones reduce LDH release and caspase-3 activity 
induced by P23H rod opsin
Following the observed decrease in inclusion incidence in P23H cells treated with 
chemical chaperones it was important to investigate if these compounds had a 
positive effect on cell death measured by LDH release and caspase-3 activity. For 
that purpose SK-N-SH cells expressing wild-type or P23H rod opsin were treated 
with the most effective concentrations of chemical chaperones: 0.25% DMSO; 5 
mM TMAO; 10 mM 4-PBA and 50 mM trehalose for 48 hours. The effect of these 
compounds on LDH release (Figure 5.10a) and caspase-3 activity (Figure 5.10b) 
were assessed. All chemical chaperones reduced LDH release in P23H cells with 
DMSO (p ^ 0.01) and TMAO (p £ 0.01) reducing LDH release by -60%  when 
compared to the untreated P23H controls whereas 4-PBA (p < 0.05) and trehalose 
(p < 0.05) were slightly less effective reducing LDH release by ~40% (Figure 
5.10a). Chemical chaperones also had a positive effect in protecting P23H cells 
against caspase-3 activity as DMSO (p ^ 0.05), TMAO (p < 0.05), 4-PBA (p < 
0.001) and trehalose (p £ 0.05) all reduced caspase-3 activity by ~30% when 
compared to the untreated P23H controls (Figure 5.10b).
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Figure 5.9 Chemical chaperones reduce the amount of insoluble P23H rod 
opsin.
A rod opsin fractionation assay was carried out in SK-N-SH cells expressing 
WT-GFP or P23H-GFP and treated with chemical chaperones as indicated for 24 
hours, a) The amount of total P23H rod opsin was -45% lower than WT and 
chemical chaperones had no effect on the amount of total WT or P23H opsin, b) 
When insoluble P23H rod opsin was quantified as percentage of total protein 
DMSO (p s 0.01) and TMAO (p £ 0.01) reduced the percentage of insoluble opsin 
from -60% to -40%. 4-PBA (p £ 0.005) and trehalose (p £ 0.005) reduced the 
percentage of insoluble opsin from -60% to -25%. Error bars represent ± 2SE.
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Figure 5.10 Chemical chaperones reduce LDH release and caspase-3 
activity in cells expressing P23H rod opsin.
SK-N-SH cells were transfected with GFP-tagged WT or P23H rod opsin and 
treated with chemical chaperones as indicated for 48 hours before LDH (a) and 
caspase-3 activity (b) assays were carried out. P23H cells showed increased 
levels of LDH release when compared to the WT. DMSO (p £ 0.01) and TMAO 
(p s 0.01) reduced LDH release in P23H cells by -60% while 4-PBA (p £ 0.05) 
and trehalose (p £ 0.05) reduced LDH release by -40%. Caspase-3 activity 
levels were higher in P23H cells than in WT cells and DMSO (p < 0.05), TMAO 
(p £ 0.05), 4-PBA (p £ 0.001) and trehalose (p < 0.05) reduced those levels by 
-30%. Error bars represent ± 2SE.
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5.2.7 Chemical chaperones do not alleviate the dominant-negative effect of 
P23H rod opsin on the wild-type protein
After investigating the effect of chemical chaperones in the P23H rod opsin gain of 
function mechanism it was assessed whether chemical chaperones could alleviate 
the dominant-negative effect of the P23H mutant on the wild-type protein. SK-N-SH 
cells were co-transfected with equal amounts of untagged WT and P23H-GFP rod 
opsin followed by treatment with optimal concentrations of chemical chaperones for 
24 hours prior to immunocytochemistry being carried out as described in Chapter 
2. 0.25% DMSO (Figure 5.11d-f), 5 mM TMAO (Figure 5.11 g-i), 10 mM 4-PBA 
(Figure 5.11j-l) and 50 mM trehalose (Figure 5.11m-o) did not appear to promote 
the normal translocation of wild-type rod opsin to the plasma membrane. However, 
chemical chaperones reduced the incidence of rod opsin inclusions in co­
transfected cells from 14.40% ± 3.81 in the untreated controls to 6.50% ± 4.72 
(0.25% DMSO; p <; 0.05), 6.80% ± 2.81 (5 mM TMAO; p < 0.001), 6.90% ± 3.01 
(10 mM 4-PBA; p £ 0.005) and 8.80% ± 2.24 (50 mM trehalose; p £ 0.05) and led 
to a increase in the percentage of cells with a predominant ER staining (Figure 
5.12). In approximate agreement with their effect on P23H inclusions, chemical 
chaperones might partially alleviate the dominant-negative effect of P23H rod opsin 
on the wild-type protein by reducing the amount of wild-type protein in inclusions. 
However, unlike retinoids, chemical chaperones failed to promote the exit of wild- 
type protein to the Golgi in cells co-expressing the wild-type and the P23H rod 
opsin.
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Figure 5.12 Chemical chaperones reduce the recruitment of WT rod opsin 
to inclusions in cells co-expressing WT and P23H rod opsin.
SK-N-SH cells were co-transfected with equal amounts of untagged WT and 
P23H-GFP rod opsin and treated with chemical chaperones as indicated for 24 
hours. The localisation of WT rod opsin in co-transfected cells was assessed and 
DMSO (p £ 0.05), TMAO (p 5 0.001), 4-PBA (p £ 0.005) and trehalose 
(p £ 0.05) reduced the incidence of inclusions containing the WT protein. None of 
these compounds promoted the translocation of WT opsin the plasma mem­
brane. Error bars represent ± 2SE.
] Inclusions
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5.3 Discussion
The chemical chaperones DMSO, TMAO, 4-PBA and trehalose appeared to 
reduce inclusion incidence in SK-N-SH cells expressing the P23H rod opsin to a 
greater extent than retinoids. The most effective concentrations of DMSO, 4-PBA 
and trehalose at reducing inclusion incidence in P23H cells were similar to other 
previously published studies. 0.5% v/v DMSO reduced aggregation in a model of 
MJD/SCA3 (Yoshida et a/., 2002), 10 mM 4-PBA was the most effective 
concentration at restoring the normal expression and attenuating ER stress 
induced by overexpression of a parkin-associated endothelin receptor-like receptor 
(Pael-R) (Kubota et al., 2006) and 2% w/v trehalose (~58 mM) reduced 
aggregation in a mouse model of Huntington’s disease (Tanaka etal., 2004). On 
the other hand, the concentration of TMAO used to reduce inclusion incidence in 
P23H cells (5 mM) were considerably lower than those reported for the reduction of 
aggregation in a MJD/SCA3 model (100-150 mM). These concentrations of TMAO 
did not appear to be tolerated in the cellular model of rhodopsin RP.
In addition, treatment with kosmotropes reduced the amount of insoluble P23H rod 
opsin as assessed by a rod opsin fractionation assay. DMSO and TMAO reduced 
insoluble rod opsin to the same extent as retinoids, whereas 4-PBA and trehalose 
were less effective. However, there were slight discrepancies between the two sets 
of data. For example trehalose was less effective than DMSO and TMAO in 
reducing inclusion incidence as determined by morphological observations in a 
fluorescence microscope but had lower levels of insoluble P23H rod opsin than 
DMSO and TMAO as determined by the fractionation assay. This might be due to 
some P23H aggregates which were scored as inclusions being soluble following 
RIPA buffer lysis. Alternatively some rod opsin aggregation might have occurred 
post-lysis during the experimental protocol of the rod opsin fractionation assay.
Soluble P23H rod opsin protein did not appear to acquire EndoH resistance 
following chemical chaperone treatment suggesting that these compounds were
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unable to assist the folding of the mutant protein and promote its exit from the ER 
to the Golgi. It is important to mention that, unlike retinoids, kosmotropes not only 
failed to produce EndoH resistant species but also did not increase the amount of 
soluble P23H rod opsin resolved in a 10% SDS-PAGE gel and immunodetected by 
1D4. The rod opsin fractionation assay following chemical chaperone treatment 
suggested that the total levels of P23H protein were unchanged following treatment 
with these compounds but the insoluble levels decreased. Consequently, an 
increase in the soluble P23H levels was expected which was not observed 
following the Western blotting of the soluble P23H rod opsin. One explanation for 
this might be that some of the misfolded P23H rod opsin might have aggregated 
during the course of the experiment preventing it from being immunodetected using 
1D4. Another possibility is that even though Triton-X soluble protein was used 
these proteins might not enter or resolve in a SDS-PAGE gel.
The data presented here suggest that DMSO and TMAO lost their efficacy in 
reducing inclusion incidence in P23H cells if added once the inclusions were 
formed. These data correlate with a study by Tatzelt and colleagues (1996) which 
investigated the role of chemical chaperones on a prion protein disease model. A 
crucial conformational change in prion diseases occurs in one or more of the a- 
helices of cellular prion protein (PrPc) which are converted into p-sheets during the 
formation of the pathogenic isoform (PrPSc). Scrapie-infected mouse 
neuroblastoma ScN2a cells were treated with DMSO and TMAO and these 
compounds prevented the conversion to the detergent-insoluble PrPSc from newly 
synthesised PrPc but failed to affect the existing population of PrPSc molecules in 
the cells. Furthermore, studies which involved the incubation of P23H rod opsin 
cells with 9-c/s-retinal once the inclusions were formed suggested that the ligand 
did not reduce inclusion incidence. Both these studies are in agreement with the 
data presented here in which chemical chaperones appeared to lose their efficacy 
at reducing inclusion incidence in P23H cells once the inclusions had formed. This 
data suggests that chemical chaperones reduce aggregation by acting before 
inclusions are formed.
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Importantly, chemical chaperones, unlike retinoids, reduced inclusion incidence in 
cells expressing K296E rod opsin. It appeared that the non-specific effect of 
kosmotropes on protein stabilisation might be beneficial for this misfolding mutation 
which disrupted the binding site for retinoids. It remains to be seen if this could be 
extrapolated to other protein misfolding diseases where mutations in the binding 
site of pharmacological chaperones render them ineffective.
Chemical chaperones protected cells expressing P23H rod opsin against LDH 
release and caspase-3 activity suggesting that they might alleviate the gain of 
function mechanism induced by the P23H rod opsin. This was in agreement with 
previously published studies which found chemical chaperones to be protective 
against cell death and apoptosis in protein misfolding disease models.
For example, the role of chemical chaperones in cell death of a model of 
MJD/SCA-3, which is an inherited neurodegenerative disorder caused by 
expansion of the polyglutamine stretch in the MJD gene-encoded protein ataxin-3, 
was assessed by Yoshida and colleagues (2002). In this model treatment with 
DMSO and TMAO reduced cell death in BHK-21 and Neuro2a cells expressing the 
N-terminal truncated ataxin-3 with an expanded polyglutamine stretch. Another 
study was carried out to investigate the role of kosmotropes on apoptosis in a 
model of the RP17 form of ADRP (Bonapace etal., 2004). The R14W mutation in 
the signal sequence of carbonic anhydrase (CA) IV was identified in patients with 
the RP 17 form of ADRP. R14W CA IV expressed in COS-7 cells misfolded and 
accumulated in the ER leading to increased apoptosis. Treatment with 4-PBA was 
effective at reducing apoptosis in these R14W CA IV expressing cells (Bonapace 
et a/., 2004).
When tested in the dominant-negative context chemical chaperones reduced the 
incidence of inclusions containing wild-type rod opsin in co-transfected cells. 
However there was no evidence that chemical chaperones prevented the 
interaction between the wild-type and the mutant protein as demonstrated by the
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inability of the wild-type rod opsin to exit the ER and re-establish its normal 
translocation through the secretory pathway when co-transfected with P23H rod 
opsin. This was in contrast with retinoids suggesting that 9-c/s-retinal and 11-c/s 
retinal might affect the folding of P23H rod opsin in order to suppress the 
dominant-negative interaction between P23H rod opsin and the wild-type protein.
The analysis of the data presented in this Chapter suggested that chemical 
chaperones might exert their effects in this cellular model of rhodopsin RP by 
stabilising misfolded P23H protein resulting in the prevention of aggregation, 
however, this did not result in the facilitation of folding of the mutant rod opsin.
Most studies involving other misfolded mutants such as the AF508 CFTR (Denning 
et al., 1992) and others have demonstrated that chemical chaperones when used 
in their models promoted folding of the respective proteins. It remains to be seen if 
the anti-aggregation effects of chemical chaperones on the misfolding of Class II 
mutant rod opsin are sufficient perse to prevent or delay the onset of blindness in 
rhodopsin RP patients.
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Chapter 6: HSP inducers and co-inducers
6.1 Introduction
Misfolded or aggregated proteins are thought to be responsible for a variety of 
neurodegenerative conditions and accumulate in inclusions of similar fibrillar 
structure despite being structurally unrelated. As a result it has been widely 
suggested that misfolding is the consequence of hydrophobic regions or other 
domains that are normally buried in the normal protein becoming exposed as 
consequence of mutations, leading to impaired interactions with the lipid 
membrane and other cellular components (Barral eta!., 2004). Molecular 
chaperones in general and HSPs in particular recognise these hydrophobic 
residues or unstructured backbone regions in misfolded proteins and promote the 
folding process through cycles of substrate binding and release regulated by their 
nucleotide binding, hydrolysis and facilitated by cofactor proteins.
As a result of their actions as promoters of the folding process it has been 
suggested that inducing the expression of molecular chaperones is likely to 
alleviate toxicity associated with misfolded protein disorders. Cummings and 
colleagues (1998) carried out work on cellular models of spinocerebellar ataxia 
type 1 (SCA1), which is an autosomal dominant neurodegenerative disorder 
caused by expansion of a polyglutamine tract in ataxin-1. These authors showed 
that the overexpression of a human DnaJ homologue, HDJ-2/HSDJ, in HeLa cells 
decreased the frequency of ataxin-1 aggregation. Consequently, these data 
indicate that protein misfolding was responsible for the nuclear aggregates seen in 
SCA1, and that overexpression of a DnaJ chaperone promoted the recognition of a 
misfolded polyglutamine repeat protein, allowing its refolding and/or ubiquitin- 
dependent degradation. Furthermore, overexpression of Hsp70 protected against 
neurodegeneration in a mouse model of SCA1 (Cummings etal., 2001). Other 
studies showed that overexpression of Hsp70 in a Drosophila melanogaster model 
of polyglutamine disease resulted in the maintenance of normal retinal structure
128
suggesting suppression of polyglutamine-induced neurodegeneration, although 
there was no reduction of inclusion incidence in this study (Warrick et al., 1999).
A pharmacological approach has been attempted in several models of 
neurodegenerative diseases using inducers and co-inducers of HSPs. An inducer 
of HSPs is a compound which can activate heat-shock transcription factors (HSFs) 
and consequently induce HSP expression by itself. On the other hand, a co­
inducer is a compound that does not induce HSPs perse, but can enhance HSP 
induction in conjunction with other mild stresses.
In this chapter, the effect of a variety of HSP inducers and co-inducers were 
assessed in a cell model of rhodopsin RP. Arimoclomol is a derivative of 
bimoclomol, a hydroxylamine derivative which acts as a co-inducer of HSPs, and 
was found to improve muscle function and neuronal survival in a mouse model of 
amyotrophic lateral sclerosis (ALS) (Kieran et al., 2004).
Celastrol, a quinone methide triterpene which is an active component from Chinese 
herbal medicine has potent anti-inflammatory and anti-oxidative effects in addition 
to activating heat shock factor 1 (HSF1) (Westerheide et al., 2004). Furthermore, it 
was recently found to extend the life span of transgenic mice in a model of ALS 
(Kiaei et al., 2005).
In addition to these compounds, three Hsp90 inhibitors were tested which included 
the benzoquinone ansamycin geldanamycin, the fungal antibiotic radicicol, and a 
geldanamycin-derivative 17-allylamino-17-demethoxygeldanamycin (17-AAG) 
whose molecular structures are shown in Figure 6.1. The rationale for using these 
Hsp90 inhibitors at low doses to induce HSPs is based on the HSF1 cycle model 
where HSF1 is usually bound to a molecular chaperone complex containing 
Hsp90, Hsp70, Hsp40 and other co-chaperones and is usually in an inactive state 
unless a stress signal is detected. Geldanamycin, radicicol and 17-AAG bind 
Hsp90 thereby disrupting the chaperone complex and resulting in the release of
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Figure 6.1 Representation of the molecular structures of the Heat shock 
protein 90 (Hsp90) inhibitors Geldanamycin, Radicicol and 17-allylamino- 
17-demethoxygeldanamycin (17-AAG).
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the inactive HSF1, which in turn leads to the activation of HSF1 and consequent 
expression of HSPs. This approach has been used in a cell model of Huntington's 
disease (HD) where treatment of COS-1 cells with geldanamycin induced the 
expression of Hsp40, Hsp70 and Hsp90 and inhibited the HD exon 1 protein 
aggregation in a dose-dependent manner (Sittler et al., 2001). The administration 
of 17-AAG markedly ameliorated motor impairments in the spinal and bulbar 
muscular atrophy (SBMA) transgenic mouse model without detectable toxicity, by 
reducing amounts of monomeric and aggregated mutant androgen receptor (AR) 
(Waza et al., 2005). Furthermore, the mutant AR showed a higher affinity for 
Hsp90-p23 and preferentially formed an Hsp90 chaperone complex as compared 
to wild-type AR. In addition, mutant AR was preferentially degraded in the 
presence of 17-AAG as compared to wild-type AR. 17-AAG also mildly induced 
Hsp70 and Hsp40 (Waza et al., 2005).
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6.2 Results
6.2.1 HSP inducers and co-inducers reduce inclusion incidence in cells 
expressing P23H rod opsin
6.2.1.1 Arimoclomol
Treatment with arimoclomol reduced inclusion incidence in cells expressing P23H 
rod opsin in a dose-dependent manner (Figure 6.2a). The lowest concentration to 
have an effect on inclusion incidence was 0.05 pM and the most effective dose 
was 1 pM arimoclomol which resulted in the inclusion incidence decreasing from 
27.19% ± 5.97 in the untreated controls to 4.23% ± 0.65 (p < 0.001). Arimoclomol 
had no effect on the wild-type rod opsin at concentrations lower than 1 pM (Figure 
6 .2 c).Higher concentrations of arimoclomol failed to decrease inclusion incidence 
further. Furthermore, deleterious effects on cellular morphology were observed in 
both the wild-type and P23H cells when concentrations higher than 20 pM were 
used. Treatment with 1 pM arimoclomol appeared to partially promote the 
translocation of P23H rod opsin to the plasma membrane of the cells (Figure 6.2e).
6.2.1.2 Celastrol
Celastrol caused a moderate decrease in inclusion incidence in P23H-transfected 
cells (Figure 6.3a). The most efficient concentration at reducing inclusion incidence 
was 2 pM which led to a reduction of inclusion incidence from 28.24% ± 5.46 in the 
untreated controls to 17.65% ± 5.89 (p < 0.05). However, despite this moderate 
reduction in inclusion incidence treatment with 2 pM celastrol appeared to have a 
detrimental rather than a beneficial effect on the P23H cells as observations using 
fluorescent and confocal microscopy indicated a high level of dead or abnormally 
shaped cells when compared to the untreated controls (Figure 6.3e). Celastrol 
when used at concentrations lower than 2 pM had no effect on cells expressing the 
wild-type protein (Figure 6.3c). It has been suggested that P23H rod opsin might 
make cells more sensitive to toxicity (M.E.Cheetham, personal communication),
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Arimoclomol (pM)
Figure 6.2 Arimoclomol reduces inclusion incidence in cells expressing 
P23H rod opsin.
a) SK-N-SH cells were transfected with P23H-GFP rod opsin and treated with 
different concentrations of arimoclomol for 24 hours. The most effective concen­
tration was 1 pM arimoclomol which reduced inclusion incidence from 27.19%
± 5.97 in the untreated controls to 4.23% ± 0.65 (p s 0.001). Error bars represent 
± 2SE. b-e) Arimoclomol reduced inclusion incidence and partially promoted the 
translocation of mutant rod opsin to the plasma membrane of the cell. Asterisks 
highlight inclusions. Scale bar = 10 pm.
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Figure 6.3 Treatment with celastrol results in a moderate reduction of 
inclusion incidence in cells expressing P23H rod opsin.
a) SK-N-SH cells were transfected with P23H-GFP rod opsin and treated with 
different concentrations of celastrol for 24 hours. The concentration of celastrol 
which reduced inclusion incidence the most was 2 pM and resulted in a decrease 
of inclusion incidence from 28.24% ± 5.46 in the untreated controls to 17.65%
± 5.89 (p £ 0.05). Error bars represent ± 2SE. b-e) Despite its moderate effect on 
inclusion incidence celastrol failed to promote the translocation of mutant rod 
opsin to the plasma membrane of the cell. Asterisks highlight inclusions. Scale 
bar = 10 pm.
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and this might account for the different observations as a result of celastrol 
treatment in wild-type and P23H cells. The levels of abnormal cells were reduced 
when lower concentrations of celastrol were used, however, these doses did not 
appear to reduce inclusion incidence.
6.2.1.3 Geldanamycin
The use of the prototypical Hsp90 inhibitor geldanamycin in a cell model of 
rhodopsin RP resulted in reduction of inclusion incidence in cells expressing P23H 
rod opsin (Figure 6.4a), although the effect was not as pronounced as with 
arimoclomol. The concentration of geldanamycin with the greatest effect on 
inclusion incidence was 2 pM which resulted in a decrease in inclusion incidence 
from 19.40% ± 6.04 in the untreated controls to 8.84% ± 5.11 (p < 0.05). 
Geldanamycin concentrations lower than 2 pM had no effect on the wild-type 
protein (Figure 6.4c). Geldanamycin treatment resulted in an increase in the 
percentage of cells with a predominantly ER staining pattern and did not lead to the 
translocation of the mutant protein to the plasma membrane of the cells (Figure 
6.4e).
6.2.1.4 Radicicol
Treatment with the Hsp90 inhibitor radicicol resulted in a reduction of inclusion 
incidence in cells expressing P23H rod opsin (Figure 6.5a) to levels similar to those 
achieved with geldanamycin. The largest decrease in inclusion incidence was 
observed when using 5 pM radicicol which caused the inclusion incidence to 
decrease from 27.49% ± 4.76 in the untreated controls to 10.16 ± 2.68 (p £ 0.001). 
When used at concentrations lower than 5 pM radicicol had no effect on the 
cellular morphology of the wild-type protein (Figure 6.5c). This decrease in 
inclusion incidence, however, was not accompanied by an increase in the number 
of cells in the population showing a plasma membrane staining (Figure 6.5e). 
Treatment with higher concentrations of radicicol resulted in the appearance of 
cells with an abnormal morphology in both the wild-type and P23H cells.
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Figure 6.4 The Hsp90 inhibitor geldanamycin reduces inclusion incidence 
in cells expressing P23H rod opsin.
a) SK-N-SH cells were transfected with P23H-GFP rod opsin and treated with 
different concentrations of geldanamycin for 24 hours. The most effective concen 
tration was 2 pM geldanamycin which reduced inclusion incidence from 19.40%
± 6.04 in the untreated controls to 8.84% ±5.11 (ps 0.05). Error bars represent 
± 2SE. b-e) Geldanamycin reduced inclusion incidence but did not promote the 
translocation of mutant rod opsin to the plasma membrane of the cell. Asterisks 
highlight inclusions. Scale bar = 10 pm.
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Figure 6.5 The Hsp90 inhibitor radicicol reduces inclusion incidence in cells 
expressing P23H rod opsin.
a) SK-N-SH cells were transfected with P23H-GFP rod opsin and treated with 
different concentrations of radicicol for 24 hours. The most effective concentration 
was 5 pM radicicol which reduced inclusion incidence from 27.19% ± 4.76 in the 
untreated controls to 10.16 ± 2.68 (p s 0.001). Error bars represent ± 2SE. 
b-e) Radicicol reduced inclusion incidence but did not to promote the transloca­
tion of mutant rod opsin to the plasma membrane of the cell. Asterisks highlight 
inclusions. Scale bar = 10 pm.
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6.2.1.5 17-allylamino-17-demethoxygeldanamycin (17-AAG)
17-AAG led to a dose-dependent reduction of inclusion incidence in cells 
expressing P23H rod opsin (Figure 6 .6 a). This compound started to have a positive 
effect on the inclusion incidence at a concentration of 50 nM and had maximal 
effect at a concentration of 1 pM where it reduced inclusion incidence from 22.20% 
± 3.56 in the untreated controls to 6.50% ± 2.09 (p < 0.001). 17-AAG doses lower 
than 1 pM 17-AAG had no effect on the cellular morphology of the wild-type protein 
(Figure 6 .6 c). In this cell model of rhodopsin RP, 17-AAG appeared to be more 
effective at reducing inclusion incidence than the other Hsp90 inhibitors used such 
as geldanamycin and radicicol. Despite this decrease in inclusion incidence 17- 
AAG did not appear to promote the translocation of P23H rod opsin to the plasma 
membrane of the cells (Figure 6 .6 e).
6.2.2 Treatment with HSP inducers and co-inducers fails to promote EndoH 
resistance in soluble P23H rod opsin species
In order to complement the morphological assessment of the effect of HSP 
inducers and co-inducers on cells expressing P23H rod opsin, a biochemical 
characterisation of soluble P23H rod opsin species was carried out. This was 
achieved by loading 10 pg of soluble cell lysate protein treated with HSP inducers 
and co-inducers onto a 10% SDS-PAGE gel followed by immunoblotting with 1D4 
as described in Chapter 2. Treatment with arimoclomol (Figure 6.7a), 
geldanamycin (Figure 6.7b) and radicicol (Figure 6.7c) did not increase the levels 
of soluble P23H protein and did not appear to promote EndoH resistance (arrow) of 
soluble mutant protein species. Treatment with 17-AAG (Figure 6.7d) appeared to 
increase the levels of soluble P23H protein although it did not appear to promote 
EndoH resistance of mature P23H rod opsin species.
6.2.3 Effect of HSP inducers and co-inducers on the total and insoluble rod 
opsin levels in SK-N-SH cell lysates
The effect of HSP inducers and co-inducers on the levels of WT and P23H rod 
opsin was assessed by a rod opsin fractionation assay as described in Chapter 2.
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Figure 6.6 17-AAG reduces inclusion incidence in cells expressing P23H 
rod opsin.
a) SK-N-SH cells were transfected with P23H-GFP rod opsin and treated with 
different concentrations of 17-AAG for 24 hours. The most effective concentration 
was 1 pM 17-AAG which reduced inclusion incidence from 22.20% ± 3.56 in the 
untreated controls to 6.50% ± 2.09 (p £ 0.001). 17-AAG was more effective at 
reducing inclusion incidence that the other Hsp90 inhibitors used namely 
geldanamycin and radicicol. Error bars represent ± 2SE. b-e) 17-AAG reduced 
inclusion incidence but did not promote the translocation of mutant rod opsin to 
the plasma membrane of the cell. Asterisks highlight inclusions. Scale bar =
10 pm.
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Figure 6.7 HSP inducers and co-inducers fail to promote EndoH resistance 
of soluble P23H rod opsin species.
SK-N-SH cells expressing untagged P23H rod opsin were treated with arimoclo­
mol (a), geldanamycin (b), radicicol (c) and 17-AAG (d) for 24 hours. Cells were 
lysed and the soluble fraction was obtained as described in Chapter 3. 10 pg of 
soluble cell lysate protein were resolved on a 10% SDS-PAGE gel followed by 
immunoblotting with 1D4. Neither of these compounds promoted mature P23H 
rod opsin species (arrows). The position of molecular weight markers in kDa are 
shown on the left.
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None of the compounds tested had an effect on the total levels of WT or P23H rod 
opsin (Figure 6 .8 a). Arimoclomol, geldanamycin, radicicol and 17-AAG, but not 
celastrol, had a positive effect in reducing the amount of insoluble rod opsin. 17- 
AAG, arimoclomol and radicicol were the most efficient and resulted in a reduction 
of insoluble P23H rod opsin from 58.70% ± 1.58 in the untreated controls to 
25.95% ± 1.13% (p < 0.01), 29.47 ± 2.84 (p < 0.01), and 29.75% ± 3.44 (p < 0.05) 
respectively. Geldanamycin was slightly less efficient reducing the levels of 
insoluble opsin to 44.07% ± 0.77 (p < 0.001).
6.2.4 Analysis of LDH release and caspase-3 activity following treatment 
with HSP inducers and co-inducers
The effect of HSP inducers and co-inducers on LDH release and caspase-3 activity 
of cells expressing P23H rod opsin was assessed as described in Chapter 2. The 
most effective compounds at reducing LDH release were arimoclomol (p < 0.01), 
radicicol (p £ 0.01) and 17-AAG (p  ^0.005) which reduced LDH release back to 
wild-type levels (Figure 6.9a). Geldanamycin reduced LDH release albeit to a 
lesser degree (p £ 0.05) and celastrol did not reduce LDH release confirming initial 
morphological observations that it was not beneficial to P23H cells. Arimoclomol (p 
< 0.005), radicicol (p £ 0.05) and geldanamycin (p < 0.001) and 17-AAG (p <
0.005) were equally effective at reducing caspase-3 activity in P23H cells (Figure 
6.9b). Celastrol on the other hand increased caspase-3 activity levels by -20%  in 
agreement with previous morphological observations.
6.2.5 Characterisation of the effect of HSP inducers and co-inducers on the 
dominant-negative interaction of P23H rod opsin on the wild-type 
protein
Assessment of the effect of HSP inducers and co-inducers on the dominant- 
negative mechanism of cell death between the P23H and the wild-type rod opsin 
was carried out as described in Chapter 2. Treatment with arimoclomol resulted in 
a decrease in the incidence of inclusions in co-transfected cells containing the wild- 
type protein (Figure 6.10d-f). Furthermore, arimoclomol resulted in an increase in
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Figure 6.8 Arimoclomol, radicicol, geldanamycin and 17-AAG, but not 
celastrol, reduce the amount of insoluble P23H rod opsin.
A rod opsin fractionation assay was carried out as described in Chapter 3. SK-N- 
SH cells expressing WT-GFP or P23H-GFP were treated with HSP inducers and 
co-inducers as indicated for 24 hours. The concentrations of these compounds 
were: 1 pM arimoclomol; 2 pM celastrol; 2 pM geldanamycin; 5 pM radicicol and 
1 pM 17-AAG . a) HSP inducers and co-inducers had no effect on the total 
protein levels of WT or P23H rod opsin b) Insoluble WT and P23H rod opsin 
quantified as percentage of total protein. 17-AAG (p £ 0.01), arimoclomol 
(p £ 0.01) and radicicol (p £ 0.05) were the most effective at reducing insoluble 
P23H rod opsin levels. Geldanamycin was less effective (p £ 0.001) and celastrol 
failed to reduce insoluble P23H levels. Error bars represent ± 2SE.
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Figure 6.9 Effect of HSP inducers and co-inducers on LDH release and 
caspase-3 activity in cells expressing P23H rod opsin.
SK-N-SH cells were transfected with WT or P23H rod opsin and treated with HSP 
inducers and co-inducers for 48h before LDH (a) and caspase-3 activity (b) 
assays were carried out as described in Chapter 3. Treatment with arimoclomol 
(p £ 0.01), radicicol (p s 0.01) and 17-AAG (p ^ 0.005) were the most efficient at 
reducing LDH release in cells expressing P23H rod opsin whereas geldanamycin 
was less effective (p £ 0.05). Treatment with celastrol failed to reduce LDH 
release levels. Arimoclomol (p £ 0.005), radicicol (p ^ 0.05), geldanamycin 
(p £ 0.001) and 17-AAG (p £ 0.005) were equally effective at reducing caspase-3 
activity levels whereas treatment with celastrol increased caspase-3 activity when 
compared with the untreated P23H controls. Error bars represent ± 2SE
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Figure 6.10 Arimoclomol partially promotes the translocation to the plasma 
membrane of WT rod opsin in cells co-expressing WT and P23H rod opsin.
SK-N-SH cells were co-transfected with equal amounts of untagged WT and 
P23H rod opsin as described in Chapter 3 and treated with arimoclomol for 24 
hours, a-c) The untreated controls showed that the WT protein failed to translo­
cate to the plasma membrane of the cells and accumulated with the P23H rod 
opsin in the ER and in large intracellular inclusions (*). d-f) Treatment with 1 pM 
arimoclomol (p £ 0.001) partially promoted the translocation of the WT rod opsin 
to the plasma membrane (arrows). Scale bars =10 pm.
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wild-type rod opsin present on the plasma membrane of co-transfected cells from 
3.94% ± 2.00 in the untreated controls to 19.49% ± 6.12 (p < 0.001) (Figure 6.12). 
Geldanamycin, radicicol and 17-AAG reduced the incidence of inclusions in co­
transfected cells which contained the wild-type protein, whereas celastrol failed to 
reduce the incidence of these inclusions (not statistically significant) when 
compared to untreated cells (Figure 6.11; Figure 6.12). The effect of the other HSP 
inducers on the facilitation of the translocation of the wild-type protein to the 
plasma membrane of co-transfected cells was less clear. Treatment with radicicol, 
17-AAG (p < 0.001) and geldanamycin (p < 0.05) resulted in a slight increase on 
the number of co-transfected cells with the wild-type protein on the plasma 
membrane (Figure 6.12), however, the wild-type protein on the plasma membrane 
was less prominent than when compared to cells treated with arimoclomol.
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Figure 6.12 Arimoclomol, radicicol, geldanamycin and 17-AAG reduce the 
inclusion incidence of WT rod opsin in cells co-expressing WT and P23H 
rod opsin.
SK-N-SH cells were co-transfected with equal amounts of untagged WT and 
P23H-GFP rod opsin as described in Chapter 3 and treated as indicated for 24 
hours with the following doses of HSP inducers and co-inducers: 1 pM arimoclo­
mol, 2 pM celastrol, 2 pM geldanamycin, 5 pM radicicol and 1 pM 17-AAG. The 
intracellular localisation of WT rod opsin in co-transfected cells was assessed 
and scored as plasma membrane, ER or inclusions. Arimoclomol reduced the 
incidence of inclusions containing the WT protein (p £ 0.001) and partially 
promoted the translocation of WT rod opsin to the plasma membrane of co­
transfected cells (p £ 0.001). Error bars represent ± 2SE.
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6.3 Discussion
The data presented in this chapter suggest that the hydroxylamine derivative 
arimoclomol and the Hsp90 inhibitors geldanamycin, radicicol and 17-AAG 
alleviated the toxic gain of function mechanism of cell death in cells expressing 
P23H rod opsin. However, none of these compounds with the exception of 
arimoclomol efficiently promoted the translocation of the mutant protein to the 
plasma membrane of the cell suggesting that the folding of P23H rod opsin was not 
improved to the extent of allowing all the mutant protein to evade ER quality control 
and progress through the secretory pathway. Although morphological observations 
suggested that arimoclomol might promote the translocation of P23H rod opsin to 
the plasma membrane this was not confirmed by the detection of EndoH resistant 
species in a Western blot of soluble cell lysates. This was in contrast with 
experiments carried out following the treatment with retinoids in cells expressing 
P23H rod opsin, where plasma membrane staining correlated with the appearance 
of EndoH resistance. Furthermore, arimoclomol did not increase the amount of 
soluble P23H rod opsin detected by Western blotting when compared to the 
untreated controls, as was observed with retinoids. There might be several 
possibilities for the absence of EndoH resistance in arimoclomol-treated cells. 
Firstly, the levels of P23H rod opsin that exit the ER to the Golgi and reach the 
plasma membrane following treatment with arimoclomol might be below the 
threshold for detection by 1D4 but not by immunocytochemistry as treatment with 
arimoclomol of cells expressing untagged P23H rod opsin promoted the 
translocation of the mutant protein to the plasma membrane. Secondly, a greater 
level of P23H opsin species, independent of drug treatment, appeared to be 
retained in the stacking gel following digestion with EndoH (Figure 5.7) when 
compared to undigested cell lysates.
In order to address this apparent discrepancy non-permeabilised SK-N-SH cells 
expressing P23H-GFP were incubated with the N-terminal-specific 4D2 rhodopsin 
antibody (a kind gift from Professor Robert Molday, UBC). The rationale for this
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approach was that a 4D2 signal would only be detected if P23H rod opsin was 
present in the plasma membrane and the 4D2 N-terminus epitope was located 
extracellularly. However, when this experiment was carried out 4D2 also stained 
the intracellular inclusions preventing the elucidation of the staining pattern 
following treatment with arimoclomol. These observations suggested membrane 
leakage and correlate with the LDH assay where the disruption of the plasma 
membrane in P23H cells resulted in increased LDH release levels indicating a 
detrimental effect of P23H rod opsin on cell viability.
In the case of the Hsp90 inhibitors geldanamycin, radicicol and 17-AAG the 
inability to detect EndoH resistant species correlated with the morphological 
observations, where despite reducing inclusion incidence these compounds did not 
appear to promote the translocation of the mutant protein to the plasma 
membrane. Furthermore, geldanamycin and radicicol did not increase the levels of 
soluble P23H rod opsin whereas 17-AAG appeared to slightly increase the levels 
of soluble mutant protein.
The rod opsin fractionation assay carried out in P23H cells following treatment with 
arimoclomol, geldanamycin, radicicol and 17-AAG reduced insoluble mutant opsin 
while having no effect on the total levels of protein. Previously published data 
suggested that 17-AAG induced the degradation of misfolded mutant AR (Solit et 
al., 2002). It would be interesting to assess if the inhibition of the proteasome 
would result in increased inclusion incidence/insoluble protein following treatment 
of P23H cells with 17-AAG. This should elucidate whether 17-AAG reduces 
inclusion incidence/insoluble protein by preventing aggregation of P23H rod opsin 
or by increasing the degradation of misfolded mutant protein.
The reduced levels of insoluble P23H rod opsin and the maintenance of the total 
levels of mutant protein following treatment with HSP inducers and co-inducers 
suggested that soluble P23H levels had increased. However, this was not 
observed in a Western blot of soluble P23H rod opsin species with the exception of
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17-AAG. This phenomenon was also present following treatment with chemical 
chaperones where the rod opsin fractionation assay suggested an increase in 
soluble P23H rod opsin which was not observed in a Western blot detecting 
soluble P23H species.
Arimoclomol, radicicol, 17-AAG, and to a lesser extent geldanamycin, reduced 
LDH release confirming that these compounds alleviated the gain of function 
mechanism induced by P23H rod opsin. Arimoclomol, radicicol and 17-AAG 
reduced LDH release back to wild-type protein levels and were more effective than 
chemical chaperones and equally as effective as retinoids. Arimoclomol, 
geldanamycin, radicicol and 17-AAG were equally effective at reducing caspase-3 
activity in cells expressing P23H rod opsin. As with chemical chaperones caspase- 
3 activity was reduced to intermediate levels between those of the wild-type and 
P23H controls. These compounds were less effective than retinoids as the 
treatment with 9-c/s-retinal and 11-c/s-retinal reduced caspase-3 activity back to 
wild-type levels.
Westerheide and colleagues (2004) have suggested that the maximal induction of 
the inducible Hsp70 promoter by celastrol occurred at a concentration of 7 pM with 
an Ec50 of 3 pM. In the cell model for rhodopsin RP presented in this study 
concentrations ranging from 0.1 pM to 5 pM failed to elicit positive effects on cells 
expressing P23H despite a marginal reduction in inclusion incidence. It would be 
interesting to assess the toxicity in cells expressing P23H rod opsin following 
treatment with celastrol was due to a long incubation with the compound. However, 
this was not likely to be the case as Westerheide and colleagues (2004) incubated 
cells with celastrol for 24 hours prior to the assessment of Hsp70 induction.
Arimoclomol appeared to have a mild effect on the dominant-negative effect of 
P23H rod opsin on the wild-type protein by reducing the recruitment of the wild- 
type protein to inclusions and by partially promoting the translocation of wild-type 
protein to the plasma membrane of co-transfected cells, however, this was less
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evident that the effects seen following treatment with retinoids. Geldanamycin, 
radicicol and 17-AAG reduced the incidence of inclusions containing wild-type rod 
opsin in co-transfected cells and that might account for a partial alleviation of the 
dominant-negative phenotype. However, as with chemical chaperones there was 
no evidence that these compounds promoted the folding of P23H rod opsin and 
consequently suppressed the dominant-negative effect of the P23H rod opsin on 
the wild-type protein, as demonstrated by the inability of the wild-type rod opsin to 
exit the ER and re-establish its normal translocation through the secretory pathway 
in co-transfected cells. This correlated with the inability to promote P23H folding as 
assessed by the absence of EndoH resistant species.
When COS-1 cells were treated with geldanamycin it resulted in the activation of 
the heat shock response and prevented the aggregation of a Huntington's disease 
exon 1 protein with a polyglutamine stretch in the pathological range (Sittler et a/., 
2001). It was proposed that the effect of geldanamycin on the HD exon 1 
aggregation was a direct consequence of the activation of Hsp40, Hsp70 and 
Hsp90 causing an increased expression of these proteins. These chaperones 
associated with the mutant HD exon 1 protein and prevented its aggregation into 
fibrillar structures. Furthermore, these authors demonstrated Hsp90 itself did not 
appear to be directly involved in the inhibition of mutant HD exon 1 aggregation. 
Therefore, it appeared that a direct interaction between Hsp90 and the HD exon 1 
protein was not necessary for the suppression of aggregation in vivo and the key 
event was the geldanamycin induced dissociation of HSF-Hsp90 complexes. 
However, Dickey and colleagues (2007) reported that inhibition of Hsp90 led to 
decreases in p-tau levels, primary pathologic component of Alzheimer's disease, 
independent of HSF1 activation. A critical mediator of this mechanism appeared to 
be carboxy terminus of Hsp70-interacting protein (CHIP), a tau ubiquitin ligase. 
Cochaperones were also involved in Hsp90-mediated removal of p-tau, while those 
of the mature Hsp90 refolding complex prevented this effect (Dickey eta!., 2007).
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Geldanamycin however has limitations as a drug candidate in protein-folding 
disorders due to its poor stability and hepatotoxicity (Supko et at., 1995). This led 
to the search for synthetic analogues with higher potency and lower toxicity. For 
example, geldanamycin binds to full-length dimeric Hsp90 with a Kd = 1.2 pM while 
radicicol has shown significantly higher affinity with a Kd = 19 nM and both 
compounds bind to intact dimeric yeast Hsp90 with stoichiometries of 
approximately one antibiotic molecule per Hsp90 monomer (Roe et al., 1999). 
These data raise important questions in relation to the cellular model for rhodopsin 
RP as the most effective concentrations for geldanamycin and radicicol were 2 pM 
and 5 pM respectively, in stark contrast with their Kd values. This might be due to 
optimal concentrations being determined based on two factors: reduction of 
inclusion incidence and absence of toxicity. Radicicol while having higher affinity 
was shown to be far less toxic than geldanamycin at equivalent concentrations 
(Sano, 2001) and this might account for the higher concentration of radicicol 
required for maximum effect in cells expressing P23H rod opsin.
Pharmacological interventions with compounds that cause the induction of HSPs 
have a great therapeutic potential in protein misfolding diseases. This is particularly 
the case as the late onset of neurodegenerative misfolding diseases may be 
triggered by an imbalance between the cellular chaperone machinery and the 
amount of misfolded protein species. This study has identified arimoclomol and 
three inducers of HSPs such as geldanamycin, radicicol and 17-AAG as potential 
pharmacological candidates for patients with Class II rhodopsin RP as they were 
able to alleviate the gain of function mechanisms induced by P23H rod opsin.
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Chapter 7: Other compounds and combination of
treatments
The data presented in this chapter relates to a variety of other compounds used on 
the cell model of rhodopsin RP. They include rapamycin an inhibitor of the 
mammalian target of rapamycin (mTOR); salubrinal an inhibitor of eukaryotic 
translation initiation factor 2 subunit a (elF2a) dephosphorylation; the anti-oxidant 
resveratrol; the deglucosidase inhibitors 1-Deoxynojirimycin (1-DNJ) and N- 
butyldeoxynojirimycin (NB-DNJ). Furthermore, this chapter also includes 
preliminary data on treatments combining more than one compound such as 9-c/s- 
retinal and chemical chaperones, or a combination of chemical chaperones.
7.1 Autophagy inducers
7.1.1 Introduction
The major pathways for protein and organelle degradation in eukaryotic cells are 
cytosolic turnover by the proteasome and autophagy. The induction of autophagy 
can be achieved by inhibiting the mammalian target of rapamycin (mTOR) which 
negatively regulates autophagy (Ravikumar etal., 2002). mTOR is a well- 
conserved 289 kDa phosphatidylinositol 3-kinase (PI 3-kinase)-related kinase 
(PIKK) which is an integrator of various extracellular and intracellular signals 
including growth factors, nutrients, energy, and stress (Tsang etal., 2007). 
Rapamycin is a macrolide that is produced by the bacterium Streptomyces 
hygroscopicus and was the first compound identified which acted as an inhibitor of 
mTOR. Rapamycin includes two separate moieties namely the TOR-binding and 
the FKBP12-binding regions. In order to be biologically active it forms a tertiary 
complex with mTOR and FKBP12 (Sabers etal., 1995).
Treatment with rapamycin protected against neurodegeneration whereas the 
rapamycin analogue CCI-779 improved the performance in behavioural tasks and 
decreased the levels of inclusions in a mouse model of Huntington's disease
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(Ravikumar et a/., 2004). More recently rapamycin was shown to enhance the 
autophagic clearance of a variety of other misfolding proteins and to reduce toxicity 
in Drosophila expressing wild-type or mutant forms of tau (Berger et al., 2006) 
suggesting a possible wider application for this therapeutic approach.
The autophagy clearance induced by rapamycin on autophagy substrates such as 
mutant huntingtin and mutant a-synuclein transfected into COS-7 cells was further 
enhanced when trehalose was used in conjunction with rapamycin (Sarkar et al., 
2007). In addition trehalose had autophagic inducing properties perse leading to 
the suggestion that trehalose might have dual protective properties in this model 
both as an inducer of autophagy and as a chemical chaperone which protected the 
cells against pro-apoptotic insults via the mitochondrial pathway (Sarkar et al., 
2007).
The results obtained in these studies suggested that the induction of autophagy by 
use of rapamycin could be beneficial in a cell model of rhodopsin RP where the 
P23H protein misfolded, was retained in the ER and accumulated in intracellular 
inclusions.
7.1.2 Results
7.1.2.1 Rapamycin reduces inclusion incidence in cells expressing P23H rod 
opsin and this is enhanced by trehalose
7.1.2.1.1 Rapamycin
Treatment with different concentrations of rapamycin resulted in a dose-dependent 
reduction of inclusion incidence in cells expressing P23H rod opsin (Figure 7.1.1). 
The most effective concentration of rapamycin at reducing inclusion incidence was 
1 pM which resulted in a decrease in inclusion incidence from 24.26% ± 4.52 in the 
untreated controls to 10.15% ± 3.11 (p  ^0.005). Rapamycin had no effect on cells 
expressing the wild-type protein at concentrations lower than 1 pM (Figure 7.1.1c).
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Figure 7.1.1 Rapamycin reduces inclusion incidence in cells expressing 
P23H rod opsin.
a) SK-N-SH cells expressing P23H-GFP rod opsin were treated with various 
concentrations of rapamycin for 24 hours. The most effective concentration was 1 
pM rapamycin which reduced inclusion incidence from 24.26 ± 4.52 in the 
untreated controls to 10.15 ± 3.11 (p s 0.005). Error bars represent ± 2SE. 
b-e) Treatment with rapamycin reduced inclusion incidencebut did not promote 
the translocation of mutant rod opsin to the plasma membrane of the cells. 
Asterisks highlight inclusions. Scale bar = 10 pm.
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Despite the reduction on inclusion incidence rapamycin did not appear to promote 
the translocation of P23H rod opsin to the plasma membrane (Figure 7.1.1e).
7.1.2.1.2 Rapamycin + Trehalose
The rationale for the combination of trehalose to rapamycin in a treatment was 
based on data from Sarkar and colleagues (2007) where treatment with both drugs 
exerted an additive effect on the clearance of aggregate-prone proteins and on the 
data presented in Chapter 5 where trehalose had a positive effect on the gain of 
function mechanism induced by P23H rod opsin. The effect of rapamycin plus 
trehalose on the inclusion incidence in cells expressing P23H rod opsin is shown in 
Figure 7.1.2. The concentrations of rapamycin and trehalose were based on the 
concentrations used while assessing the effect of each individual compound on the 
inclusion incidence in P23H cells (shown in Figure 7.1.1 and Figure 5.5 
respectively). The most effective concentrations were 5 pM rapamycin (which was 
not more effective than 1 pM rapamycin in the absence of trehalose) and 100 mM 
trehalose (which was not more effective than 50 mM trehalose in the absence of 
rapamycin) and resulted in a decrease in inclusion incidence from 22.93% ± 5.64 in 
the untreated controls to 6.81% ± 2.00 (p £ 0.005). The most effective 
concentrations determined here were higher when used in conjunction than when 
used separately and this may be mainly due to the cumulative protective effect of 
these drugs when used together.
7.1.2.2 Rapamycin reduces the amount of insoluble rod opsin in P23H- 
transfected cells and this is enhanced by the presence of trehalose
A rod opsin fractionation assay of cells expressing the WT or P23H protein and 
treated with 1 pM rapamycin or 5 pM rapamycin plus 100 mM trehalose is shown in 
Figure 7.1.3. Treatment with rapamycin or rapamycin plus trehalose had no effect 
on the total levels of WT or P23H rod opsin (Figure 7.1.3a). The percentage of 
insoluble P23H rod opsin was reduced by treatment with rapamycin from 60.56% ± 
2.72 in the untreated controls to 38.73 ± 5.47 (p < 0.01) whereas rapamycin plus 
trehalose was more efficient, reducing the percentage of insoluble mutant protein
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Figure 7.1.2 Trehalose enhances the reduction of inclusion incidence by 
rapamycin in cells expressing P23H rod opsin.
a) SK-N-SH cells expressing P23H-GFP rod opsin were treated with various 
concentrations of rapamycin (Rap) and trehalose (Tre) for 24 hours. The most 
effective concentration was 5 pM rapamycin + 100 mM trehalose which reduced 
inclusion incidence from 22.93 ± 5.64 in the untreated controls to 6.81 ± 2.00 
(p s 0.005). Error bars represent ± 2SE. b-e) Despite enhancing the reduction of 
inclusion incidence the combined treatment of P23H cells with rapamycin and 
trehalose did not promote the translocation of mutant rod opsin to the plasma 
membrane of the cells. Asterisks highlight inclusions. Scale bar =10 pm.
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Figure 7.1.3 Rapamycin reduces the amount of insoluble P23H rod opsin 
and this reduction is increased by optimal concentrations of rapamycin 
plus trehalose.
A rod opsin fractionation assay was earned out as described in Chapter 3. SK-N- 
SH cells expressing WT-GFP or P23H-GFP were treated with 1 pM rapamycin or 
5 pM rapamycin + 100 mM trehalose, a) The amount of total WT and P23H rod 
opsin in cells treated with tapamycin and rapamycin + trehalose, b) Quantification 
of insoluble P23H rod opsin as percentage of total protein. Rapamycin (p £ 0.01) 
and rapamycin + trehalose (p s 0.05) reduced the percentage of insoluble P23H 
rod opsin. Error bars represent ± 2SE.
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to 32.44% ± 2.56 (p < 0.005) (p < 0.05) (Figure 7.1.3b).
7.1.2.3 Rapamycin reduces LDH release and caspase-3 activity in P23H- 
transfected cells
LDH release and caspase-3 activity were measured in cells expressing P23H rod 
opsin and treated with rapamycin or rapamycin plus trehalose as described in 
Chapter 3. Treatment with rapamycin or rapamycin plus trehalose reduced LDH 
release levels in P23H cells to those observed with the wild-type protein (Figure 
7.1.4a). These treatments were also effective at reducing caspase-3 activity. 
Rapamycin reduced caspase-3 activity from 0.80 ± 0.18 in the untreated controls to 
0.56 ± 0.05 (p < 0.01) whereas rapamycin plus trehalose reduced caspase-3 
activity to 0.51 ± 0.02 (p < 0.005). The degree of protection against caspase-3 
activity by these compounds was similar to that observed with chemical 
chaperones and HSP inducers, with the exception of celastrol, but was less than 
that seen with retinoids.
7.1.2.4 Characterisation of the effect of rapamycin and rapamycin plus 
trehalose on the dominant-negative effect of P23H rod opsin on the 
wild-type protein
The assessment of the effect of rapamycin and rapamycin plus trehalose on the 
dominant-negative mechanism of cell death between the P23H and the wild-type 
rod opsin was carried out by co-transfecting cells with equal amounts of WT and 
P23H rod opsin as described in Chapter 2 . Treatment with 1 pM rapamycin (p < 
0.005) and 5 pM rapamycin plus 100 mM trehalose (p < 0.001) reduced the 
incidence of inclusions in co-transfected cells which contained the wild-type protein 
(Figure 7.1.5). Furthermore, rapamycin (p < 0.05) and rapamycin plus trehalose (p 
< 0.005) resulted in a very small increase in the percentage of co-transfected cells 
apparently showing plasma membrane staining (Figure 7.1.5). However, the vast 
majority of cells showed co-localisation of wild-type and P23H rod opsin in the ER 
suggesting that these compounds largely failed to alleviate the effect of the mutant 
rod opsin on the wild-type protein (Figure 7.1.6).
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Figure 7.1.4 Rapamycin reduces LDH release and caspase-3 activity in cells 
expressing P23H rod opsin and trehalose enhances these effects.
SK-N-SH cells expressing WT or P23H rod opsin were treated with 1 pM rapamy­
cin or 5 pM rapamycin + 100 mM trehalose as described for 48h before LDH (a) 
and caspase-3 activity (b) assays were carried out as described in Chapter 3.
LDH release decreased following treatment with rapamycin (p < 0.01) and rapa­
mycin + trehalose (p s 0.001). Caspase-3 activity was reduced by treatment with 
rapamycin (p £ 0.01) and rapamycin + trelalose (p £ 0.005). Error bars represent 
± 2SE.
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Figure 7.1.5 Rapamycin and rapamycin plus trehalose fail to promote the 
translocation of WT rod opsin to the plasma membrane in cells co­
expressing WT and P23H rod opsin.
SK-N-SH cells were co-transfected with equal amounts of untagged WT and 
P23H-GFP rod opsin and treated with 1 pM rapamycin or 5 pM rapamycin plus 
100 mM trehalose (Rap+Tre) as described for 24 hours. In the untreated controls 
(a-c) the WT protein failed to translocate to the plasma membrane of the cells 
and accumulated with the P23H rod opsin in large intracellular inclusions (*). 
Treatment with rapamycin (d-f) and rapamycin plus trehalose (g-i) reduced WT 
inclusion incidence in cells co-expressing WT and P23H rod opsin. Scale bars = 
10 pm.
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Figure 7.1.6 Rapamycin and rapamycin plus trehalose reduce the inclusion 
incidence and slightly increase the translocation to the plasma membrane 
of WT rod opsin in cells co-expressing WT and P23H rod opsin.
SK-N-SH cells were co-transfected with equal amounts of untagged WT and 
P23H-GFP rod opsin and treated with 1 pM rapamycin and 5 pM rapamycin plus 
100 mM trehalose as indicated for 24 hours. The localisation of WT rod opsin in 
co-transfected cells was assessed and scored as plasma membrane, ER or 
inclusions. Rapamycin (p £ 0.05) and rapamycin plus trehalose (p £ 0.005) 
reduced the incidence of inclusions containing the WT protein. In addition, treat­
ment with rapamycin (p £ 0.005) and rapamycin plus trehalose (p < 0.001) 
resulted in a slight increase in the percentage of co-transfected cells containing 
WT rod opsin in the plasma membrane. Error bars ± 2SE.
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7.1.3 Discussion
The data presented here suggest that rapamycin was effective in reducing 
inclusion incidence in cells expressing the P23H mutant rod opsin. However, 
rapamycin did not appear to promote the translocation of P23H rod opsin to the 
plasma membrane. Furthermore, rapamycin protected P23H cells against LDH 
release and caspase-3 activity suggesting that by preventing the P23H rod opsin 
accumulation in intracellular inclusions it alleviated a gain of function mechanism 
induced by the mutant rod opsin. When tested in the dominant-negative context 
rapamycin reduced the incidence of inclusions containing wild-type rod opsin in co­
transfected cells. Although there was a small increase in the percentage of co­
transfected cells which appeared to have the wild-type protein in the plasma 
membrane there was no evidence to suggest that rapamycin suppressed the 
interaction between the wild-type and the mutant protein as the vast majority of the 
cells had co-staining of both rod opsin species in the ER. Treatment with 
rapamycin plus trehalose reduced inclusion incidence, LDH release and caspase-3 
activity further than rapamycin alone but did not appear to suppress the dominant- 
negative effect of the P23H rod opsin on the wild-type protein. Inclusion incidence 
and caspase-3 activity following treatment with rapamycin plus trehalose were 
similar to those observed with 50 mM trehalose, however, rapamycin plus 
trehalose conferred P23H cells greater protection against LDH release than 
trehalose alone. These data suggested that the combination of these compounds 
might have a positive cumulative effect on protecting cells the gain of function 
mechanism induced by the P23H protein.
The data suggest that treatment with rapamycin or rapamycin plus trehalose could 
be beneficial in a range of diseases including ADRP which caused by toxic gain of 
function mutations which cause protein misfolding. Although these compounds 
were previously found to have positive effects on cell and animal models of 
Huntington's disease by inducing autophagy (Berger et al., 2006; Sarkar et al., 
2007) we have not yet confirmed if this is the mechanism of action by which
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rapamycin exerted its positive effects in this model of rhodopsin RP. This could be 
assessed, for example, by transfecting cells with wild-type and P23H rod opsin and 
treating them with rapamycin in the presence of an autophagy inhibitor such as 3- 
methyl adenine (3-MA).
Kaushal (2007), however, suggested that upon incubation with rapamycin, the 
levels of P23H rod opsin were reduced more rapidly than in untreated controls 
while no observable changes in the amounts of wild-type rod opsin was seen. 
Furthermore, the autophagy specific marker proteins, Atg7, Atg8  (LC3), and LAMP- 
1, which associate with autophagic vacuoles, co-localised with P23H rod opsin 
suggesting that autophagy might be directly responsible for the clearance of 
mutant protein (Kaushal, 2007). Furthermore, this author suggested that neither 
the unfolded protein response nor the heat shock response were induced upon 
rapamycin-associated degradation of P23H opsin.
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7.2 Preliminary data on additional pharmacological agents
7.2.1 Salubrinal
Salubrinal, whose molecular structure is shown in Figure 7.2.1a, was identified in a 
screen for pharmacological agents that protected the rat pheochromocytoma cell 
line PC12 from ER stress-induced apoptosis (Boyce et al., 2005). This study also 
reported that salubrinal engaged the translational control branch of the UPR by 
inducing elF2a phosphorylation without inducing the transcription-dependent 
component of the UPR. EIF2a phosphorylation has been suggested to be 
cytoprotective during ER stress as an induced recessive mutation in the gene 
encoding the ER stress-activated elF2a kinase abolished the phosphorylation of 
elF2a in response to accumulation of misfolded proteins in the ER which resulted 
in abnormally elevated protein synthesis and higher levels of ER stress (Harding et 
al., 2000). It was therefore important to test if salubrinal could protect cells 
expressing P23H rod opsin against the gain of function mechanism induced by the 
mutant protein.
SK-N-SH cells expressing wild-type and P23H rod opsin were treated with 25 pM, 
50 pM and 75 pM salubrinal for 24 hours. These concentrations of salubrinal 
increased the incidence of inclusions in cells expressing P23H rod opsin from 
26.00% ± 1.816 in the untreated controls to 36.97% ± 7.92 (p < 0.001), 43.24% ± 
6.97 (p < 0.001) and 43.56% ± 6.78 (p < 0.001) respectively (Figure 7.2.1).
Boyce et al (2005) identified a small-molecule inhibitor of elF2a dephosphorylation, 
salubrinal, which specifically inhibits the PP1-GADD34 phosphatase activity, 
resulting in sustained elF2a phosphorylation. Although the mechanism of salubrinal 
inhibition is not clear, salubrinal might reduce the effective function of the PP1- 
GADD34 complex in the cell either by direct binding or through yet-to-be- 
determined indirect signaling pathways (Boyce etal., 2005). Although elF2a 
phosphorylation has been suggested to be cytoprotective during ER stress there
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Figure 7.2.1 Salubrinal increases inclusion incidence in cells expressing 
P23H rod opsin.
a) Representation of the molecular structure of salubrinal. b) SK-N-SH cells were 
transfected with WT-GFP and P23H-GFP as described in Chapter 3 and treated 
with different concentrations of salubrinal for 24 hours. 25 pM salubrinal 
(p £ 0.001), 50 pM salubrinal (p s 0.001) and 75 pM salubrinal (p £ 0.001). Error 
bars represent ± 2SE.
I | Control 
Q  25 pM salubrinal 
I 150 pM salubrinal 
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are several properties of salubrinal which might account for the increase in 
inclusion observed in P23H cells. A downside of salubrinal pharmacological 
treatments is that the global inactivation of the elF2 complex might have 
unanticipated effects on cellular and tissue demands for many other regulatory and 
housekeeping proteins. Furthermore, the administration of salubrinal is also likely 
to affect the response of folding pathways in tissues not meant to be targeted for 
correction. Currently, it is poorly understood just how long or at what levels 
sustained inactivation of the elF2  complex would be beneficial although it was 
observed that recovery from PERK-stimulated phosphorylation of elF2a is 
essential for a successful UPR (Novoa et al., 2003).
7.2.2 Resveratrol
Resveratrol (Figure 7.2.2) is a polyphenol which is present in abundance in red 
grapes and red wine and was found to prevent or slow the progression of a variety 
of diseases such as cancer, ischaemic injuries and cardiovascular disease as well 
as extending stress resistance and lifespan of various organisms (Baur and 
Sinclair, 2006). Furthermore, it has been suggested that resveratrol had a potent 
anti-amyloidogenic activity as it reduced the levels of Ap produced from different 
cell lines expressing wild-type or mutant APP (Marambaud et al., 2005). Moreover 
the resveratrol-mediated decrease of Ap was dependent on the proteasome as 
proteasome inhibition ablated its effects (Marambaud et al., 2005). These results 
suggested resveratrol could be a potential candidate in a cell model of rhodopsin 
RP where an increased proteasome function could reduce the mechanisms of cell 
death induced by P23H rod opsin. SK-N-SH cells expressing wild-type and P23H 
rod opsin were treated with various concentrations of resveratrol for 24 hours prior 
to quantification of inclusion incidence (Figure 7.2.2). The concentration of 
resveratrol which elicited the largest reduction in inclusion incidence in P23H cells 
was 5 pM which reduced inclusion incidence from 25.90% ± 2.33 in the untreated 
controls to 15.18% ± 2.55 (p < 0.005).
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Figure 7.2.2 Resveratrol reduces inclusion incidence in cells expressing 
P23H rod opsin.
a) Representation of the molecular structure of resveratrol. b) SK-N-SH cells 
expressing P23H-GFP rod opsin were treated with different concentrations of 
resveratrol for 24 hours. The most effective concentration was 5 pM resveratrol 
which reduced inclusion incidence from 25.90% ± 2.33 in the untreated controls 
to 15.18% ± 2.55 (p £ 0.005). Error bars represent ± 2SE.
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Resveratrol was identified as a potent activator of the human sirtuin SIRT1 in vitro 
and of the yeast homologue Sir2 in vivo, a mechanism that may extend life span in 
yeast (Howitz eta!., 2003). Furthermore, resveratrol and SIRT1 activation have 
recently been linked to neuroprotective pathways in models of axonal degeneration 
(Araki et al., 2004) and of neuronal dysfunctions caused by mutant polyglutamines 
(Parker et al., 2005). It would therefore be interesting to assess if the same 
neuroprotective mechanisms apply to P23H cells and if these are related to the 
decrease in inclusion incidence observed in P23H cells.
7.2.3 Glucosidase inhibitors: 1-Deoxynojirimycin (1-DNJ) and N- 
butyldeoxynojirimycin (NB-DNJ)
It has recently been suggested that functional AF508 CFTR could be rescued by 
the use of the glucosidase inhibitor N-butyldeoxynojirimycin (NB-DNJ) in human 
and mice epithelial cells (Norez etal., 2006). Furthermore NB-DNJ prevented the 
AF508 CFTR/calnexin interaction suggesting that the inhibition of deglucosylation 
of nascent proteins might be the molecular mechanism of action of this compound. 
Because different protein misfolding diseases might share common mechanisms 
for mutant protein recognition by calnexin and consequent retention in the ER, 
glucosidase inhibitors might be pharmacological candidates for a variety of these 
diseases including ADRP. SK-N-SH cells expressing WT and P23H rod opsin were 
treated with the glucosidade inhibitors 1-deoxynojirimycin (1-DNJ) (Figure 7.2.3a) 
and NB-DNJ (Figure 7.24a) for 24 hours. 10 pM 1-DNJ (p < 0.001), 20 pM 1-DNJ 
(p < 0.005), 50 pM 1-DNJ (p < 0.05) decreased inclusion incidence in cells 
expressing P23H rod opsin. 10 pM NB-DNJ (p < 0.001), 20 NB-DNJ (p < 0.005) 
and 50 pM NB-DNJ (p < 0.05) also reduced inclusion incidence in P23H cells. 
However, neither of these compounds appeared to promote the translocation of the 
P23H rod opsin to the plasma membrane, in contrast to the functional rescue 
observed in AF508 CFTR (Norez et al, 2006).
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Figure 7.2.3 1-deoxynojirimycin (1-DNJ) decreases inclusion incidence in 
cells expressing P23H rod opsin.
a) Representation of the molecular structure of 1-DNJ. b) SK-N-SH cells express­
ing WT-GFP or P23H-GFP were treated with different concentrations of 1-DNJ, 
as described, for 24 hours. 10 pM 1-DNJ (p £ 0.001), 20 pM 1-DNJ (p £ 0.005) 
and 50 pM 1-DNJ (p s 0.05) reduced inclusion incidence in P23H cells. Error 
bars represent ± 2SE.
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Figure 7.2.4 N-butyldeoxynojirimycin (NB-DNJ) reduces inclusion incidence 
in cells expressing P23H rod opsin.
a) Representation of the molecular structure of NB-DNJ. b) SK-N-SH cells 
expressing WT-GFP or P23H-GFP were treated with different concentrations of 
NB-DNJ, as described, for 24 hours. 10 pM NB-DNJ (p <; 0.001), 20 pM NB-DNJ 
(p :£ 0.005) and 50 pM NB-DNJ (p £ 0.05) reduced inclusion incidence in P23H 
cells. Error bars represent ± 2SE.
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7.3 Multiple compounds used in conjunction
7.3.1 Retinoids and chemical chaperones
Following the positive results obtained with retinoids and chemical chaperones in 
reducing the gain of function mechanism induced by P23H rod opsin in the cell 
model for rhodopsin RP, treatment combining these two groups of compounds was 
attempted in order to assess if their effects could be cumulative. SK-N-SH cells 
expressing WT, P23H and K296E rod opsin were treated with 9-c/s-retinal and 
chemical chaperones for 24 hours prior to the assessment of inclusion incidence 
(Figure 7.3.1). Treatment with 10 pM 9-c/s-retinal reduced inclusion incidence in 
cells expressing P23H rod opsin from 24.12% ± 7.00 in the untreated controls to 
12.41% ± 1.67. Treatment with 10 pM 9-c/s-retinal and 0.25% DMSO reduced 
inclusion incidence further in P23H cells to 5.93% ± 1.50 (p < 0.001). A similar 
result was observed when cells were treated with 10 pM 9-c/s-retinal and 5 mM 
TMAO as the inclusion incidence in P23H cells was reduced to 6.14% ± 1.74 (p < 
0.001). However, the degree of inclusion incidence reduction was similar to that 
obtained when chemical chaperones were used alone. It is therefore necessary to 
test these compounds at lower concentrations in order to determine whether the 
treatment with these multiple compounds is cumulative.
Treatment with 10 pM 9-c/s-retinal failed to reduce inclusion incidence in cells 
expressing K296E rod opsin as it has previously been described in this study. 
Treatment with 10 pM 9-c/s-retinal and 0.25% DMSO reduced inclusion incidence 
in K296E cells from 13.75% ± 5.60 in the untreated controls to 7.08% ± 4.5 (p < 
0.01). Treatment with 10 pM 9-c/s-retinal and 5 mM TMAO also reduced inclusion 
incidence to 7.95% ± 1.28 (p < 0.05). Both these decreases in inclusion incidence 
were similar to those obtained when chemical chaperones were used alone (Figure 
5.8).
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Figure 7.3.1 Chemical chaperones enhance the effects of 9-c/s-retinal on 
inclusion incidence in cells expressing P23H rod opsin.
The inclusion incidence in SK-N-SH cells expressing WT-GFP, P23H-GFP and 
K296E-GFP rod opsin was assessed following treatment with 10 pM 9-c/s-retinal, 
10 pM 9-c/'s retinal + 0.25% DMSO and 10 pM 9-c/s retinal + 5 mM TMAO, as 
described, for 24 hours. DMSO (p s 0.001) and TMAO (p < 0.001) enhanced the 
reduction in inclusion incidence caused by 9-c/s-retinal in P23H cells. DMSO 
(p £ 0.01) and TMAO (p £ 0.05) also reduced inclusion incidence in K296E cells. 
Error bars represent ± 2SE.
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7.3.2 Multiple chemical chaperones
In order to assess if chemical chaperones had a cumulative effect in protecting 
cells against the gain of function mechanism induced by the mutant protein, SK-N- 
SH cells expressing P23H rod opsin were treated with 0.25% DMSO, 5 mM TMAO 
or 0.25% DMSO plus 5 mM TMAO for 24 hours prior to the quantification of 
inclusion incidence (Figure 7.3.2). DMSO and TMAO when used alone reduced 
inclusion incidence from 24.40% ± 2.00 in the untreated controls to 6.21% ± 0.51 
and 6.00 ±1.04 as previously described. The combination of DMSO and TMAO led 
to an enhanced decrease in inclusion incidence resulting in the presence on 
inclusions in 3.80% ± 1.74 (p < 0.001) of the cells. Although these preliminary data 
suggest that treatment with multiple chemical chaperones might increase the 
protection of cells against the gain of function mechanism induced by the P23H rod 
opsin further experiments are needed to confirm these initial observations. In 
hindsight, the preliminary experiment shown in Figure 7.3.2 might not be the most 
appropriate in order to assess the cumulative effect of chemical chaperones in the 
inclusion incidence of P23H cells, as it used optimal concentrations of DMSO and 
TMAO which by themselves lead to large reductions in inclusion incidence. It might 
be more appropriate for DMSO and TMAO to be used at lower concentrations, 
which are less effective at reducing inclusion incidence, so that the cumulative 
effect of these compounds on P23H rod opsin inclusion incidence might become 
more evident when compared to the effect of each drug alone.
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Figure 7.3.2 Treatment of cells expressing P23H rod opsin with DMSO and 
TMAO enhances the decrease in inclusion incidence observed when these 
compounds are used alone.
SK-N-SH cells expressing P23H rod opsin were treated with 0.25% DMSO,
5mM TMAO or 0.25% DMSO + 5 mM TMAO as described for 24 hours. DMSO 
and TMAO reduce the incidence of inclusions from 24.40% ± 2.00 in the 
untreated controls to 6.21% ± 0.51 and 6.00 ± 1.04 respectively. Treatment with 
DMSO and TMAO reduced inclusion incidence to 3.80 ± 1.74 (p £ 0.001). Error 
bars represent ± 2SE.
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Chapter 8: General Discussion
For a protein to be functionally active it must attain a correct three-dimensional 
structure until the protein is turned over to degradation mechanisms. This balance 
between formation and maintenance of the active conformation is vital to the cell 
and any disturbances in the amino acid sequence by inherited mutations or 
acquired amino acid modifications may compromise either the folding or the 
conformational structural maintenance leading to the disruption of cellular function, 
aggregation and inhibition of the proteasome which was implicated in neurotoxicity 
(Hooper, 2003). Several therapeutic strategies have been developed for protein 
misfolding disorders with the objective of re-establish the balance between the 
disease protein synthesis, degradation and functional activity.
A potential treatment of a protein misfolding disorder is to enhance the folding of 
mutant proteins and increasing the abundance of active protein. This would result 
in a decrease of the amount of accumulated misfolded proteins and alleviate the 
pathogenic mechanisms of cell death. A different strategy involves the reduction of 
the misfolding cellular load by promoting the desegregation of accumulated 
misfolded proteins. One could suggest that there might be an adverse effect of 
dissolving intracellular inclusions which might be protecting the cell against toxic 
oligomeric misfolded proteins. However, the number of vital cellular components 
including molecular chaperones which might be released into the cell are likely to 
overcome this potential adverse effect. Furthermore, this might confer susceptibility 
to degradation and therefore suppression of cell death caused by the accumulated 
misfolded monomers and oligomers. Finally, a strategy in inherited disorders might 
be to decrease or inhibit the expression of the mutant protein. This could be 
achieved by repairing the gene defect by targeted gene correction. Alternatively, in 
the case of a dominant-negative mechanism of cell death the suppression of the 
mutant protein must be carried out while leaving the wild-type protein at 
heterozygous expression levels.
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Additional considerations when developing a potential therapeutic strategy for 
rhodopsin RP involves the fact that RP is a chronic disease which leads to 
blindness, not death. Consequently, any compound must have relatively low side- 
effects and be well tolerated for a long period of time. In addition, compounds must 
be able to cross the blood-retinal barrier or being able to be administered as eye 
drops. In this study, using a cellular model of rhodopsin RP, several of these 
therapeutic strategies were pursued by using a variety of pharmacological agents 
whose effects are summarised in Table 8.1.
The retinoids 9-c/s-retinal and 11-c/s-retinal, acted as pharmacological chaperones 
for rod opsin, reduced inclusion incidence and promoted the folding of the P23H 
rod opsin. The potential use of these compounds in ADRP patients is questionable, 
however, as they lost their efficacy when bleached and one could not envisage 
patients being injected with these compounds in the dark. This problem was 
circumvented by administering vitamin A in RP patients (Berson et a/., 1993). 
These authors carried out a randomised, controlled and double-marked clinical trial 
where RP patients receiving 15000 lU/d of vitamin A had, on average, a slower 
rate of decline of retinal function measured by the ERG than the two groups not 
receiving this dosage. However, no significant difference occurred for the slow loss 
of visual field with time between the groups of patients receiving vitamin A or 
placebo. Prolonged daily consumption of < 25000 IU of vitamin A were considered 
safe in a clinical trial of adults aged 18-54 with RP (Sibulesky etal., 1999), 
although other studies reported side-effects such as increased intracranial 
pressure, hepatomegaly and elevated blood lipids with these doses of vitamin A 
(Bauernfeind, 1980). In addition to the moderate effects of vitamin A on the decline 
of retinal function they were highly variable between patients and this compound 
failed to stop the progression of retinal function decline (Berson et al., 1993). 
Furthermore, there was no available genotypic information on RP patients in this 
clinical trial and this might account for the high patient variability observed in this 
study. Finally, questions raised about the toxicity associated with high doses of 
vitamin A together with the fact that similar data are yet to be replicated
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Compound Inclusions EndoHresistance
Insoluble
protein
LDH
release
Caspase-3
activity
Dominant-
negative
9-c/s-retinal ++ Yes ++ +++ +++ +++
11 -c/s-re tinal ++ Yes ++ +++ +++ +++
DMSO +++ No ++ +++ ++ +
TMAO +++ No ++ +++ ++ +
4-PBA +++ No + ++ +
Trehalose ++ No ++
Arimoclomol +•+•+ No + + +++ ++
Celastrol + N.A No effect No effect Detrimental No effect
Geldanamycin ++ No + ++ -f+ +
Radicicol ++ No ++ +++ ++ +
17-AAG +++ No +++ ++ +
Rapamycin ++ N.D ++ +++ + +
Rapamycin + 
Trehalose +++ N.D ++ +++ + +
Salubrinal Detrimental
Resveratrol ++
1-DNJ +++
NB-DNJ +++
9-c/s-retinal + +++
DMSO
9-c/s-retinal + +++
TMAO
DMSO + +++
TMAO
Table 8.1 Summary of the effects of compounds used in this study on the 
different parameters of the cellular model of rhodopsin RP.
Positive effects of compounds on the mechanisms of cell death induced by the 
P23H rod opsin were classified between + and +++ according to the extent to 
which these effects were reduced. This was assessed by measuring inclusion 
incidence, insoluble protein determined by the rod opsin fractionation assay, LDH 
release, caspase-3 activity and suppression of dominant-negative interaction. 
N.A: Not applicable; N.D: Not done.
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suggest that vitamin A might be of marginal benefit, at best, in patients with RP and 
that this must be weighted with the uncertain risks associated with the long-term 
exposure to high doses of this compound.
Treatment with retinoids or vitamin A poses another difficulty based on the 
possibility that in patients with a healthy diet, there might be an adequate supply of 
1 1 -c/s-retinal to the photoreceptors and supplements might not enhance this 
further. This is not mimicked in this cell model of rhodopsin RP, therefore the 
results observed in this model might not be possible to replicate in vivo. Noorwez 
and colleagues (2003) have successfully rescued P23H rod opsin with the locked 
form of retinal, 11-c/'s-7-ring retinal. These authors showed that treatment with 11- 
c/s-7-ring retinal increased amounts of the correctly folded P23H protein and is 
specific as shown by the lack of activity observed with several structural homologs 
(11-c/s-9-demethyl-ring retinal and 11-c/s-6-ring retinal). However, unlike the wild- 
type rod opsin, purified rescued P23H protein appeared to be in a less compact 
conformation (Noorwez etal., 2003). Therefore, the identification of other 
compounds which might be beneficial for RP patients is necessary.
The use of chemical chaperones in the cell model of rhodopsin RP suggested that 
these compounds alleviated the gain of function mechanism induced by the P23H 
rod opsin but did not appear to promote the folding of the mutant protein. In 
addition chemical chaperones, unlike retinoids had a positive effect on the gain of 
function mechanism induced by the K296E rod opsin.
As the concentrations of chemical chaperones necessary for an effect in cell 
culture studies of protein misfolding disorders were in the milimolar range is was 
important to assess if these concentrations could be achieved in vivo.
Bai and colleagues (1998) used CD1 mice to assess if the equivalent in vitro 
concentrations of chemical chaperones could be maintained. These authors 
reported that potentially therapeutic concentrations of TMAO could be sustained in
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mice in vivo. Single intraperitoneal or subcutaneons doses of TMAO (7 g/kg, 8% 
solution in water) resulted in serum TMAO greater than 50 mM with a half-life of
18-21 hours. Sustained high serum and tissue TMAO concentration higher than 52 
mM for 3 days was achieved by the administration of TMAO (7 g/kg) in water every 
8 hours. However, this resulted in the death approximately half of the mice. 
Although the remaining mice had nearly normal liver, renal, and pancreatic 
function. A lower dose of TMAO (5 g/kg) given by the subcutaneons route every 8 
hours resulted in serum TMAO concentration of 22 mM, a level that was well 
tolerated by all mice for 72 h. Despite the lower toxicity, a similar therapeutic 
regime both in terms of quantity and periodicity is not applicable to rhodopsin RP 
patients.
4-PBA is a low molecular weight fatty acid with FDA approval for clinical use in 
patients with urea cycle disorders (Burlina et al., 2001) which might suggest that is 
the most applicable kosmotrope to rhodopsin RP patients. 4-PBA induced CFTR 
channel function on the plasma membrane of AF508-CFTR airway epithelial cells 
in vitro (Rubenstein et al., 1997). In order to assess if 4-PBA could induce epithelial 
CFTR function in patients homozygous for AF508-CFTR a randomized, double­
blind and placebo-controlled trial in 18 patients was performed with the maximum 
approved adult dose of 4-PBA: 19 grams/day (116 mM/day) divided in three oral 
doses of 6, 6, and 7 grams for 1 week (Rubenstein and Zeitling, 1998). Nasal 
potential difference (NPD) response patterns and sweat chloride concentrations 
were determined before and after study drug treatment, and 4-PBA and 
metabolites were assayed in plasma and urine at the end of drug treatment. 
Subjects in the 4-PBA group demonstrated small, but statistically significant 
improvements of the NPD response to perfusion of an 
isoproterenol/amiloride/chloride-free solution. This measure reflected epithelial 
CFTR function and was highly discriminatory between patients with and without 
CF. Subjects who had received 4-PBA did not demonstrate significantly reduced 
sweat chloride concentrations or alterations in the amiloride-sensitive NPD. Side 
effects due to drug therapy were minimal and comparable in the two groups.
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These data suggest that chemical chaperone concentrations used to alleviate the 
effects of P23H rod opsin in vitro (0.25% DMSO; 5 mM TMAO; 10mM 4-PBA; and 
50 mM trehalose) can by sustained in vivo. It would be interesting to assess the 
effect of chemical chaperones on a P23H mouse model of retinal degeneration 
(Olsson etal., 1992) and investigate if the positive effect of these compounds on 
the cell model of rhodopsin RP could be replicated in vivo.
Treatment with the HSP co-inducer arimoclomol in the cell model of rhodopsin RP 
alleviated the gain of function mechanism of induced by P23H rod opsin. 
Furthermore, arimoclomol partially promoted the folding of P23H rod opsin, and 
wild-type rod opsin, in co-transfected cells. When used in a mouse model of ALS 
(10 mg/kg intraperitoneally) arimoclomol delayed disease progression and resulted 
in marked improvement in hind limb muscle function (Kieran et al., 2004). 
Significantly, a significant delay in ALS disease progression was observed when 
arimoclomol was administered after the visible onset of disease symptoms. 
Arimoclomol was well tolerated in a phase I study of healthy volunteers. And a 
dose ranging, phase II study of arimoclomol in ALS has finished enrollment 
(http://www.clinicaltrials.gov/ct/show/NCT002442447ordeM). Safety, optimum 
dose, and pharmacokinetics of arimoclomol, however, are still unknown for patients 
with ALS.
Treatment of P23H cells with the Hsp90 inhibitors geldanamycin, radicicol and 17- 
AAG alleviated the gain of function and the dominant-negative mechanism induced 
by P23H rod opsin. However, these compounds did not appear to promote the 
folding of P23H or wild-type rod opsin in co-transfected cells respectively. Although 
it was suggested that the mechanism of action of these compounds on protein 
misfolding disorders involved the enhanced degradation of the mutant protein (Solit 
et al., 2002) this did not appear to be the case in this cellular model of rhodopsin 
RP. It would therefore be interesting to assess if the positive effects of these 
compounds observed in this study could be replicated in vivo. 17-AAG was
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examined as a anti-tumour agent in a Phase I clinical trial for paediatric patients 
with recurrent or refractory neuroblastoma, and a dose of 270 mg/m2 administered 
twice weekly for 2 of 3 weeks was well tolerated (Bagatell et al., 2007). The sub- 
inhibitory doses necessary for an induction of Hsp90 by 17-AAG in a potential 
rhodopsin RP in vivo study (25 mg/kg) should not be associated with toxicity.
Rapamycin protected P23H cells against the gain of function mechanism induced 
by the mutant protein. It was unclear, however, if these actions were due to an 
autophagy induction. Rapamycin reduced huntingtin accumulation and cell death in 
cell models of Huntington’s disease and against neurodegeneration in a Drosophila 
melanogaster model of Huntington’s disease (Ravikumar et al., 2004). It would be 
interesting to investigate the effects and the mechanism of action of rapamycin in 
an in vivo in a model of rhodopsin RP. Rapamycin has been approved for clinical 
trials by the FDA for use at a fixed dose of 2-5 mg/day. However, pharmacokinetic 
and clinical data showed that rapamycin was a critical-dose drug requiring 
therapeutic drug monitoring to minimise drug-related toxicities and maximise 
efficacy (Mahalati and Kahan, 2001) which might not be ideal for the long-term use 
required by rhodopsin RP patients.
Preliminary data was produced by treating cell expressing P23H rod opsin with 
salubrinal, resveratrol, 1-DNJ and NB-DNJ. Of these compounds the glycosidase 
inhibitors 1-DNJ and NB-DNJ appeared to be the most promising as they resulted 
in a large decrease in inclusion incidence without any observable deleterious 
effects on cellular morphology. Moreover, a Phase II clinical trial with NB-DNJ was 
recently completed (http://www.clinicaltrials.gov/ct/show/NCT00002079?order=2).
The initial observations regarding a the use of multiple compounds on the cellular 
model of rhodopsin RP suggested that 9-cis-retinal plus chemical chaperones and 
multiple chemical chaperones had a cumulative effect in decreasing inclusion 
incidence in cells expressing P23H rod opsin. However, more data is required in
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order to assess if this positive effect on inclusion incidence is accompanied by 
cytoprotection and if the suppression of the dominant-negative can be enhanced.
This study has developed and characterised a cell model which can mimic the gain 
of function and dominant-negative disease mechanisms in rhodopsin RP. This 
resulted in the creation of a template which could be used for the identification and 
development of drugs for rhodopsin RP patients. Furthermore, this study has 
identified compounds which demonstrate the ‘proof of principle’ that some gain of 
function and dominant-negative mechanisms of cell death induced by a Class II rod 
opsin mutation can be manipulated. In would be interesting to establish the efficacy 
of these pharmacological agents in animal models prior to a potential translation 
into the clinic.
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Chapter 10: Appendix A -  Mutations and deletions 
identified in the rhodopsin gene
Phenotype Mutation Basechange Exon Reference
ADRP Thr 4 Lys ACA-AAA 1 Bunge (1993)
ADRP Asn 15 Ser AAT-AAG 1 Kranich (1993)
ADRP Thr 17 Met ACG-ATG 1 Sheffield (1991)
ADRP Val 20 Gly 1 Schuster (2006)
ADRP Pro 23 Ala CCC-GCC 1 Oh (2000)
ADRP Pro 23 His CCC-CAC 1 Dryja (1990)
ADRP Pro 23 Leu CCC-CTC 1 Dryja (1991)
ADRP Gin 28 His CAG-CAT 1 Bunge (1993)
ADRP Leu 40 Arg CTG-GTG 1 al-Maghtheh (1994)
ADRP Met 44 Thr ATG-ACG 1 Reig (1994)
ADRP Phe 45 Leu TTT-CTT 1 Sung (1991)
ADRP Leu 46 Arg CTG-CGG 1 Rodriguez (1993)
ADRP Gly 51 Ala GGC-GCC 1 Macke (1993)
ADRP Gly 51 Arg GGC-CGC 1 al-Maghtheh (1993)
ADRP Gly 51 Val GGC-GTC 1 Dryja (1991)
ADRP Pro 53 Arg CCC-CGC 1 Ingleheam (1992)
ADRP Thr 58 Arg ACG-AGG 1 Dryja (1990)
ADRP Gin 64 ter CAG-TAG 1 Macke (1993)
ADRP 68-71 12 bp deletion 1 Keen (1994)
ADRP Val 87 Asp GTC-GAC 1 Sung (1991)
ADRP Gly 89 Asp GGT-GAT 1 Sung (1991)
ADRP Gly 106 Arg GGG-AGG 1 Ingleheam (1992)
ADRP Gly 106 Trp GGG-TGG 1 Sung (1991)
ADRP Gly 109 Arg GGA-AGA 1 Goliath (1998)
ADRP Cys 110 Phe TGC-TTC 1 Fuchs (1994)
ADRP Cys 110 Tyr TGC-TAC 1 al-Maghtheh (1993)
ADRP Gly 114 Asp GGC-GAC 1 Vaithinathan (1994)
ADRP Gly 114 Val GGC-GTC 1 Dryja (2000)
ADRP Leu 125 Arg CTG-CGG 2 Dryja (1991)
ADRP Ser 127 Phe TCC-TTC 2 Souied (1994)
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ADRP Leu 131 Pro CTG-CCG 2 Fuchs (1994)
ADRP Arg 135 Gly CGG-GGG 2 Bunge (1993)
ADRP Arg 135 Leu CGG-CTG 2 Andreasson (1992)
ADRP Arg 135 Pro CGG-CCG 2 Gal (1997)
ADRP Arg 135 Trp CGG-TGG 2 Sung (1991)
ADRP Tyr 136 ter TAC-TAA 2 Sanchez (1996)
ADRP Val 137 Met GTG-ATG 2 Ayuso (1996)
ADRP Cys 140 Ser TGT-TCT 2 Macke (1993)
Glu 150 Lys GAG-AAG 2 Kumaraman (1994)
ADRP Ala 164 Glu GCG-GAG 2 Vaithinathan (1994)
ADRP Ala 164 Val GCG-GTG 2 Fuchs(1994)
ADRP Cys 167 Arg TGC-CGC 2 Dryja (1991)
ADRP Cys 167 Trp TGC-TGG 2 Prelsing (1997)
Pro 170 Arg CCC-CGC 2 Sohocki (2001)
ADRP Pro 171 Gin CCA-CAA 2 Antinolo (1994)
ADRP Pro 171 Glu CCA-GAA 2 Rodriguez (1994)
ADRP Pro 171 Leu CCA-CTA 2 Dryja (1991)
ADRP Pro 171 Ser CCA-TCA 2 Vaithinathan (1994)
ADRP IVS2-2a-g A-G IVS2
Martinez-Gimeno
(2000)
Gly 174 Ser GGC-AGC Fujiki (1995)
Ser 176 Phe Schuster (2006)
ADRP Tyr 178 Asn TAC-AAC 3 Souied (1994)
ADRP Tyr 178 Cys TAC-TGC 3 Sung (1991)
ADRP Pro 180 Ala CCC-GCC 3 Sohocki (2001)
ADRP Glu 181 Lys GAG-AAG 3 Dryja (1991)
ADRP Gly 182 Ser GGC-AGC 3 Sheffield (1991)
ADRP Gin 184 Pro CAG-CCG 3 Dryja (2000)
Cys 185 Arg TGC-CGC 3 Sohocki (2001)
ADRP Ser 186 Pro TCG-CCG 3 Dryja (1991)
ADRP Ser 186 Trp TCG-TGG 3 Gal (1997)
Cys 187 Ala 3 Hwa (1999)
ADRP Cys 187 Tyr TGT-TAT 3 Richards (1995)
ADRP Gly 188 Arg GGA-AGA 3 Dryja (1991)
ADRP Gly 188 Glu GGA-GAA 3 Macke (1993)
ADRP Asp 190 Asn GAC-AAC 3 Keen (1991)
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ADRP Asp 190 Gly GAC-GGC 3 Sung (1991)
ADRP Asp 190 Tyr GAC-TAC 3 al-Maghtheh (1993)
ADRP Thr 193 Met ACG-AUG 3 Cydeciyan (1998)
ADRP Met 207 Arg ATG-AGG 3 Farrar (1992)
ADRP Val 209 Met ATG-GTG 3 Macke (1993)
ADRP His 211 Arg CAC-CGC 3 Macke (1993)
ADRP His 211 Pro CAC-GAC 3 Keen (1991)
Pro 215 Leu 3 Schuster (2006)
ADRP Pro 215 Thr CCC-CTC 3
Martinez-Gimeno
(2000)
ADRP Met 216 Arg ATG-AGG 3 Haim (1996)
ADRP Met 216 Lys ATG-AAG 3 al-Maghtheh (1994)
ADRP Phe 220 Cys TTT-TGT 3 Bunge (1993)
ADRP Cys 222 Arg TGC-CGC 3 Bunge (1993)
Lys 248 Arg Kucinskas 1999
ADRP 255 / 256 ATC (I) deletion 4 Ingleheam (1991)
ADRP 264 TGC (C) deletion 4 Vaithinathan (1993)
ADRP Pro 267 Arg CCC-CGC 4 Souied (1994)
ADRP Pro 267 Leu CCC-CTC 4 Sheffield (1991)
ADRP Ser 270 Arg AGC-AGA 4 Sohocki (2001)
ADRP Thr 289 Pro ACC-CCC 4
Martinez-Gimeno
(2000)
Lys 296 Asn AAG-AAT Sohocki (2001)
ADRP Lys 296 Glu AAG-GAG 4 Keen (1991)
ADRP Lys 296 Met AAG-ATG 4 Sullivan (1993)
ADRP Ser 297 Arg AGC-AGA 4 Souied (1994)
ADRP Gin 312 ter CAG-TAG 4 Ingleheam (1991)
ADRP IVS4+1g-t G-T IVS4 Macke (1993)
ADRP 314-316
150 bp insertion / 30 
bp deletion
IVS4 al-Maghtheh (1994)
ADRP IVS4-1g-t G-T IVS4 Reig (1996)
ADRP IVS4-1g-a G-A IVS4 Bell (1994)
ADRP 5168del9bp 5 al-Maghtheh (1993)
ADRP Leu 328 Pro CTG-CCG 5 Gal (1997)
ADRP 332-338 17 bp deletion 5 Rodriguez (1994)
ADRP 998ins4bp duplication in 5 Bareil (1999)
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rhodopsin gene
ADRP 340-348 42 bp deletion 5 Restagno (1993)
ADRP 340 1 bp deletion 5 Horn (1992)
ADRP 341-343 8 bp deletion 5 Horn (1992)
ADRP Glu 341 Lys GAG-AAG 5 Gal (1997)
ADRP Glu 341 ter GAG-TAG 5 Zhao (2001)
ADRP Thr 342 Met ACG-ATG 5 Stone (1993)
ADRP Gin 344 ter CAG-TAG 5 Sung (1991)
ADRP Val 345 Leu GTG-CTG 5 Vaithinathan (1994)
ADRP Val 345 Met GTG-ATG 5 Dryja (1991)
ADRP Ala 346 Pro GCC-CCC 5 Borrego (1996)
ADRP Pro 347 Ala CCG-GCG 5 Macke (1995)
ADRP Pro 347 Arg CCG-CGG 5 Gal (1991)
ADRP Pro 347 Gin CCG-CAG 5 Vaithinathan (1994)
ADRP Pro 347 Leu CCG-CTG 5 Dryja (1990)
ADRP Pro 347 Ser CCG-TCG 5 Dryja (1990)
ADRP Pro 347 Thr CCG-ACG 5 Sohocki (2001)
ADRP Ter 349 Glu
TAA-GAA —> stop 
codon abolished 
and 51 aa added to 
C-terminus of 
rhodopsin
5 Bessant (1999)
ARRP Glu 150 Lys GAG-AAG 2
Kumaramanickavel
(1994)
ARRP Gly 174 Ser GGC-AGC 2 Fujiki (1995)
ARRP Glu 249 ter GAG-TAG 4 Rosenfeld (1992)
ARRP Gly 284 Ser GGT-AGT 4 Ruther (1995)
CSNB Gly 90 Asp GGC-GAC 1 Sieving (1995)
CSNB Gly 90 Val 1 Kabaranou (2004)
CSNB Thr 94 Ser ACC-ATC 1 al-Jandal (1999)
CSNB Ala 292 Glu GCG-GAG 4 Dryja (1993)
j Polymorphism 269g-a G-A 5'UTR Dryja (1991)
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Polymorphism Val 104 lie GTC-ATC 1 Macke (1993)
Polymorphism Pro 107 Pro CCC-CCT 1 Gal (1997)
Polymorphism -26A/G A/G 5'UTR Bareil (1999)
Polymorphism Gly 120 Gly GGC-GGT 1 Dryja (1991)
Polymorphism 721c-t G-A IVS1 Trujillo (1998)
Polymorphism (CA)n IVS1 Weber (1989)
Polymorphism Thr 160 Thr ACC-ACA 2 Sung (1991)
Polymorphism Ala 173 Ala GCC-GCT 2 Dryja (1991)
Polymorphism IVS3+4c-t C-T IVS3 Dryja (1990)
Polymorphism IVS3+62c-a C-A IVS3 Saga (1993)
Polymorphism IVS3+106g-a G-A IVS3
Polymorphism Lys 248 Lys AAG-AAA 4 al-Maghtheh (1993)
Polymorphism IVS4-22g-a G-A IVS4 Sung (1991)
Polymorphism Cys 323 Cys TGC-TGT 5 Trujillo (1998)
Polymorphism 5300g-t gt-tt 3'UTR Bell (1994)
Polymorphism 5311 c-t C-T 3'UTR
Polymorphism 5312g-a G-A 3’UTR Ruiz (1997)
Polymorphism 5321 c-a C-A 3'UTR Dryja (1990)
Retinitis
punctata Arg 135 Trp CGG-TGG 2 Souied (1996)
albescens
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